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Abstract 
Human T cells expressing CD56 are capable of tumour cell lysis following 
activation with interleukin-2 but their role in viral immunity has been less well 
studied. The work described in this thesis aimed to investigate CD56+ T-cells in 
relation to cytomegalovirus infection in healthy subjects and kidney transplant 
patients (KTPs). Proportions of CD56+ T cells were found to be highly 
significantly increased in healthy cytomegalovirus-seropositive (CMV+) 
compared to cytomegalovirus-seronegative (CMV-) subjects (8.38% ± 0.33 versus 
3.29%± 0.33; P < 0.0001). In donor CMV-/recipient CMV- (D-/R-)- KTPs levels 
of CD56+ T cells were 1.9% ±0.35 versus 5.42% ±1.01 in D+/R- patients and  
5.11% ±0.69 in R+ patients (P 0.0247 and < 0.0001 respectively). CD56+ T cells 
in both healthy CMV+ subjects and KTPs expressed markers of effector memory-
RA T-cells (TEMRA) while in healthy CMV- subjects and D-/R- KTPs the 
phenotype was predominantly that of naïve T-cells. Other surface markers, CD8, 
CD4, CD58, CD57, CD94 and NKG2C were expressed by a significantly higher 
proportion of CD56+ T-cells in healthy CMV+ than CMV- subjects. Functional 
studies showed levels of pro-inflammatory cytokines IFN-γ and TNF-α, as well as 
granzyme B and CD107a were significantly higher in CD56+ T-cells from CMV+ 
than CMV- subjects following stimulation with CMV antigens. This also resulted 
in higher levels of proliferation in CD56+ T-cells from CMV+ than CMV- 
subjects. Using class I HLA pentamers, it was found that CD56+ T-cells from 
CMV+ subjects contained similar proportions of antigen-specific CD8+ T cells to 
CD56- T cells in healthy donors of several different HLA types. A comprehensive 
gene expression profile by microarrays of CMV-stimulated sorted CD56+ T-cells 
was conducted which showed that expression of 106 genes involved in innate and 
adaptive immune responses was significantly changed, almost all being increased. 
Some of these changes were validated via RT-PCR and flow cytometry, the latter 
indicating higher ISG-15 protein expression in response to CMV stimulation in 
CMV+ than CMV- subjects. Overall, these differences may reflect the expansion 
and enhanced functional activity of CMV-specific CD56+ memory T cells. In 
view of the link between CD56 expression and T-cell cytotoxic function, this 
strongly implicates CD56+ T cells as being an important component of the 
cytotoxic T-cell response to CMV.   
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1. The immune system 
The mammalian immune system is composed of two main components, the innate 
and the adaptive immune system, which work with each other to protect the body 
from harmful pathogens. The immune system has to adapt rapidly to detect and 
neutralize different types of pathogens. Furthermore, the immune system has 
methods to discriminate between self and non-self cells; these methods are 
essential to avoid targeting host cells. However in some abnormal states self-cells 
can be targeted by immune effector mechanisms, leading to the development of 
autoimmune diseases. If the activity of the immune system is modulated and 
reduced, this may lead to an invasion by pathogens, even those that were not able 
to form a real threat previously (Abbas and Lichtman 2009).  
The innate immune system is relatively non-specific; it includes humoral barriers, 
secretory molecules, cells and anatomical barriers. Furthermore, anatomical 
barriers involve mechanical factors such as the epithelial surfaces that are 
normally impervious to pathogen infiltration (Kimbrell and Beutler 2001). 
Chemical factors also are part of these barriers for example fatty acids in the 
sweat that prevent the growth and colonization of bacteria. Also, biological 
factors are part of these barriers and assist in preventing infection such as the 
normal flora that competes with pathogenic bacteria for nutrients inside the 
gastrointestinal tract of the body. Humoral factors also have essential roles in 
defending against infection when anatomical barriers are penetrated by the 
pathogens. Humoral components are effective in initiating inflammation that is 
characterised by recruitment of phagocytic cells to the site of pathogen invasion. 
This system involves for example complement components, the coagulation 
system, and lysozyme. Cellular components are important in the inflammatory 
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response to pathogens. Cells involved include neutrophils, macrophages, NK cells 
and eosinophils. Both macrophages and neutrophils are essential parts of the 
phagocytic system that engulf the pathogens and neutralize them (Abbas and 
Lichtman 2009).  
The adaptive immune system is the more specific type of host immunity. This 
system is antigen specific and requires antigen presentation. Lymphocytes are a 
crucial part of the adaptive immune system, of which there are several types. The 
major subsets are B-cells that mediate humoral immune responses and T-cells that 
regulate cell mediated responses, and both of these cell types are derived from the 
bone marrow as a result of haematopoietic stem cell division (Kimbrell and 
Beutler 2001). 
  
1.1 Antigen presentation 
Human leucocyte antigens (HLA) that are also named MHC have an essential role 
in adaptive immune system. HLA is expressed on cell surfaces and their main 
function is to facilitate communication of the body cells with leucocytes. HLA is 
divided into two types, HLA-I and HLA-II (Penn 2005).  
HLA-I is expressed on all nucleated body cells, and this class’s main function is 
to express peptides to CD8+ T-cells. This peptide is either self-antigen expressed 
by healthy cells or foreign antigen that is expressed by abnormal cells under 
intracellular stress. Endogenous proteins are digested into peptides in the cytosol 
via proteolytic proteasomes, then transported by transporter proteins into the ER 
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where peptides are bound to newly synthesized HLA-I due to affinity and then 
transported to the cell surface (Van Hateren, 2010).  
HLA-II, however, is expressed mainly by APC. The latter cells are macrophages, 
dendritic cells (DC) and B-cells. Extracellular pathogens are engulfed by a 
process called phagocytosis or endocytosis by APC, then extracellular pathogens 
are digested by proteases in the endosome. In the ER α, β and invariant chains are 
synthesized and assembled, then transported via the Golgi body to endosomes and 
here invariant chain is digested. Moreover, peptides from extracellular pathogens 
are loaded into HLA-II molecule and transported into the cell surface for CD4+ T-
cell recognition (Penn 2005).     
 
1.2 T-lymphocytes  
T-lymphocytes have several different subsets. These subsets share the expression 
of TCR or T-cell receptor. TCR activates in response to the expression of antigen 
on HLA-I or II by antigen presenting cells (APC).  
 
1.2.1 CD4 + T-cells 
Activated CD4+ T-cells were identified by Mosmann and Coffman to have 2 
different subsets Th1 and Th2 in 1986. Moreover, currently about four different 
types have been described, Th1, Th2, Th17 and iTreg cells (Zhu and Paul 2008). 
T-helper cells have essential functions in modulating the adaptive immune 
system, these roles are exerted by their ability to produce cytokines and 
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chemokines to activate and recruit other types of cells (figure 1.1) (Zhu and Paul 
2008).  
A role for Th1 cells is in resistance to intracellular pathogens; the cytokines 
mainly produced by Th1 cells are IFN-γ and IL-2 and lymphotoxin-α (LTα). In 
addition, LTα is considered a marker for multiple sclerosis disease progression 
(Selmaj et al. 1991). IFN-γ released by Th1 is essential for increasing macrophage 
antimicrobial activity (Suzuki et al. 1988).  
The other main type of T-helper cells are Th2 cells, which are important in 
mediating host defence against extracellular pathogens. Th2 cells are potent 
cytokine producers of amphiregulin, IL-4, IL-5, IL-9, IL-10, IL-13 and IL-25 
(Zhu and Paul 2008). The release of IL-4 by Th2 cells is the major mediator of 
IgE class switching in B-cells. Furthermore, IgE targets FceRI receptors on 
basophils and mast cells, when cross linked with a multivalent ligand leading to 
the release of active mediators like histamine and serotonin and cytokines like IL-
4, IL-13 and TNF-α (Zhu and Paul 2008). 
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 Th17 cells are one of the helper cells subsets; this subtype releases IL-17A and F, 
IL-21 and IL-22. Additionally, IL-17A and F target the IL-17RA receptor, and 
they have the ability to recruit and activate neutrophils in response to extracellular 
pathogens. IL-21 plays a role in stimulating Th17 differentiation, similar to the 
role of IFN-γ to Th1 and IL-4 to Th2 (Korn et al. 2007, Nurieva et al. 2007, Zhou 
et al. 2007). 
 T regulatory cells or classically known as suppressor T cells, are a subset of T-
cells that preserve tolerance to self-antigens and regulate immune response 
homeostasis (Zhu and Paul 2008, Sakaguchi 2004, Joffre et al. 2008). T-regs are 
CD4+CD25+ cells and develop and emigrate from the thymus. Increase in 
percentage of T-reg cells was found to help prevent autoimmune diseases and 
 
Figure 1.1 Naïve CD4+ T-cells differentiate. In response to different cytokines 
aanaive CD4+T-cells differentate into specific types of CD4+ T-cells (Zhu and 
Paul 2008). 
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allograft rejection (Joffre et al. 2008). Several studies have investigated the 
mechanism of T-reg function and they are thought to mediate their function 
through direct contact with target cells (Shevach 2006). Moreover, T-regs are able 
to release the cytokines TGF-β, IL-10 and IL-35 (Zhu and Paul 2008).   
 
1.2.2 CD8+ T-cells 
CD8+ T-cells are a subset of lymphocytes also known as T-killer cells, cytolytic 
T-cells, Killer T-cells or Cytotoxic T lymphocytes (CTL). This subset acquired 
these several names due to their function in killing cancer cells; pathogen infected 
cells and impaired cells due to any effect. CTL have the ability to recognise 
peptides presented on the extracellular part of MHC-I molecules. These peptides 
are generated in the intracellular region of the cells via the degradation of 
cytosolic proteins in the proteasome. Consequently, CD8+ T-cells eliminate cells 
that express their specific antigen peptides presented on MHC-I. 
 
1.2.3 γδ-T-cells  
This subset of T-cells expresses TCR that is distinct from other types of T-cells. 
γδ-cells TCR is made of one γ chain and one δ chain. Additionally, the frequency 
of γδ-cells is much less than αβT-cells, but this type of T-cells is found more in 
gut mucosal and is more abundant in intraepithelial lymphocytes.  
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1.2.4 Natural Killer cells (NK cells) 
NK cells have a critical role in the rapid immune response of the innate immune 
system. NK cells, a type of lymphocyte,  are cytotoxic against foreign pathogen-
infected cells that have down regulated class I MHC. NK cells express inhibitory 
receptors that detect self-class I MHC and prevent NK cells from initiating the 
killing process against self-cells that are not infected. The NK cell activation 
process is regulated by activating and inhibitory receptors and, also, by MHC-I 
associated proteins on the target cells (Iversen et al. 2005); (Lanier 2005). 
 
1.3 B-cells (B Lymphocytes)  
The other type of effector immune response is the humoral immune response; this 
type is modulated by B-cells. As well as being responsible for antibody 
production, B-cells also perform an essential role in antigen presentation. B-cells 
have a B-cell receptor (BCR) which is a membrane-bound immunoglobulin that 
also helps to distinguish B-cells from T-cells. Once B-cells become activated they 
differentiate into plasma cells or memory B-cells.    
 
1.4 CD56+ T cells (CD56+CD3+ cells) 
1.4.1 History  
Several efforts have been attempted in recent decades for the development of 
effective immunotherapy against tumours by using cytotoxic antitumor cells (Lu 
and Negrin 1994). LAK cells (Lymphokine-activated killer cells) are described as 
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the primary prototype of CIK cells (Cytokine-induced killer cells) (Linn and Hui 
2010). Rosenberg and colleagues first generated LAK cells in 1980. LAK cells are 
described as lymphoid cells that highly proliferate several folds after being 
induced by IL-2 that is essential for cell growth, proliferation and differentiation. 
LAK cells show cytotoxic capabilities different from NK cells and CTL 
(cytotoxic T lymphocytes) (Grimm et al. 1983), still they share some properties 
with NK cells such as the surface marker CD56 and the lack of MHC restriction 
(Ramsdell and Golub 1987). Leu19 is the previous name for CD56 (Linn and Hui 
2010). Moreover, LAK cells are not MHC restricted and they are capable of 
specifically lysing cancerous cells, even those resistant to killing by NK cells. 
Also, LAK cells do not target self-cells and are specific for tumour cells (Fagan 
and Eddleston 1987). These cells are cytotoxic against autologous and allogeneic 
tumour cells types (Grimm et al. 1983).  The molecularcloning of IL-2 in 1983 by 
Taniguchi and colleagues subsequently allowedintravenous administration of IL-2 
and LAK cells in bulk amounts reducing the number and size of secondary 
tumours in animal tumour models and preliminary human studies (Fagan and 
Eddleston 1987), though IL-2 administration can lead to toxicities such as 
hypotension and vascular leakage (Jennings et al. 2013). LAK cells derived from 
peripheral blood cells of tumour patients were introduced with IL-2 by 
intravenous administration into tumour patients with hepatic or pulmonary 
metastases and reduced the size of the tumour more than 50% in less than three 
weeks. Each tumour patient received LAK cells obtained from his/ her peripheral 
blood cells (Rosenberg et al. 1985).  
Moreover, NK/LAK cell immunotherapy illustrates potent immune responses 
toward MHC-I negative tumours such as neuroblastoma and by the use of MD-
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DCs (monocyte–derived dendritic cells) removes the requirement for the use of 
potentially toxic IL-2 (Valteau-Couanet et al. 2002).  
Even though LAK cells have shown some benefits toward tumour treatment, the 
use of these cells was held back by shortage of enough cells for cancer 
immunotherapy (Rosenberg et al. 1986). Furthermore, LAK cells are CD3- and 
hence are unable to generate an antigen-specific response (Ramsdell and Golub 
1987).    
In 1986, tumour-infiltrating lymphocytes (TILs) show about 100 times more 
effective therapeutic outcomes than LAK cells in metastatic tumours (Rosenberg 
et al. 1986). TILs are lymphocytes that migrated from the blood stream toward the 
tumour site then infiltrated the tumour; their major effector cell phenotype is 
MHC-restricted CD3+CD56-CD8+ (Lu and Negrin 1994); (Yoo et al. 1990). 
These cells are efficient in treatment of mice with tumours resistant toward 
LAK/IL-2 adoptive immunotherapy (Rosenberg et al. 1986). Preparation of these 
cells is different from LAK cells. They are harvested from tumours and then 
incubated with IL-2 in culture medium (Rosenberg et al. 1986). However, as with 
LAK cells these cells are also held back by the complexity of generating enough 
cells to use them in cancer immunotherapy. Moreover, functional modifications 
occur during the harvesting process from the human tissue (Lu and Negrin 1994). 
TILs have been reported to have a beneficial outcome in extending survival in 
cancers such as skin cancer (Haanen et al. 2006) and ovarian cancer (Ma and Gu 
1991) (Sharma et al. 2007). LAK cells are limited by the inability to generate high 
numbers that is further hampered after applying chemotherapy to the cancer 
patients. On other hand, TILs are more effective than LAK cells, although those 
TILs cells harvested from metastatic and advanced tumours were reported to have 
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less cytotoxicity and proliferation ability than those harvested from primary 
tumours (Yoo et al. 1990); (Lu and Negrin 1994).       
In 1991, a new study reported an advanced procedure to generate high numbers of 
effector cytotoxic cells against human B lymphoma cell lines. This study was 
conducted in SCID (severe combined immunodeficiency) mice that lack both T 
and B-lymphocytes. Additionally, human lymphoma cells were injected into these 
mice to grow and allow examination of the interaction between human 
lymphocytes and these lymphoma tissues (Schmidt-Wolf et al. 1991). CIK cells 
(cytokine induced killer cells) were generated through ex-vivo culturing of 
peripheral blood mononuclear cells (PBMCs) with the periodic introduction of 
IFN-γ, anti-CD3(OKT-3) molecular antibody and interleukin 2 (IL-2) over a 21- 
28 day period (Schmidt-Wolf et al. 1991). The purpose of using these specific 
cytokines as well as anti-CD3 mAb was to induce T cells to proliferate several 
folds. Moreover, IFN-γ was used to induce the cytotoxic capability of these cells 
by the induction of IL-2 receptors on these cells before adding IL-2. Additionally, 
IFN-γ induces monocytes to produce IL-12 and up-regulate LFA-3 (CD58) which 
are essential for CD56+CD3+ cell expansion (Lopez et al. 2001). After that, 
adding IL-2 to these cells will result in activation of more cells even those that 
have not been activated by using IL-2 alone in LAK cell cultures. Also, 
integrating IL-2 genes into CIK cells has boosted IL-2 secretion when cultured 
with DC, that in turn improved CIK antitumour activity towards a pancreatic 
cancer cell line (Nagaraj et al. 2004). Moreover, the addition of IL-1α can enhance 
the cytotoxicity of the cells (Schmidt-Wolf et al. 1991). As a result of using these 
cytokines to generate these cells they are then named Cytokine-Induced killer 
cells or CD56+ T-cells. In this study CIK cells showed greater cytotoxicity 
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against B-lymphoma cells than LAK cells, and only slight cytotoxicity against 
mouse bone marrow stem cells and human haematopoietic engraftment (Schmidt-
Wolf et al. 1991). Moreover, the use of CIK cells against tumours does not require 
the administration of IL-2 into the host (Linn and Hui 2010). The higher 
capability of CIK cells than LAK cells can be due to the higher number of 
generated cells (Lu and Negrin 1994). CIK cell can also be generated from cord 
blood (Introna et al. 2006).  
CIK cells are phenotypically different from LAK cells and are CD3+CD56+; 
furthermore the levels of these cells in normal human peripheral blood are 
between 1% and 5%. However, during ex vivo expansion they are generated from 
CD3+CD56- cells and not generated from CD3-CD56+ cells in an ex vivo 
environment. CD56 acquisition is correlated with increased cytotoxicity of these 
cells. CD56 was acquired by lymphocytes in an ex vivo environment that already 
expressed the phenotype CD4+CD8+, CD4-CD8- and CD4-CD8+ after the cells 
were cultured with IL-2 and anti-CD3 mAb. However, CD4+CD8- cells did not 
acquire CD56 under these conditions (Lu and Negrin 1994). Among the expanded 
population of CIK cells the majority of the cells are CD8+ cells, moreover, 
CD3+CD56+ cells comprise almost 90% whereas the rest are CD3+CD56- cells 
and CD3-CD56+ cells (Sangiolo 2011); (Niam et al. 2011); (Hontscha et al. 
2011).  
CIK cells share some properties with NK cells such as the bulky granular 
morphology, killing targets in non-MHC restricted manner and the physical 
expression of CD56, and lectin-like glycoprotein NKG2A, CD94, NKG2C (Saikh 
et al. 2003) and NKG2D. However, CIK cells lack the NK cell markers NKp46, 
NKp44 and have only low expression of NKp30 (Pievani et al. 2011).  
 
- 34 - 
1.4.2 CD56+ T-cell functional capability combines that of T-cells and NK 
cells  
On the surface of CD56+ T-cells there are high levels of expression of TCR/CD3 
receptors. Studies involving stimulation of TCR/CD3 receptor using P815 tumour 
cells loaded with anti-CD3 monoclonal antibody led to the production of the 
cytokines IFN-γ and TNF-α. In addition, CD56+ T-cells retained antigen 
specificity when PBMCs from CMV seropositive donors were cultured for 21 
days after which the proliferated cells showed potent specificity when stained 
using CMV peptide loaded HLA-A*0201 tetramers. Furthermore, activated 
CD56+ T-cells that retained their specificity expressed the NK cell activation 
markers NKG2D, NKp30 and DNAM-1 that indicated the capacity of these cells 
to exert TCR specificity and NK cell killing capacity (Pievani et al. 2011).     
   
1.4.3 CD56 / neural adhesion molecule (NCAM)  
CD56 is a membrane glycoprotein and generally known to be a marker of NK 
cells and central nervous system (CNS) cells, however many studies showed the 
expression of this marker on T-cells and other types of cell. Moreover, this cluster 
of differentiation is not well studied. Some studies suggested a possible role in 
establishing effector to target cell adhesion and conjugation functions (Vergelli et 
al. 1996). CD56 is part of the Ig super-family and is a 140kDA isoform, which has 
six sites for N-linked glycosylation modified by polysialic acid (Pittet et al. 2000).  
CD8+ T-cell cytolytic effector activity has been found to correlate with increase 
in CD56 surface expression. Moreover, CD8+ T-cells with high levels of CD56 
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expression were found to have more IFN-γ and granzyme-B, also, direct cytolysis 
by CD8+ T-cells is conducted through CD8+CD56+ cells only (Pittet et al. 2000). 
As well as being expressed on neuronal tumours, CD56 has been found on several 
other tumours such as myeloma and myeloid leukaemia and anti-CD56 has been 
developed for purposes of antibody based applied immunotherapy of cancer 
(Jensen and Berthold 2007).  
 
1.4.4 CD56+ T-cell functions in infectious disease 
CD56+ T-cells have been studied for many years in relation to tumours; however, 
they have not been studied thoroughly with regards to microbial infection. Some 
studies have shown that CD56+T-cells increase during infection. Parasitaemia in 
malaria induced CD56+ T-cells to expand in patients more than healthy subjects 
(Watanabe et al. 2003) (Figure 1.2).  
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These cells were abundant in the liver of those patients infected with malaria 
(Watanabe et al. 2003). During influenza viral infection considerable numbers of 
CD8+ T-cells develop CD56 which was noted in mice (Assarsson et al. 2000); 
(Kambayashi et al. 2000), moreover, CD8+ T-cells develop NK cell associated 
molecules that may be involved in regulation of MHC-I-dependent T-cell effector 
functions (Kambayashi et al. 2000); (Slifka et al. 2000).  
CD4+CD56+ T-cells expand in response to Hepatitis B virus antigens restricted to 
MHC-II; also CD4+CD56+ T cells migrated to the nasopharynx in response to 
herpes simplex virus infection, consequently, these cells correlate with the 
adaptive immune response mechanism toward infection (Barnaba et al. 1994); 
 
Figure 1.2 CD56+ T-cells levels between healthy and malaria patients. Two 
colour scatter plots displaying the difference between the levels of CD56+ T-cells 
in healthy and two malaria patients infected with two different parasites. CD56+ T 
cells have expanded more in the patient infected with P. vivax than P. falciparum 
(Watanabe et al. 2003). 
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(Taddesse-Heath et al. 2003). Moreover, two days incubation with the 
superantigen staphylococcal enterotoxin B (SEB) of mononuclear cells purified 
from NK cells resulted in 3 fold expansion of CD56+ T-cells (Figure 1.3) (Saikh 
et al. 2003).  
CD4+CD56+ T-cells are abundant in the liver of mice, they produce IL-4 and 
furthermore can support Th2 cell development (Emoto et al. 1999). These cells 
shifted their IL-4 production to IFN-γ after infection by M. bovis BCG (Emoto et 
al. 1999). Increase of IFN-γ expression by CD56+ T-cells was also detected when 
PBMCs were cultured and stimulated with an EBV-transformed lymphoblastoid 
cell line (Fu et al. 2012). CD56+ T-cells also increased in HIV-positive Chinese 
offspring born from HIV infected mothers, moreover, the phenotype 
characteristics of the cells in HIV positive children showed down-regulation of 
 
Figure 1.3 CD56+ T-cell responses to SEB. Two color scatter plots showing 
CD56+ T cells after stimulation by SEB for two days at 37°C/ 5% CO2. The 
mononuclear cell population was depleted of NK cells, and a clear expansion of 
CD56+CD3+ cells from 5.8% (A) to 16%  (B) is seen (Saikh et al. 2003). 
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other NK cell markers: CD16, NKp80, NKp44, NKp30 and CD244 (Paiardini et 
al. 2005). Moreover, up-regulation of NKG2D, KIR3DL1and CD45RO was also 
observed on CD56+ T cells (Fu et al. 2012). CD56+ T-cells have also been found 
to enhance DC function; this was noticed when DCs from HIV positive children 
were incubated with CD56+ T-cells which induced the expression of CD83, CD86 
and CD80 on DCs more than co-culturing DCs obtained from HIV negative 
controls with CD56+ T-cells. Clearly, the previous finding show that CD56+ T-
cells are capable of inducing the maturation of DCs in an HIV positive 
environment, which also has indirect effects on other immune cells regulated by 
DCs (Fu et al. 2012).  
In normal adult liver, proportions of CD56+ T-cells were found to range from 
13.7% to 27.2% of total lymphocytes stained by anti-CD3 and anti-CD56 
conjugated antibodies. Moreover, after purifying these cells into three groups: 
CD56+CD3+, CD56+CD3- and CD56-CD3+ cells; only CD56+CD3- cells were 
capable of direct lysis of K562. Furthermore, inducing MNC obtained from 
normal adult liver by using PMA/ionomycin showed that both CD3+CD56- and 
CD3+CD56+ cells produced IFN-γ, TNF-α, IL-2 and IL-4. However, 
CD56+CD3- cells produced only IFN-γ and TNF-α (Figure 1.4) (Doherty et al. 
1999). 
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In contrast to the previous findings that showed increase percentages of CD56+ T-
cells in response to infection, CD56+ T-cells numbers have been found to 
decrease in hepatitis E virus (HEV) infected patients compared to healthy 
subjects. However, even though their numbers are reduced, the cells express 
 
Figure 1.4 Hepatic CD56+/- T-cell and NK cell cytokine response.  MNC 
obtained from the liver and stimulated with PMA/ionomycin, MNC were 
stained by three conjugated antibodies CD3, CD56 and the third colour for 
detection of intracellular cytokine; the latter is displayed in the histograms. The 
shaded histograms represent the un-stimulated negative control. NT cells are 
CD56+ T cells and the histograms show that these cells produced Th1 cytokines 
IFN-γ, TNF-α, IL-2 and the Th2 cytokine IL-4 but no IL-5 (Doherty et al. 
1999). 
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activation marker CD69 more strongly than healthy controls; this could be 
explained as these cells are migrating toward the liver which is the site of 
inflammation and also the clearance site of apoptotic cells (Srivastava et al. 2008). 
To clarify this, HEV seropositive patients were treated by IFN-α and it was found 
that NK cells in these patients started to express both CD69 and annexin-V, the 
latter being an apoptosis marker. Therefore, both NK and CD56+ T-cells migrated 
to the site of inflammation and their activation was due to activation-induced 
death of both NK and CD56+ T-cells which led to reduction in their number 
(Srivastava et al. 2008). Moreover, in HCV seropositive patients CD56+ T-cell 
levels were found to be non-significantly lower in patients than healthy subjects 
which was apparently due to continuous activation and apoptosis leading to a net 
reduction in total number of CD56+ T-cells (Lucas et al. 2003).  
 
1.5 Human Cytomegalovirus (HCMV) 
HCMV is the largest virus among human herpes-viruses family, which has a 
genome size of 235 kb encoding 165 genes. HCMV is a β-human herpes virus 
type 5, the envelope of this virus consists of a lipid bilayer that include several 
significant viral glycoproteins. Moreover, the envelope surrounds a virion 
composed of a linear double stranded DNA inside an icosahedral nucleo-capsid 
that surrounded by a proteinaceous matrix named the tegument  (Figure 1.5) 
(Crough and Khanna 2009); (Chen et al. 1999); (Mocarski 2007).  
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Figure 1.5 HCMV 3-D structures. This figure  illustrating different components 
of the virus (Crough and Khanna 2009). 
  
The virion diameter of HCMV ranges between 200–300 nm. The tegument 
section holds several large proteins, minor proteins and RNA of cellular and viral 
source (Crough and Khanna 2009); (Mocarski 2007); (Varnum et al. 2004). The 
large proteins such as that encoded by the UL48 gene and UL99-encoded pp28, 
also, the phospho-protein 65 (pp65) also named unique long 83 (UL83) are 
present abundantly and form the lower matrix. Moreover, the virion trans-
activator pp71 also known as unique long 82 (UL83) is present plentifully and 
forms the upper matrix protein. Furthermore, the large matrix phospho-protein, 
which is the herpes-virus, core virion maturation protein pp150 is encoded by the 
UL32 gene (Crough and Khanna 2009); (Varnum et al. 2004).  
The proteins of the tegument have several functions that assist in virus activities. 
These functions generally consist of assembly and disassembly of virions during 
virus invasion of the target cell. Also, other functions of the tegument proteins are 
to modify the target cell response and to control interaction of virus infection and 
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invasion (Crough and Khanna 2009); (Mocarski 2007). The target cell or the host 
cell provides a lipid bi-layer envelope enclosing the tegument, which is derived 
from endoplasmic reticulum and Golgi body. Moreover, the tegument has more 
than 20 glycoproteins encoded by the virus. These glycoproteins gB, gH, gL, gM, 
gN and gO are for cell attachment and penetration (Crough and Khanna 2009, 
Varnum et al. 2004). After cell invasion by the virus, synthesis of viral proteins is 
commenced in three phases, first is the immediate early (IE) which begins from 
zero time up to 2 hours after successful invasion, second is the delayed early 
between 2 hours after the invasion to 24 hours and the late phase at 24 hours after 
successful infection (Figure 1.6) (Crough and Khanna 2009); (Stinski 1978). 
 
1.5.1 Cytomegalovirus Transmission, Latency and Pathogenicity 
1.5.1.1 Transmission  
Human cytomegalovirus sero-positivity prevalence ranges between 30%-90% in 
developed countries, this also increases in developing countries and old people 
(Crough and Khanna 2009); (Staras et al. 2006). In healthy individuals HCMV 
mostly remains non-pathogenic in the latent state. However, in immune-
compromised patients, the fetus or in neonates HCMV can be reactivated and give 
rise to pathological sequelae. In addition, HCMV transmission occurs by several 
methods from infected individuals. HCMV can be transmitted by direct contact 
between body secretions or fluids such as saliva and blood, also, through organ 
transplantation. Moreover, it can be transmitted from the mother to baby by 
breast-feeding or during pregnancy via placental transfer (Crough and Khanna 
2009, Sia and Patel 2000).  
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Figure 1.6 HCMV invasion of the host cell. It commences via the endocytic 
pathway or by direct fusion; attachment to the host cell occurs by viral 
glycoproteins that bind to the host surface receptors. After that, nucleocapsids 
are released into the host cytoplasm as a result of the fusion between cellular 
membrane and virus envelope. Then, nucleocapsids migrate to the nucleus 
where virus DNA is released and the expression of virus genes starts, followed 
by viral replication, maturation and viral synthesis, and encapsulation of the 
viral DNA to form the capsids. Moreover, a second envelopment occurs in the 
ER-Golgi intermediate compartment and another two stages of envelopment 
before release of new viruses by exocytosis from the plasma membrane 
(Crough and Khanna 2009).    
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1.5.1.2 HCMV latency and reactivation  
HCMV latency mechanisms have been studied and examined in infected host 
cells via both in vitro and ex vivo experimental models. Some investigations 
suggested that HCMV proceeds to latency in the absence of active virus 
replication (Cheung et al. 2006); (Goodrum et al. 2002). UL138 viral sequences 
were the first viral sequences discovered to be very significant for HCMV latency, 
this was supported through studies on CD14+ monocytes and CD34+ progenitor 
cells in HCMV sero-positive individuals (Crough and Khanna 2009); (Goodrum 
et al. 2007). The mechanisms of latency may start upon virus access to the body 
and proceed to the latent phase without viral gene expression. Furthermore, the 
virus expresses genes necessary for effective latency upon entry and may not 
express genes required for infection. Also, disturbance of active HCMV infection 
after virus entry leads to advancement into the latency phase (Crough and Khanna 
2009);  (Cheung et al. 2006); (Goodrum et al. 2002); (Kondo et al. 1994); (Reeves 
et al. 2005). Additionally, granulocyte-macrophage progenitor (GMP) infection 
with HCMV induces virus latency-associated transcripts encoded in the MIE 
promoter region of the genome of HCMV, and also detected in seropositive 
healthy individuals, though this type of infection was not successful for in vitro 
infection (Crough and Khanna 2009); (Kondo et al. 1994); (Kondo and Mocarski 
1995); (Kondo et al. 1996); (Landini et al. 2000); (White et al. 2000). Transcripts 
of the UL111.5A region that encodes a variant IL-10 homologue were detected in 
latently infected GMP cells, in naturally infected bone marrow cells and in 
granulocyte colony stimulating factor (G-CSF) mobilized peripheral blood 
samples collected from allograft donors (Crough and Khanna 2009); (Jenkins et 
al. 2004). However, the mechanism of change from the latency phase to 
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reactivation is still unclear, nevertheless, HCMV reactivates during situations of 
stress, infection, immunosuppression and inflammation (Crough and Khanna 
2009); (Kutza et al. 1998); (Mutimer et al. 1997); (Prosch et al. 2000). Moreover, 
several other factors can facilitate a change of HCMV status from latency towards 
the reactivation phase such as TNF-α, catecholamines, norepinephrine and 
epinephrine. Moreover, TNF-α has a significant role in the reactivation process of 
HCMV, as the HCMV IE enhancer/promoter region is found to be induced by 
TNF-α. Correspondingly, TNF-α binds to TNF receptor on CMV-infected cells, 
leading to protein kinase C and NF-kB activation (Crough and Khanna 2009); 
(Prosch et al. 1995); (Stein et al. 1993). Cyclic AMP (cAMP) induces the 
stimulation of IE enhancer/promoter leading to HCMV reactivation where cAMP 
concentration rises due to stress, epinephrine, norepinephrine and pro-
inflammatory prostaglandins (Crough and Khanna 2009);  (Varnum et al. 2004); 
(Kline et al. 1998). 
 
1.5.1.3 HCMV Pathogenicity  
CMV is a potent immunogen that activates the immune system rapidly. HCMV 
can cause serious health problems in individuals with non-developed immune 
systems or who are immunocompromised. However, CMV hardly causes any 
health problems in healthy individuals.  
 
1.5.1.3.a Solid Organ Transplantation (SOT) 
In solid-organ transplantation, HCMV activation in immunosuppressed recipients 
can lead to undesired outcomes such as viremia from HCMV and other 
opportunistic pathogens, damage to the graft leading to rejection, and mortality 
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(Table 1.1). HCMV infection is a major risk factor for failure in graft adaptation 
in recipients resulting from direct and indirect clinical effects of HCMV activation 
leading to graft rejection. Additionally, preventive methods were found to reduce 
the danger of HCMV infection in SOT patients, however, late-onset HCMV 
viraemia can lead to graft rejection and mortality in liver transplantation (Eid and 
Razonable 2010); (Helantera et al. 2006). The most significant risk group during 
transplantation is when transplanting an organ from an HCMV sero-positive 
donor to a recipient who is HCMV sero-negative (D+/R-) (Crough and Khanna 
2009); (Limaye et al. 2002); (Rubin 2007). Generally, organ recipients acquire 
HCMV infection as a primary type when the virus is transmitted through an 
infected organ from an HCMV sero-positive donor. This also occurs when the 
donor has active HCMV infection, or when latent HCMV reactivates in the 
recipient due to the immune-suppressed status (Eid and Razonable 2010).    
Morbidity in SOT due to HCMV infection is high and several prevention methods 
have been introduced to reduce HCMV infection in transplanted organ recipients 
by using anti-viral prophylaxis and pre-emptive treatment (Eid and Razonable 
2010); (Razonable and Paya 2003). In HCMV sero-negative recipients, 
nonexistence of previous immunity to HCMV assists the virus to replicate, when 
receiving an organ from HCMV sero-positive donor. This is also facilitated by the 
immune-suppressed status of the recipient (Eid and Razonable 2010). The high-
risk group (D+/R-) continues to develop HCMV infection (38%), usually after 
completion of the anti-viral course, and this type of HCMV infection is called 
late-onset (Eid and Razonable 2010); (Arthurs et al. 2008); (Arthurs et al. 2007); 
(Kijpittayarit-Arthurs et al. 2007), and several studies state that this type of late-
onset infection is the reason behind a high proportion of cases of graft rejection 
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and mortality (Eid and Razonable 2010); (Limaye et al. 2006, Arthurs et al. 2008). 
This is also supported by the absence of HCMV-specific T-cell-immunity to 
counteract virus replication (Eid and Razonable 2010); (Kumar et al. 2009). Also, 
deficient T-cell mediated immunity against HCMV is a consequence of 
introducing immune-suppressive medication following the transplantation process 
that leads to depletion of lymphocytes for a period of time which HCMV uses to 
begin its replication; examples of these medications are Muromonab-CD3 (OKT-
3) and Anti-thymocyte Globulin (Eid and Razonable 2010); (Razonable and Paya 
2003). The use of this immune-suppressive medication is essential in order to 
prevent immediate acute graft rejection, however HCMV activation is a major 
drawback of these medications (Razonable et al. 2001). Moreover, CMV was 
found to play a critical part in promoting acute graft rejection, immune-
modulation and up-regulation of alloantigen, enhancing the rejection process. 
Moreover, acute rejection of the graft promotes CMV activation; this is due to 
administration of anti-rejection treatment therefore to prevent CMV from re-
activating an anti-CMV prophylaxis should be administered as well (Eid and 
Razonable 2010); (Peleg et al. 2007a).  
SOT recipients who show CMV activation can suffer major symptomatic disease 
or can show asymptomatic features and these depend on the degree of immune-
suppression of the recipient where strong immune-suppression results in less 
capability to inhibit CMV activation (Eid and Razonable 2010). There are direct 
and indirect clinical impacts of CMV activation in SOT (Table 1.1).  
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Table 1.1 Direct and indirect clinical effects caused by HCMV activation in 
SOT (Eid and Razonable 2010). 
 
The direct effects of CMV syndrome are symptoms resembling virulent 
mononucleosis infections such as fatigue, body pains, fever, diarrhea and 
myelosuppression (Table 1.1). Some SOT recipients suffer from CMV invasive 
disease and that can occur in all types of organ transplantation, and is common in 
the gastrointestinal tract, CMV-induced ulceration leading to hemorrhage, 
diarrhea, and perforation (Eid and Razonable 2010, Eid et al. 2010). Indirect 
clinical impacts of CMV infection in SOT recipients are caused by several 
subsidiary effects due to the modulation of the immune system (Razonable and 
 Type of morbidity caused due to HCMV infection 
  
 Direct effects  Indirect effects 
CMV disorder 
 Fever, myalgia,                        
 arthralgia 
 myelo-suppression 
Tissue-invasive CMV disease 
 Gastrointestinal disease 
 Hepatitis 
 Pneumonitis 
 CNS disease 
 Retinitis 
 Nephritis 
 Pancreatitis 
 Carditis 
  
Acute rejection 
Chronic rejection 
 Bronchiolitis obliterans 
 Transplant vasculopathy 
 Tubulointerstitial fibrosis 
Immunosuppression leads to co-
infection with opportunistic pathogens 
 Fungal infections 
 Bacterial infections  
 (nocardiosis, listeriosis) 
 Viral infections (HHV-6,  
 HHV-7, HCV) 
 Viral-associated neoplasia  
 (PTLD) 
New-onset diabetes mellitus 
Mortality 
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Paya 2003). Therefore, opportunistic pathogens infect SOT patients at the same 
time of CMV infection activation, an example of these pathogens are fungi (Husni 
et al. 1998), bacteria such as Nocardia spp (Peleg et al. 2007b) HHV-6, HHV-7, 
hepatitis C and EBV (Eid and Razonable 2010). SOT patients who develop CMV 
infection or fail to obtain successful CMV preventive treatment are far more likely 
to undergo chronic or acute graft rejection in lung transplantation and in heart 
transplant recipients (Eid and Razonable 2010); (Fearon et al. 2007); (Hussain et 
al. 2007); (Ozdemir et al. 2007); (Thomas et al. 2009).  
 
1.5.2 Immune response to CMV infection 
1.5.2.1 Innate Immunity 
The innate immune system differs from the adaptive immune system in being 
non-specific, generic and also for being rapid and represents the first line of 
defence against foreign pathogens. Also, the innate immune system assists in 
priming the response of the adaptive immune system. Pattern recognition 
receptors (PRRs) are involved in the recognition of CMV, they can detect 
pathogen associated molecular patterns (PAMPs), which are specific small motifs 
conserved in microbes such as bacterial lipopolysaccharide (LPS) that is 
recognized by TLR4. 
 
1.5.2.2 Natural Killer (NK) cells  
During HCMV infection, NK cell function and number have been reported to 
increase (Coudert et al. 2010); (Hokland et al. 1988); (Venema et al. 1994) and 
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patients who suffer NK cell deficiencies are at risk of recurrent HCMV and HSV-
1 infection (Coudert et al. 2010); (Orange and Ballas 2006). When HCMV infects 
cells, it down-regulates the expression of class I MHC (HLA) on the surface of 
these cells, leading to NK cells initiating the cytotoxic process (Iversen et al. 
2005); (Lodoen and Lanier 2005). Nevertheless, immune evasion strategies of 
CMV have advanced to overcome NK cells killing strategies by producing UL-40 
glycoprotein that can induce the expression of HLA-E which interact with the 
cognate inhibitory receptor of the NK cell, CD94-NKG2A (Iversen et al. 2005); 
(Tomasec et al. 2000); (Wang et al. 2002). Adoptive transfer of NK cells led to 
postulation of an innate protection role against MCMV and assistance in the 
clearance of experimental MCMV infection (Crough and Khanna 2009); (Polic et 
al. 1998); (Bukowski et al. 1985); (Bukowski et al. 1983), furthermore, some mice 
strains have shown resistance toward MCMV and they become infected with 
MCMV when NK cells are depleted (Figure 1.7) (Crough and Khanna 2009); 
(Scalzo et al. 1990); (Scalzo et al. 1992). 
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Figure 1.7 MCMV infections in three different mice strains. (A) no signal for 
activation of NK cells is available. (B) reduction in MHC-I due to CMV infection 
leading to activation of NK cells and killing of the cell. (C) even the infected cell 
is recognized however due to the strong inhibitory signal of Ly49 no killing by 
NK cells is started. (D) in this mouse strain NK cells lack Ly49, even though 
MHC-I is reduced however activating receptors cannot recognize the infected cell 
therefore NK cell is not activated and the cell survives (Jensen and Berthold 
2007). 
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1.5.2.2.a Missing self-hypothesis (Reduction in MHC-I expression) 
NK cell function is regulated by a group of activating and inhibitory receptors. 
Moreover, MHC-I is the traditional ligand for inhibitory receptors of NK cells. 
Additionally, the inhibitory receptors that prevent NK cells from confronting self-
cells are KIRs, LIR, NKG2A/CD94 and in mice Ly49 (Coudert et al. 2010). If the 
inhibitory receptors of NK cells were not able to detect MHC-I, this would 
activate NK cells (Coudert et al. 2010). CMV has the ability to encode several 
genes that modulate the expression of MHC-I, these genes are US2, US3, US6 
and US11 (Table 1.2) (Coudert et al. 2010); (Hengel et al. 1999). In mice, MCMV 
encodes three viral genes that affect the surface expression of H-2 or MHC-I and 
they are M152, M06 and M04 (Coudert et al. 2010) 
 
1.5.2.2.b Self cells expression of self-induced Ligands  
The NKG2D receptor is expressed by NK cells in both mice and humans and is 
encoded by the KLRK1 gene; the function of this receptor is to activate NK cells 
after it binds to a family of ligands called the stress induced proteins. Moreover, 
stress induced proteins are expressed on cells that are infected or under genomic 
stress, such as in cancer. The stress induced proteins are for example in mice Rae-
1, Mult-1 and H-60, and MICA, MICB and ULBP 1 to 6 in humans (Coudert et al. 
2010). NKG2D in humans is different in structure than mice where it exists with 
one long NKG2D isoform that initiates an activating signal through DAP10, and 
in mice as two isoforms (Coudert et al. 2010). CMV has evolved in mice and 
humans in order to evade the binding of NKG2D+ NK cells to the expressed 
ligands on CMV infected cells. These evasions strategies act to prevent NKG2D 
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binding to the ligands by encoding immune evasion genes in human and mice’ 
also, by obstructing the surface expression of NKG2D ligands through the 
encoding microRNAs (Coudert et al. 2010).  
 
1.5.2.3 Adaptive Immune response  
The immune system has two mechanisms to fight the infection and protect the 
body. The specific immune system or the adaptive immune system comprises the 
humoral response mediated by B-cells and the secretion of antibodies and cell-
mediated immunity that involves activation of T-cells, macrophages and cytokine 
secretions. The most important feature of the adaptive immune response is the 
building of immunological memory from previous infection, which protects the 
body from future recurrent infection.  
 
1.5.2.3.1 Humoral Response to CMV 
CMV glycoproteins gB and gH are the major targets for neutralizing antibodies 
(Crough and Khanna 2009); (Rasmussen et al. 1991); (Mathew et al. 2001, Britt et 
al. 1990). Immunization with immune-affinity-purified gB induced the production 
of immunoglobulin to neutralize CMV (Gonczol et al. 1990), also, recombinant 
gB induced the production of neutralizing immunoglobulin but this immune-
memory did  not last for a long period (Frey et al. 1999); (Pass et al. 1999). 
Antibodies against HCMV in babies have been transferred from sero-positive 
mothers to infants and have proven to protect the infants from HCMV infection 
(Crough and Khanna 2009, Yeager et al. 1981).  
 
- 54 - 
1.5.2.3.2 T-cell-mediated immune responses 
CMV is an opportunistic pathogen causing infection in immunocompromised 
individuals and patients. The immune system reacts mostly to CMV infection 
through cell-mediated-immunity  and the participating immune cells are CD8, 
CD4 and γδ T cells specific to CMV (Crough and Khanna 2009).  
 
1.5.2.3.2.a  γδT-cells in response to CMV 
γδ T-cell levels were noticed to be elevated in renal transplant recipients during 
effective HCMV infection, in which the levels of γδ T-cells reached about 40% in 
blood, and the cells further expanded in response to increase in the severity of the 
infection (Crough and Khanna 2009); (Dechanet et al. 1999a); (Lafarge et al. 
2001). In mouse models, γδ T-cell depletion resulted in a rise in MCMV infection 
(Crough and Khanna 2009); (Ninomiya et al. 2000). Also, MCMV infection led to 
increased γδ T-cell numbers in salivary glands (Crough and Khanna 2009); 
(Cavanaugh et al. 2003).  
 
1.5.2.3.2.b  CD8 + T cells in response to CMV 
In mouse models, lymphocyte depletion led to reactivation of viruses such as 
MCMV; adoptive transfer of CD8+ T-cells provided protection against MCMV 
which assisted in clarifying the significant role of CD8+ T-cells in preventing the 
reactivation of pathogens such as MCMV (Crough and Khanna 2009); (Mutter et 
al. 1988); (Polic et al. 1998); (Reddehase et al. 1985). In humans, it was noted that 
HCMV could be reactivated in individuals deficient in CD8+ CMV-specific T 
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cells (Crough and Khanna 2009) and HCMV specific-CD8+ T-cells have been 
noted to provide protection against viraemia in several groups of transplant 
patients such as BMT, lung and SOT (Riddell et al. 1992b); (Li et al. 1994); 
(Quinnan et al. 1982). It is estimated that healthy CMV+ individuals can have 
about 10% HCMV-specific-CD8+ T-cells, and this percentage increase to 40% in 
the elderly in a process called memory inflation (Crough and Khanna 2009); 
(Crough et al. 2007); (Gillespie et al. 2000); (Khan et al. 2004); (Sylwester et al. 
2005). Additionally, CD8+ T-cells that are specific for the HCMV IE-1 protein 
were detected in lung and heart transplant recipients and found to provide a 
protective role against HCMV reactivation (Bunde et al. 2005). Furthermore, 
obtaining both HCMV-specific CD8+  and CD4+ T-cell immunity assisted in 
preserving successful lung allograft function and stability, in contrast to those who 
developed HCMV infection due to the failure of developing competent CD8+ T-
cell immunity against HCMV (Shlobin et al. 2006). Primary HCMV infection in 
utero induced foetal CD8+ T-cells to expand in response to CMV infection 
(Marchant et al. 2003). CD8+ T-cells specific for HCMV have been shown to 
have significant function in recovery from HCMV reactivation in bone marrow 
transplant patients (BMT) (Quinnan et al. 1982); (Radha et al. 2005, Reusser et al. 
1991); (Li et al. 1994). Furthermore, HCMV specific CD8+ T-cells restored 
cellular specific immunity against HCMV when obtained from donors with 
HCMV-specific-CD8+ T-cells and infused into allogeneic BMT recipients 
(Riddell et al. 1992b); (Walter et al. 1995). In renal transplant patients, CD8+ T-
cells specific to CMV provided protection against viral reactivation (Radha et al. 
2005, Reusser et al. 1999, Sester et al. 2005). Distinct epitopes are targeted by 
HCMV-specific-CD8+ T-cells that include immune modulators encoded by the 
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virus such as pp28, pp150, and several structural and replication antigens such as 
IE, early, early-late and late virus antigens and functions-associated-proteins such 
as capsids and immune evasion proteins (Elkington et al. 2003); (Manley et al. 
2004); (Sylwester et al. 2005).    
 
 
 
Figure 1.8 CD4 + and CD8+ T cell responses to HCMV. A) the pie graphs 
represent the response of CD4+ and CD8+ T cells to HCMV proteins encoded 
through the virus replication process (IE, early, early-late, and late; left) and HCMV 
proteins correlated with diverse functions (capsid, matrix/tegument, glycoprotein, 
DNA/regulatory, and immune evasion; right). B) Schematic representation of the 
magnitude of CD4+ and CD8+ T-cell responses against immune-dominant HCMV-
encoded ORFs such as UL123 (IE-1), UL122 (IE-2), and UL83 (pp65) (Crough and 
Khanna 2009). 
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Studies of CD8+ T cells during HCMV acute and chronic infection have revealed 
during acute infection CD8+ T cells are CD45RA-, CD45RO+, CD27+, CD28+/- 
and CCR7-. Moreover, during chronic infection two types of HCMV-CD8+ T 
cells co-exist, effector memory and terminally differentiated cells; the first are 
CD45RA-, CD45RO+, CD27-, CD28-, CCR7- and the terminally differentiated 
cells are CD45RA+, CD45RO-, CD27-, CD28-, CCR7- (Appay et al. 2002); 
(Gamadia et al. 2003). Additionally, a study indicated that the expansions of 
HCMV-specific CD8+ T cells are oligo-clonal with some clones displaying the 
CD28-, CD57+, and CCR7- phenotype of differentiated effector memory cells 
(Khan et al. 2002). The clonal expansion of HCMV specific CD8+ T cells may 
lead to domination of these HCMV specific cells and may hinder the immune 
response toward other pathogens; this is supported by the findings connecting 
lower success of influenza vaccination with HCMV sero-positivity, and also 
HCMV being a factor that assists the advance of AIDS (Sabin et al. 2000, 
Webster et al. 1989).  
 
1.5.2.3.2.c CD4+ T cells in response to CMV 
T helper lymphocytes have significant and central roles in directing the adaptive 
immune system. They produce a variety of cytokines and chemokines with several 
immune functions, play an important role in B-cell antibody class switching, 
inducing phagocyte functions, assisting the growth of cytotoxic T-cells and 
attracting neutrophils, basophils and eosinophils to the infection site. The median 
frequency of HCMV-specific CD4+ T-cells in the blood is about 9% and in some 
individuals this  rises to 40% (Sylwester et al. 2005); (Sester et al. 2002).  
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In murine studies, repeated infection with MCMV resulted in mice undergoing 
CD4+ T-cell depletion (Polic et al. 1998), also, the role of CD4+ T-cells to 
regulate MCMV infection was noted after depletion of CD8+ T-cells (Jonjic et al. 
1994). The role of HCMV-specific- CD4+ T-cells was revealed when clinical 
complication of HCMV infection appeared in lung transplant recipients following 
acute deficiency of HCMV-specific-CD4+ T-cells, and this was also noted in 
renal transplant recipients (Sester et al. 2002); (Sester et al. 2005). During the 
latent status of the virus HCMV-specific-CD4+ T-cells assist indirectly to induce 
B-cell production of antibodies and expansion of cytotoxic CD8+ T-cells (Walter 
et al. 1995); (Davignon et al. 1996). Also, the recovery of CD4+ T-helper cells is 
essential for the reconstitution of cytotoxic CD8+ T-cells (Reusser et al. 1991). 
The importance of effector memory CD4+ T-cells to control HCMV was further 
studied in renal transplant recipients. A longitudinal study showed that the 
HCMV-specific- CD4+ T-cell response was hindered in symptomatic compared 
to asymptomatic recipients following HCMV infection, suggesting a significant 
role of these cells in regulating recovery from HCMV infection (Gamadia et al. 
2003). In BMT patients, helper T-cells were shown to help in protection from 
HCMV infection as long they were present in detectable quantities (Hebart et al. 
2002); (Krause et al. 1997); (Li et al. 1994). Another study suggested that CD8+ 
T-cell activation required the assistance of CD4+ helper T-cells; in this study 
predominantly HCMV-specific-CD4+ T-cell lines were infused into the seven 
patients and five showed progression in clearing HCMV infection, moreover, the 
infusion of HCMV-specific-CD4+ T-cells lines was followed by expansion of 
CD8+ T-cells (Einsele et al. 2002). Furthermore, the study of HCMV-specific-
CD4+ T-cell specificity showed the capability of gB and gH and several other 
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antigens to be recognised as frequent targets of HCMV (Figure 1.8) (Sylwester et 
al. 2005). Likewise, antigen presenting cells (APC) that present endogenous gB to 
CD4+ T-cells resulted in production of granzyme-B (Hegde et al. 2005); an 
immune-dominant peptide epitope of gB-specific CD4+T-cells is 
DYSNTHSTRYV restricted to HLA DRB*0701 (Elkington et al. 2004).  
 
1.5.3 CMV immune-evasion 
The Herpesvirus family has developed several strategies to evade both the innate 
and adaptive immune systems during the life cycle of the virus in the body. CMV 
specific evasion strategies assist in maintaining the existence of the virus inside 
the body between active and dormant states. These techniques of evasion can 
cause minor effects in healthy seropositive individuals when the virus reactivates, 
however, in immune-compromised or immune-suppressed individuals the virus 
can cause major health impacts and can lead to mortality. CMV has acquired 
genes homologous to host genes that occupy about 20% of the total CMV genome 
and can encode components of the host immune response such as MHC-I, 
cytokines and chemokines, extracellular and intracellular receptors (Loenen et al. 
2001). MHC-II that is generally expressed by APCs is also affected by the CMV 
gene US2 via several methods; US2 can degrade DR-α and DM-α and also MHC-
II induced expression by IFN-γ is interfered with by the expression of the protein 
during immediate early and early CMV infection (Loenen et al. 2001); (Crough 
and Khanna 2009).  
Non-classical HLA-E binds to CD94/NKG2A and suppresses the activation of 
NK cells. CMV, however, reduces the expression of classical MHC-I on the 
surface therefore to evade CTL lysis, while the CMV gene UL-40 induces the 
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expression of HLA-E on the cells infected with the virus and protects them from 
NK cell attack (Loenen et al. 2001); (Tomasec et al. 2000).   
 
1.5.3.1 CMV genes homologous to host genes  
CMV has evolved to acquire genes that are homologous to host genes with 
potential roles in the immune response to the virus. MHC-I of the host has a 
homologous gene in CMV named UL18 that binds to leucocytes immunoglobulin 
like receptor 1 (LIR-1) and can inhibit several immune cells that express the 
ligands CD94/NKG2 such as NK cells and T-cells and including B-cells, DC and 
γδ T-cells. UL33, UL78M, US28 and US27 are homologues to G protein coupled 
chemotactic cytokine receptor or chemokine receptor 1 (CCR1) that has an 
essential role in directing and migrating cells to the site of the infection and 
inflammation (Loenen et al. 2001); (Lalani et al. 2000); (Beisser et al. 1999). 
UL111A is homologous to IL-10 and the potential functions of this gene are to 
inhibit cytokines IFN-γ and IL-12 and immune cells such as DC (Loenen et al. 
2001). The viral gene UL144 encodes a tumor necrosis factor receptor super gene 
family (TNFR) homologue that stimulates several subsets of lymphocytes 
(Loenen et al. 2001). Mutually UL146 and UL147 are homologous to IL-8 and 
have a role in lymphocyte trafficking to the site of inflammation and infection. 
Research correspondingly is expecting to discover genes that induce FcR on cells 
invaded by CMV and can protect the cells from antibody mediated immune 
response that leads to elimination of cells hosting this virus (Loenen et al. 2001); 
(Farrell et al. 1999).   
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1.5.3.2 CMV evading detection by Cytotoxic T cells 
Peptides from intracellular antigen are degraded by proteasomes into short 
peptides 8 to 12 amino acids in length which are presented on MHC-I and can be 
recognized by CD8+ cytotoxic T cells. In order for HCMV to evade CTL it has 
evolved to acquire several different gene products: gpUS2, gpUS3, gpUS6, 
gpUS10 and gpUS11, furthermore, MCMV encodes three genes that interfere 
with MHC-I intracellular trafficking and their mechanisms of action are quite 
different from HCMV US genes; they are: m04, m06 and m152 (Loenen et al. 
2001); (Crough and Khanna 2009). These gene products perform a variety of 
function and are expressed at several time points to interfere with MHC-I 
production and expression. US2 is an early gene that binds MHC-I in the ER and 
rapidly reduces the life-span of MHC-I from about six hours to less than two 
minutes (Loenen et al. 2001); (Tortorella et al. 1998). Next is US3, an immediate 
early gene that holds MHC-I inside the ER by binding to heavy chain/β2m 
complexes, though it does not block peptide binding to MHC-I (Loenen et al. 
2001); (Jones et al. 1996). US6 appears later beyond the expression of US2 and 
US3 and remains expressed by the virus through its life span, this gene affect the 
loading of the peptides on MHC-I inside the ER (Jun et al. 2000). Another early 
gene is US11 that functions to retain MHC-I in the cytoplasm of the cell (Wiertz 
et al. 1996).  
 
1.6 Kidney Transplant Rejection 
Renal transplantation is the favoured method of treatment for patients at end-stage 
renal failure or patients with established renal failure. This treatment provides 
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many advantages that overcome the long repeated haemodialysis, which is high in 
cost and in general can transmit infection to the patients under repeated 
haemodialysis. Moreover, patients under repeated courses of haemodialysis are in 
danger of pain and mortality. The survival of the kidney is dependent on not being 
rejected by the immune system so to avoid short-term kidney rejection requires 
the use of immunosuppressive therapy (Issa et al. 2010). Rejection of a 
transplanted organ by the immune system is a general reason leading to graft 
failure. Even though the organ donor is selected after satisfying several criteria to 
match the recipient, rejection may occur and can lead to several adverse 
complications in both the graft and the body of the recipient.  
The treatment to tackle allograft rejection was directed toward inhibiting T cell 
immune responses, due to the belief that T cell-mediated responses lead to 
inflammation and that have been alleged for more than half a century to be the 
main reason behind allograft rejection. These treatments managed to prolong graft 
survival but were not able to stop acute and chronic graft rejection which through 
immunohistochemical visualisation techniques provided evidence of cell- 
antibody- and complement-mediated damage leading to graft rejection (Gonzalez 
and Torres-Lopez 2012). The binding of receptors to their corresponding ligands 
such as LFA-1 (ICAM-1), CD40-CD40L and CD28-B7 are important to trigger 
the T-cell dependent immune response. Additionally, long term-survival of the 
graft can be achieved by blockade of these interactions, promoting graft tolerance 
(Seino et al. 2001). 
Donor MHC can be targeted by recipient T cells through two mechanisms of 
recognition, the first is through direct allorecognition in which T cells directly 
recognise donor MHC and target it. The other process is called indirect 
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allorecognition in which recipient APC take up donor alloantigen and present it to 
T cells, initiating an immune response against the graft (Gonzalez and Torres-
Lopez 2012). Also, alloantibodies targeting non-classical MHC-I alloantigens 
MICA and MICB have been recognised as one cause of acute renal allograft 
rejection (Sumitran-Holgersson et al. 2002); (Zou et al. 2006, Mizutani et al. 
2005). MHC-II DR and DQ are only expressed on APC and B cells and can 
stimulate the development of alloantibodies and T cells activation; MHC-II is also 
found on micro-vascular endothelial cells (Erlich et al. 2001).  
The rejection mechanism of kidney transplants results from interactions between 
innate and adaptive immune systems. Additionally, the outcome of this interaction 
is hyperacute, chronic or acute graft rejection by the immune system (Issa et al. 
2010).     
 
1.6.1 T cells and B cells interface and generation of alloantibodies  
The assistance of neighbouring T cells is essential for B cells in order to generate 
high affinity antibody. As APC present antigen to T cells, a general change in T 
cell shape arises and is followed by up-regulation of chemokine receptor CXCR5 
(von Andrian and Mackay 2000, Ono et al. 2003). T cells then respond to 
chemokine CXC13 and migrate toward B cells located in primary follicles (Ono et 
al. 2003). This is followed by B cells becoming activated and acquiring CCR7 
that interacts with both CCL19 and CCL2 chemokines and then B cells express 
antigenic peptide on MHC-II (Zinkernagel and Doherty 1997), that, specifically, 
in a transplantation situation is derived from donor MHC. B and T cells, after that, 
extend their contact surface area to allow thorough communications between their 
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receptors and other ligands (Huppa and Davis 2003). B cell presentation of 
peptide to T cells through the MHC-II groove leads to generation of efficient 
antibodies against this peptide. The bridging between B and T cells is further 
improved due to other links to allow the production of first signal in which CD4+ 
T-cells bind to MHC-II molecules at the non-polymorphic region. This is 
followed by high affinity binding between LFA-1 (CD11a-CD18) of T cells and 
its ligands or intercellular adhesion molecule (ICAM-CD54) on B cells which 
strengthen the bridge between T and B cells (Joosten et al. 2002). After that, the 
antigen bridge relocates centrally to trigger the signal between T and B cells 
(Scholl and Geha 1994).     
 
1.6.2 T-cell role in graft rejection and graft tolerance  
T-cell immune surveillance recognises the graft either directly or through 
allorecognition of donor peptides, followed by T-cell activation. Furthermore, 
effector responses triggered by T cells direct the immune system toward this graft 
leading to damage to or rejection of this graft (Issa et al. 2010). Allogeneic 
transplantation of organs is always under the direct danger of acute and chronic 
rejection that is directed by CD4+ and CD8+ T-cells (Issa et al. 2010). T-cells 
allorecognition of the mismatched MHC or alloantigen of the graft follows by 
their activation in the presence of the costimulation signal required by T-cells 
(Issa et al. 2010). Activation of T-cells leads to their expansion to generate allo-
reactive T-cells against the graft (Issa et al. 2010).      
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1.6.2.1 The allorecognition process 
Mismatch in MHC between the graft and the recipient is the first trigger to initiate 
the immune response. Generally, allorecognition is defined as the process of 
detecting non-self-antigen although this antigen is from the same species as the 
host or graft recipient (Issa et al. 2010). In addition to polymorphic MHC, 
allorecognition can occur with minor histocompatibility antigens (miH). The latter 
are defined as peptides from allelically polymorphic proteins other than the 
donor’s MHC antigens, and further expressed by MHC of the host or recipients to 
T-cells of the host (Issa et al. 2010, Game and Lechler 2002). Multiple miH 
mismatches between the graft and the recipient can evoke the host immune 
response against the graft leading to damage and rejection, which can speed up the 
rejection process if MHC is mismatched as well (Issa et al. 2010). Moreover, miH 
can evoke a slow rejection process even when MHC of the graft is compatible to 
the recipients (Dragun and Hegner 2009). Minor-histocompatibility antigens can 
be presented on both MHC-I and –II and have been encoded in both human (such 
as HA-2 antigen derived from myosin class I and restricted to HLA-A2) and mice 
(about 40 miHs identified) on sex chromosomes, DNA of mitochondria and 
autosomes (Game and Lechler 2002). Instead of MHC-I presenting self antigen to 
T cells to inhibit their cytotoxic activity, in case of transplantation the antigen 
from the graft is presented to T cells by self-MHC-I and this method is defined as 
indirect allorecognition. Moreover, APC from the donor migrating from the graft 
can present the donor self antigen to TCR of T-cells of the recipient which 
triggers the activity of T-cells and this way is defined as direct allorecognition. 
The third pathway is defined as semi-direct allorecognition pathway where APC 
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of the recipient present the donor antigen to TCR of T-cells of the recipient (Issa 
et al. 2010).  
 
1.6.2.1.a. Direct allorecognition pathway 
This allorecognition pathway was believed to be the single method of 
allorecognition of graft antigen, which led to immune responses toward the graft 
and maybe followed by rejection (Figure 1.9:A) (Afzali et al. 2007). The specific 
nature of the ligand that stimulates alloreactive T-cells is unclear however two 
theories have been suggested regarding the method of allorecognition of 
alloantigen on MHC-I molecule. The first hypothesis called high determinant 
density, which implies the capability of alloreactive T-cells to recognise the clear 
polymorphism of any allogeneic MHC and the peptide that is expressed in the 
groove of this allogeneic MHC is less priority (Afzali et al. 2007, Game and 
Lechler 2002) 
Therefore, any non-self MHC will be addressed by TCRs of alloreactive T-cells 
as ligands, this however results in high number of allogeneic non-self MHC as 
ligands capable of triggering the immune response against the graft. In addition, 
even TCRs of lower affinity will respond against non-self-polymorphic MHC 
(Game and Lechler 2002, Afzali et al. 2007). What supports this hypothesis is the 
incidence of alloreactivity even in the absence of the peptides, moreover, there are 
several studies that show blocking (Schneck et al. 1989) or site mutation 
(Villadangos et al. 1994) of TCR and MHC contacting regions would inhibit the 
generation of an alloresponse (Game and Lechler 2002, Afzali et al. 2007). The 
other hypothesis is the multiple binary complex model that proposes that T-cell 
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alloreactivity is due to the non-self peptide expressed in the groove of MHC-I; 
this hypothesis claims that even a single non-self peptide is capable of inducing 
many T-cells against this peptide; this hypothesis was explained by the occurrence 
of alloreactive CD8+ T cells toward self-antigen expressed in the groove of a non-
self MHC-I molecule (Whitelegg et al. 2005); Game and Lechler 2002, Afzali et 
al. 2007). Both hypotheses do not comply with the concept of thymic positive 
selection, but the resemblance of several alleles of MHC at the TCR contact 
region permit the probability of alloresponse in the context of positive selection 
(Game and Lechler 2002).  
Several attempts have been made to avoid direct allorecognition and expand the 
survival period of the graft, for example by purifying the graft from leucocytes via 
depleting the donor of leucocytes. In addition, rat kidney transplantation studies 
have managed to reach the point of thorough tolerance by the recipient immune 
system toward the kidneys; this was achieved after transplanting the kidneys into 
an intermediate recipient for the goal of depleting the kidneys of any donor 
derived leukocytes, however, the other way around by introducing DC from the 
donor into the recipient circulation resulted in acute rejection (Game and Lechler 
2002).   
 
1.6.2.1.b Indirect allorecognition pathway 
This pathway is defined as expression of donor peptide by self-MHC on APC, 
which is generally different from the direct pathway in the process of antigen 
processing. Recipient APC obtain the alloantigen from the graft and treat it as a 
foreign antigen and express this peptide on MHC-II to CD4+ T-cells (Afzali et al. 
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2007), which CD4+ T-cells are essential for B-cell function to generate 
antibodies, or CTL (Figure 10:B). Furthermore, this pathway is believed to be 
responsible for the long-term rejection of the graft as the direct pathway depends 
on the availability of donor APC that disappear with time (Afzali et al. 2007). 
This pathway is further supported by two approaches in which immunizing 
animals with allogeneic peptides resulted in strong rejection. Moreover, prolonged 
survival of the graft was detected upon intra-thymic injection of its peptide (Afzali 
et al. 2007). 
 
1.6.2.1.c Semi-direct allorecognition pathway  
This pathway of allorecognition implies that many surface expressed molecules 
even MHC can be moved and transferred between cells in order to stimulate the 
immune system of the recipient cells (Herrera et al. 2004). The methods involved 
molecular transfers through cell-to-cell contact (Game et al. 2005), and exosomes 
or small vesicles transfer (Morelli et al. 2004). This allorecognition pathway is 
directed by recipient APC receiving donor MHC-peptide complex via the process 
of MHC-transfer. Moreover, this APC after receiving MHC-peptide complexes 
are able to stimulate CD8+ T cells (the direct allorecognition pathway) and also 
process the peptide and express it to CD4+ T cells (indirect allorecognition 
pathway). Therefore, this method combines both allorecognition pathways and 
recruits both CD4+ and CD8+ T cells (Figure 10:C) (Afzali et al. 2007).  
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1.6.3 NK cell allorecognition 
NK cell mediated allorecognition in solid organ transplantation is poorly 
identified. KIRs recognise self-MHC-I to stop the activation and killing of target 
cells by NK cells. Therefore, mismatched allografts can lead to graft targeting by 
NK cells due to lack of self MHC-I on the graft (Afzali et al. 2007). Studies 
demonstrated evidence of NK cell infiltration as part of the innate immune 
response into the graft prior to T-cell infiltration; NK cells can secrete IFN-γ to 
induce both MHC-I and II expression (Pratschke et al. 2009). During 
development, NK cells undergo ‘licensing’ whereby those cells with inhibitory 
receptors for self-MHC class I alleles are allowed to mature. Hence, NK cells will 
recognise and kill target cells lacking self-MHC (Jonsson and Yokoyama 2009). 
 Alloreactivity can be triggered due to mismatches between the donor MHC and 
NK cell inhibitory receptors against self-MHC expressed on recipient cells (Afzali 
et al. 2007). Moreover, depletion of NK cells has not been shown to prevent the 
occurrence of rejection, which is different from T-cell depletion that assisted in 
preventing rejection (van der Touw and Bromberg 2010). Moreover, following 
NK cells after transplantation showed that they become activated due to the stress 
ligands of the allograft, therefore, activated NK cells produce IFN-γ and other 
proinflammatory cytokines that activate T-cells (Obara et al. 2005, Maier et al. 
2001). 
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Figure 1.9 Three allorecognition pathways. A) the direct pathway where donor 
APC express donor-self antigen on donor self-MHC and prime both CD4+ and 
CD8+ T-cells. CD4+ T-cells assist CD8+ T-cells to inflict effector cytotoxic 
functions against the graft. B) Indirect pathways where recipient APC obtain 
donor antigens through necrotic and apoptotic cell material which are then 
processed and presented to CD4+ T cells. C) semi-direct pathway that includes 
molecule exchange between cells, (a) APC from both donor and recipient transfer 
membrane components such as allo-MHC-peptide complex. (b) Donor APC 
release endosomes containing MHC that fuse with membrane of the recipient 
APC (c). Then donor APC stimulate the immune system through both direct and 
indirect allorecognition pathways (Afzali et al. 2007). 
 
1.6.4 Development of the Alloresponse 
The stress caused in the region of graft due to injuries caused by surgical 
procedures leads to local release of several cytokines and chemokines, moreover, 
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these release of these immune mediators promotes the attraction of immune 
effector cells to this region and promotes rejection of the graft (Issa et al. 2010).  
  
1.6.4.1 The alloresponse of CD4+ T-cells 
It was thought that Th2 cells only mediate tolerance and Th1 cells promote graft 
rejection, however, recent studies suggested that both types of Th cells promote 
rejection (Issa et al. 2010). Th1 promote rejection through the release of IFN-γ 
and IL-2 that activates CD8+ T-cells, B-cells release IgG2 that activates 
complement and CD8+ T-cells also promote macrophage dependent delayed-type 
hypersensitivity. What is more, CD8+ T cells also may express Fas-L that 
promotes CD8+ T-cell cytotoxicity (Issa et al. 2010). Increases in Th2 cytokine 
gene expression were noticed in murine cardiac allograft rejection (Martinez et al. 
1993a). Th2 cytokines IL-10, IL-4, IL-5, IL-13 and IL-9 promote rejection 
through activation of B-cells and eosinophils (Issa et al. 2010, Martinez et al. 
1993b). Another study has shown Th2 cytokines within the graft are responsible 
for graft infiltration by eosinophils (Martinez et al. 1993b).  
 
1.6.4.2 The alloresponse of CD8+ T-cells 
CD8+ T-cells are believed to be the main participant leading to acute rejection, 
however, even after depletion of CD8+ T-cells acute rejection still occurs (Issa et 
al. 2010) although CD8+ T-cells are one of the main causes of apoptosis and graft 
rejection. In kidney graft rejection, CD4+ and CD8+ T-cells infiltrate the regions 
surrounding the tubules and express mediators promoting apoptosis: FasL, 
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granzymes and perforin (Cornell et al. 2008, Robertson et al. 1996). Moreover, 
mRNA expression of granzyme B, FasL and perforin were elevated in the regions 
of tissue rejection (Issa et al. 2010). CD4+ T cells may mediate rejection without 
the participation of CD8+ T cells by a mechanism similar to delayed 
hypersensitivity by attracting macrophages into the graft (Cornell et al. 2008). 
 
1.6.5 CD56+ T-cell response in allografts 
The role of CD56+ T-cells in transplantation has not been established thoroughly. 
Few studies have investigated their activities and whether these cells are 
promoting rejection or inducing tolerance of the kidneys or other grafts. In animal 
models, after liver transplantation donor NK and CD56+T-cells were detected in 
the blood of the recipients for two weeks after liver transplantation; however, 
these were not detected in renal transplantation (Moroso et al. 2010). In another 
study performed on mice, iNKT cells have been found to induce tolerance of the 
immune system towards cardiac allografts. In this study, iNKT cell deficient mice 
were not capable of developing long-term tolerance and acceptance to the cardiac 
graft, however, adoptive transfer of iNKT cells to the deficient mice assisted in 
development of long-term tolerance and acceptance of the cardiac graft. 
Moreover, the blockade of LFA-1-ICAM-1 or CD40-CD40L interactions induced 
long-term survival of cardiac grafts in the presence of iNKT cells (Seino et al. 
2001). In bone marrow transplantation in rodent models, CIK cells exerted graft-
versus-host-tumour (GVT) effects (Edinger et al. 2003), which is due to their 
potent production of IFN-γ that exerts protective functions against GVHD (Baker 
et al. 2001).   
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1.6.6 The role of CMV in allograft rejection 
In renal transplant patients CMV infection and disease can occur acutely or from 
reactivation of latent CMV. Acute primary infection can be triggered in the first 
months due to suppression of the immune system, however, it can be delayed until 
after the administration of prophylactic treatment (Weikert and Blumberg 2008). 
In renal transplant recipients CMV infection can be asymptomatic, identified by 
CMV replication or CMV disease may ultimately lead to organ rejection (Weikert 
and Blumberg 2008).        
The activation of CMV triggers the host immune response, CMV releases 
immediate early antigens after it penetrates the cells; these genes are involved in 
the regulation of DNA replication. Following this by 6 to 24 hours, the virus 
releases late antigens to direct the production of nucleo-capsid proteins and the 
up-regulation of IL-2 (Brennan 2001, Weikert and Blumberg 2008).      
Several studies on the association between CMV and kidney rejection, identified 
‘CMV syndrome’ by the presence of CMV antigen in the blood and fever, muscle 
pain, leucopoenia, hepatitis, gastroenteritis, pneumonitis and thrombocytopenia 
(Hartmann et al. 2006, Weikert and Blumberg 2008). A prospective study in 
patients who did not receive prophylactic treatments showed about two thirds of 
the patients developed CMV infection during the first 100 days, among the 
different groups of donor and recipient status. Moreover, D+R- patients had three 
times higher chance of developing CMV disease than other groups D-R+ and 
D+R+ (Hartmann et al. 2006).  
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1.7. Aims and objectives 
CMV infection has minor effects in healthy subjects; however, the activation of 
this virus in immunocompromised subjects can lead to serious clinical outcomes. 
The reactivation of this virus in organ transplant recipients can lead to viraemia 
and graft rejection. CD56+ T-cells have many roles in different types of diseases, 
however the response of these cells to CMV has not been established. The main 
aim of the study is to examine the relationship between CD56+ T-cells and CMV, 
and in kidney transplant patients to assess whether this relationship affects CMV 
disease:  
 To compare the levels of CD56+ T-cells between CMV positive and CMV 
negative healthy individuals.  
 To compare the levels of CD56+ T-cells in kidney transplant patients 
according to CMV status of donor and recipient.  
 To investigate the phenotype of CD56+ T-cells in both healthy subjects 
and kidney transplant patients according to CMV status. 
 To study the functional capabilities of CD56+ T-cells when stimulated by 
CMV lysate. For this purpose several tests will be applied.   
 To investigate changes in gene expression in CD56+ T-cell when 
stimulated by CMV lysate.     
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2. Materials and Methods 
2.1 CMV IgG ELISA 
CMV IgG ELISA kits were purchased from Genway Biotech (Lot # 40-521-
475373 San Diego, Ca). This kit was used for qualitative detection of IgG 
antibodies against CMV in healthy donors participating in this study. The kit is 
suitable for detection of CMV IgG antibodies in human serum and plasma.  
 
2.1.1 CMV IgG ELISA assay Principle 
Detection occurs after the binding of CMV IgG antibodies to CMV antigen that is 
pre-coated in the microtiter strip wells. The washing of the wells is set to remove 
any background and unbound sample substances, then anti-human IgG conjugate 
that is labelled with horseradish peroxidase (HRP) binds to the CMV IgG 
antibodies and CMV antigen complex on the well. This complex is visualised via 
the addition of Tetramethylbenzidine substrate (TMB) to generate a blue colour in 
the wells. Sulphuric acid is further added to stop the reaction to generate a yellow 
endpoint colour (Figure 2.1), and the micro-well plate is analysed by Thermo 
Labsystems Opsys MR ELISA at an absorbance of 450 nm as recommended by 
the company’s protocol.  
 
2.1.2 Reagents and materials supplied and preparation 
CMV coated wells, IgG sample diluents, stop solution (Sulphuric acid), washing 
solution, CMV anti-IgG conjugate (Peroxidase labelled antibody to human IgG), 
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TMB substrate solution (Tetramethylbenidine), CMV IgG positive control, CMV 
IgG cut-off control, CMV IgG negative control. All reagents are ready to use 
except the washing solution 20 x, this reagents was diluted 1:20 by adding sterile 
distilled water. Serum or plasma was prepared by diluting 5 µl serum or plasma 
with 500µl IgG sample diluent (1:100) and the mixture was suspended thoroughly 
by vortex.  
 
2.1.3 ELISA assay procedure and measurement 
ELISA was performed manually and five different controls were allocated and 
added in duplicate manner except the substrate blank; one well for substrate 
blank, two wells for the negative control, four wells for the cut-off control and 
two wells for the positive control. Donor serum or plasma was aliquoted into the 
microtiter plate in duplicate using sterilized pipette tips. At the beginning one well 
was left for substrate blank, then 100 µl controls were added and 100 µl diluted 
samples were added to their allocated wells, and the microtiter plate was covered 
with foil and incubated for an hour at 37 
ᴼ
C. After that, the microtiter plate was 
aspirated from the contents and washed manually three times with 300 µl washing 
solution followed by tapping the microtiter plate on tissue paper to remove any 
remaining fluids that can result in poor precision and fluctuating absorbance 
value. The next step was to add 100 µl CMV anti-IgG conjugate to all wells 
except the substrate blank wells and the microtiter plate was incubated for 30 
minutes at room temperature in the dark. Again the microtiter wells were washed 
manually with 300 µl washing solution three times and contents were aspirated 
and tapped on tissue paper. Then, 100 µl TMB substrate solution was added to the 
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wells and the microtiter plate was incubated for 15 minutes in the dark. This 
followed by adding 100 µl stop solution into all wells and at this step all wells that 
previously emitted a blue colour well turned into a yellow colour. The 
measurement of the plate was performed at 450 nm and the substrate blank well 
was adjusted to zero (Figure 2.1).  
 
 
Figure 2.1 ELISA assay principle. IgG from seropositive donors binds to wells 
pre-coated with CMV antigen, peroxidase conjugated antibody binds to CMV 
antigen-antibody complex. Subsequently, addition of TMB visualizes the immune 
complex and the reaction is stopped by the addition of stop solution that generates 
a yellow colour. 
 
2.2 CMV lysate preparation  
2.2.1 Fibroblast Cell Culture 
Fibroblasts (SL fibroblast) were provided from Dr. Neil Blake, CIMI, Institute of 
Infection and Global Health. The cells had been stored frozen in liquid nitrogen 
and thus were left to thaw quickly. Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10 % FBS, 2 mM L-glutamine, 50 IU/ml penicillin, 
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streptomycin and Amphotericin B was added to the vial slowly to avoid causing 
hypotonic shock to the cells. Then the cells were washed twice with DMEM at 
400g for 10 minutes to remove DMSO from the cells. The cells were then 
incubated in a T-75 flask with 20 ml DMEM in a humidified 5% CO2 atmosphere 
at 37
o
C. The cells were checked every day for growth until the growth was >90% 
confluent, subsequently the fibroblasts were passaged by removing from the flask 
by using Cell Dissociation Solution (Sigma Aldrich, lot number C5914-100ML). 
The removal of cells was performed in a class II cabinet as follows: cell 
dissociation buffer was warmed in a water bath at 37ᴼC for 10 minutes. The media 
was removed from the flask and the fibroblasts were washed with sterile PBS to 
remove all traces of DMEM from the flask. After that, 5 ml of cell dissociation 
buffer was added to the flask and the flask was rocked to distribute buffer around 
the flask, then it was incubated for 10 minutes in a humidified 5% CO2 
atmosphere at 37
o
C. The flask was tapped firmly with the palm of the hand to 
remove the adherent cells and DMEM was added to inhibit cell dissociation buffer 
and the cells washed twice at 400g for 10 minutes. The cells were then counted 
and cultured in further flasks to acquire enough proliferative cells for all 
subsequent experiments.         
 
2.2.2 CMV lysate preparation protocol-  
CMV lysate was prepared by infecting cultured fibroblasts with live CMV of 
Towne and AD169 strains (obtained from Dr. Naeem Khan). Fibroblasts were 
cultured according to the steps described earlier (2.2.1). Adequate cell numbers to 
perform infection at a multiplicity of infection (Wolf et al.) of 10 were obtained 
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when confluence reached 75 % which is equal to ~ 1.5 × 10 
6
 cells. Then the cells 
were infected with live CMV, therefore, each cell was infected with a mean of 10 
viruses, that is equal to 1.5 × 10
7 
viruses diluted in 5 ml DMEM. Before adding 
the virus to the flask the media was removed, and then 5 ml of DMEM containing 
the live virus was added to the cells and incubated for 90 minutes in a humidified 
5% CO2 atmosphere at 37
o
C, agitating the flasks every 15 minutes. After that, the 
media was removed and 20 ml fresh DMEM media was added to the flasks. The 
supernatant was collected daily after the cells began to show cytopathic effect 
(CPE) for three days until the cells detached totally from the flask when a sterile 
scraper was used to harvest any adherent fibroblasts. The supernatants were 
washed at 400g for 10 minutes and the pellet was collected. Moreover, the pellets 
from all flasks were processed by freezing rapidly for 10 min at -80ᴼC then 
warming rapidly to 57ᴼC for 10min several times to rupture and destroy all cells 
in the pellet, then the lysate were exposed to UV light to eradicate all live viruses 
in the pellet. The lysate was then collected in several eppendorfs and stored at -
80ᴼC. The efficiency of the lysate to stimulate lymphocytes was tested by 
intracellular cytokine staining of IFN-γ production; furthermore, the cells were 
stimulated with different CMV lysate concentraions (0.1 µl, 0.5 µl, 1 µl, 1.5 µl, 2 
µl, 2.5 µl, 3 µl) and the optimal concentration to stimulate 1 X10
6
 PBMCs/ml was 
2 µl CMV lysate.  
2.3 Peripheral blood 
2.3.1 PBMC Donors 
PBMCs were collected from two groups of donors. The first group were healthy 
donors who were CMV seropositive and sero-negative. The second group were 
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post-transplant kidney recipients. PBMCs were collected into 20ml universal 
tubes containing 600 units of preservative-free heparin (Wockhardt, Wrexham). 
The patient PBMCs were divided into three groups according to their CMV sero-
status as follows: donor negative / recipient negative (D-R-), donor positive / 
recipient negative (D+R-) and the third group was donor either donor negative or 
positive / recipient positive (R+). Patient PBMCs were provided by Mr A 
Hammad, Transplant Unit, Royal Liverpool University Hospital. Blood samples 
from both healthy subjects and transplant patients were taken following informed 
consent.    
 
2.3.2 PBMC Isolation  
Isolation of PBMC from peripheral blood was carried out in a Class II 
microbiological safety cabinet. Blood samples obtained from both healthy 
subjects and transplant patients were slowly layered onto the same volume of 
Ficoll-Paque
TM 
(Sigma, UK) in universal tubes in a diluted quantity 1:1. This was 
followed by centrifugation at 400g (1800 rpm) for 25 min at 18
o
C with the brake 
off. After centrifugation, different layers were formed as shown in Figure 2.2.  
Before harvesting PBMCs, the plasma of healthy donors were collected into 
autoclaved eppendorf tubes and stored at -80
o
C for anti-CMV IgG ELISA testing. 
The buffy coat interface containing PBMCs was harvested into universal tubes 
and washed twice with autoclaved PBS (Sigma) by centrifugation at these 
settings: 10 minutes, 400g (1800 rpm) and brake on. Following the washing step, 
the cells were resuspended in culture medium, counted and prepared for further 
analysis.  
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Figure 2.2 PBMC 
separations. This figure 
illustrates the layers of cells 
after separation by Ficoll-
Paque centrifugation. This 
figure is adapted from 
(www.Nature.com).  
 
2.3.3 Counting of PBMCs 
A TC10 Bio-Rad automated cell counter was used for counting the number of 
cells. 10 µl of cell suspension was loaded into TC10 counting slides, the loading 
being performed at an angle of 45° gently to permit capillary loading of the slide 
by the cell suspension. The loading was performed with care to avoid damaging 
the slide optical surface and to avoid the formation of bubbles that would interfere 
with the reading. TC10
TM
 Counting slides are not reusable and they are disposed 
of as a biohazard waste.         
 
2.4 Flow cytometry (FACSCalibur™ BD Biosciences)  
A FACSCalibur was used to analyze cell surface and intracellular staining of 
lymphocyte populations with fluorescently conjugated mAb. Initially, labelled 
mononuclear cell populations were run through the FACS and the lymphocytes 
gated using a combination of FSC (Forward scatter) and SSC (Side scatter) 
(Figure 2.3A). To define the position of CD56+CD3+ cells, PBMCs were stained 
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by the mAbs anti-CD3 and anti-CD56 (Figure 2.3B). The FACSalibur is equipped 
with a mirror to allow the analysis of both APC and PerCP-Cy5.5.   
 
2.4.1 Surface staining for phenotypic analysis 
Mononuclear cells were aliquoted into FACs tubes for staining with different 
fluorochrome-conjugated monoclonal antibodies (Umeshappa et al.). These mAb 
were optimized according to the mAb manufacturer’s recommendations. To 
identify CD56+ T-cells both anti-CD3 mAb and anti-CD56 mAb were used to 
stain the cells (Figure 2.3B). Furthermore, several different mAb were also 
included as a third mAb for the purpose of identifying the phenotypic 
characteristic of CD56+ T-cells in CMV seropositive and seronegative healthy 
and kidney post-transplant patients (Table 2.1). Densty blot were used to measure 
the level of expression of the third marker on CD3+CD56+ cells after overlaying 
with the suitable isotype control antibody to allow for possible non-specific 
binding.   
About 2–5 x 105 mononuclear cell aliquots were placed in FACs tubes, after 
which the cells were stained with mAb and placed at 4
o
C in the dark for 20 
minutes. Following that, each tube was washed twice with sterile PBS for 10 
minutes at 400g (1800 rpm) at 4
o
C to remove unbound fluorochrome-conjugated 
mAb. The cells were then resuspended in 300 µl PBS to analyze them by 
FACSCalibur. The results were then analyzed by using WinMDI 2.9 software 
(http://facs.scripps.edu/software.html; accessed 25/02/2014).    
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Table 2.1 List of antibodies against surface markers and their suitable 
fluorochrome that have been used to phenotype CD56+ T-cells in healthy 
subjects and patients.  
Monoclonal antibody Fluorochrome Manufacturer Catalogue no. 
Anti-CD3 PerCP-Cy5.5 BD Pharmingen 560835 
Anti-CD56 FITC BD Pharmingen 562794 
Anti-CD4 PE BD Pharmingen 555347 
Anti-CD8 PE BD Pharmingen 555635 
Anti-CD57 PE BD Pharmingen 560844 
Anti-CD58 PE BD Pharmingen 555921 
Anti-CD94 PE BD Pharmingen 555889 
Anti-NKG2C PE R&D Systems FAB138P-100 
Anti-CCR7/CD197 PE eBioscience 12-1979 
Anti-CD45RA PE BD Biosciences 66038 
Anti-CD45RO PE BD Biosciences 64968 
Anti-CD161 PE BD Pharmingen 556081 
Anti-CD16 PE BD Biosciences 76180 
Anti-CD127 PE BD Pharmingen 70755 
Anti-CD28 PE BD Biosciences 75801 
Anti-CD25 PE BD Biosciences 555432 
Anti-CD62L PE BD Biosciences 65617 
Anti-γδ-TCR PE BD Biosciences 562511 
Anti-CD69 PE BD Biosciences 54963 
Anti-TCR Vα7.2 PE Biolegend 351704 
Anti-CD158a/h PE Miltenyi Biotec 130-092-684 
Anti-CD158e PE Miltenyi Biotec 130-092-473 
Anti-CD158f PE Miltenyi Biotec 130-096-200 
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2.4.2 Functional analysis of CD56+ T-cells 
2.4.2.1 Intracellular staining of CD56+ T-cells 
For the purpose of studying the capability of CD56+ T-cells response to CMV, 
PBMCs were intracellularly stained for the production of IFN-γ, TNF-α, IL-2, 
Perforin, Granzyme-A and Granzyme-B when induced by CMV lysate. 
Mononuclear cells were isolated according to 2.3.2. The cells were then washed 
Figure 2.3 Gating strategies. These figures illustrate the gating strategy followed 
in this study to identify CD56+ T-cells and their phenotypic characteristics. A. 
Density blot illustrates the gating of lymphocytes. B. This is a two colour density 
blot that shows the percentage of four different types of cell in the lymphocyte 
region after they were stained with anti-CD56 and anti-CD3. The percentage of 
NK cells (CD56+CD3-) is 9.3%, the percentage of CD56+-T-cells (CD56+CD3+) 
is 8.4% and the percentage of T-cells (CD56-CD3+) is 66.4%. C. After gating 
CD56+CD3+ cells, the level of expression of a third marker that is in this case 
CD45RO was measured via density blot after compared to a negative control 
illustrated in D. 
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twice using culture media RPMI 1640 (Sigma) containing (10% heat inactivated 
foetal calf serum + 2mM glutamine + 5000 unit Penicillin and Streptomycin). The 
cells were cultured in 48 well plates, in which some of the wells were treated as 
negative controls with culture medium alone, some wells were stimulated using 
1:10 (prepared in the laboratory) or 200ng/ml CMV extract (The Native Antigen 
Company, Upper Heyford) and for the positive control Staphylococcal enterotoxin 
B  (SEB) (Sigma Aldrich) was used. The cells were incubated overnight in a 
humidified 5% CO2 atmosphere at 37
o
C. The following day, 1 µl/ml of Brefeldin-
A (eBioscience, lot # 00-4506) was added to all wells of the plate and it was 
further incubated in a humidified 5% CO2 atmosphere at 37
o
C for 4 hours. Next, 
the cells were washed twice with culture media (RPMI 1640) for 10 min, 400g 
(1800 rpm) and brake on. Then, 5 x 10
5
 cells were harvested into FACs tubes and 
surface stained with anti-CD3 and anti-CD56 mAb using the same steps as in 
Section 2.4.1. After that, the cells were washed twice with sterile PBS and fixed 
using 100 µl IC Fixation buffer (eBioscience) for 20 minutes in the dark at room 
temperature. The cells were then permeabilized by washing with 2 ml of 1 X 
Permeabilization buffer (eBioscience) at 400g (1800 rpm) for 5 minutes with the 
brake on. Moreover, the permeabilization step was repeated three times. Each tube 
was stained with one of the intracellular antibodies (Table 2.2), and the tubes were 
incubated for 30 minutes at room temperature in the dark. Subsequently, the tubes 
were washed by 1X permeabilization buffer and further resuspended in 300 μl 
PBS. The staining was analyzed using the FACSCalibur and subsequently 
analyzed by WinMDI 2.9 software. The production of these cytokines and 
expression of cytotoxic mediators by CD56+ T-cells was measured by the same 
procedure explained in Figure 2.3.    
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IC mAb Manufacturer fluorochrome Isotype  Surface mAb 
Anti-IFN-γ 
560704 
BD Pharmingen PerCP-Cy5.5 
Mouse IgG1 k 
550795 
CD3-FITC, CD56-
APC 
Anti-TNF-α 
560679 
BD Pharmingen PerCP-Cy5.5 
Mouse IgG1 k 
550795 
CD3-FITC, CD56-
APC 
Anti-IL-2 
560708 
BD Pharmingen PerCP-Cy5.5 
Mouse IgG1 k 
550795 
CD3-FITC, CD56-
APC 
Anti- Perforin 
12-9994 
eBioscience 
PE 
Mouse IgG2b 
12-4732 
CD3-FITC, CD56-
APC 
Anti-Granzyme A 
78238 
BD Pharmingen PE 
IgG1, k 
400137 
CD3-FITC, CD56-
APC 
Anti-Granzyme B 
515403 
Biolegend FITC 
IgG1, k 
400137 
CD3-PerCP-Cy5.5, 
CD56-PE 
Table 2.2 List of intracellular mAb that have been used in these experiments. 
Different types of surface mAb were used with IC mAb.      
 
2.4.2.2 Degranulation assay of CD56+ T-cells; detection by LAMP-1 
(CD107a) expression 
2.4.2.2.1 MHC negative targets 
K562 is a human erythroleukaemic cell line that lacks the expression of MHC-I 
that make them a susceptible target for NK cell detection. K562 cells were 
maintained in culture media, RPMI 1640 media, supplemented with 10% FBS, 2 
mM L-glutamine, 50 IU/ml penicillin and the cells were incubated in a humidified 
5% CO2 atmosphere at 37
 ᴼ
 C.  
 
- 88 - 
NK cell cytotoxicity is mediated by two pathways, cross-linking of NK cell 
surface ligands such as FAS-L and the target cell death receptors expressed on 
their surface such as FAS. Additionally, the second pathway is dependent on lack 
of inhibitory signals via KIRs and is mediated via the releasing of perforin and 
granzyme (L. Wang et al. 2012, Ozoren and El-Deiry 2003, Trapani 2012). 
CD107a is a marker for NK cell and CD8+ T-cell degranulation as part of the 
perforin-dependent cytotoxic process therefore it was investigated whether 
CD56+ T-cells express this marker after their induction by CMV lysate and K562, 
and if there were any significant difference between healthy CMV seropositive 
and seronegative subjects.     
 
2.4.2.3.2 PBMC stimulation by K562 cells and CMV lysate 
PBMCs were isolated according to section 2.3.2. Samples from healthy adults 
participated in this experiment and their CMV sero-status was detected by ELISA 
as identified in section 2.1.3. The stimulation of PBMCs by K562 and CMV 
lysate was carried out in 48 well culture plates, at a ratio of 1:2 (PBMCs: K562); 
the cells numbers were counted according to section 2.3.3. Unstimulated PBMCs 
were used as a negative control and the levels of CD107a detected in the negative 
control were subtracted from those measured after K562 and CMV lysate 
stimulation. PBMCs were stimulated by K562 and CMV lysate for four hours in a 
humidified 5% CO2 atmosphere at 37
o
C, then 1 µl/ml Brefeldin A was added to 
the culture and the plate was left in the incubator for about 4 hours. The cells then 
were washed twice with sterile PBS in FACs tubes at 400g (1800 rpm) for 10 
minutes. Following that, the cells were pelleted and stained with anti-CD3 PerCP-
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Cy5.5, anti-CD56 FITC and Anti-CD107a PE (555801, Isotype Mouse IgG1, k 
555749) (the three antibodies were purchased from BD Pharmingen) and left on 
ice for 20 minutes, then the cells were washed with PBS and immediately 
analysed by BD FACSCalibur. The analyses were performed by using WinMDI 
2.9 as mentioned in Figure 2.3. 
 
2.4.2.4 Proliferation assay of CD56+ T-cells 
2.4.2.4.1 Carboxy-Fluorescein Succinimidyl Ester (CFSE) assay 
CFSE dye is frequently used to determine the capability of lymphocytes to 
proliferate and generate daughter cells in response to specific antigen. Each new 
generation of cells retains half the amount of CFSE of the parent cells. CFSE is 
integrated into the cells in a colourless and non-fluorescent condition; emission of 
CFSE is triggered when intracellular esterases cleave the acetate group. The 
parent cells preserve the dye, moreover, during mitosis and proliferation to 
daughter cells the dye is halved with each new generation. The list of reagents 
used in this test is identified in Table 2.3. 
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Reagent Manufacture Conjugated fluorochrome 
CFSE Molecular Probes
TM
 Invitrogen fluorescein 
Anti-CD3 BD Pharmingen PerCP-Cy5.5 
Anti-CD56 BD Pharmingen APC 
Table 2.3 Reagents that were used in proliferation assays of CD56+ T-cells.  
 
2.4.2.4.2 PBMC CFSE labelling 
The isolation and counting of the cells were performed as identified in sections 
2.3.2 and 2.3.3 respectively. The labelling process was performed in universal 
tubes with sterile PBS to remove the incidence of generating backgrounds. CFSE 
was purchased from Molecular Probes
TM
 Invitrogen. At a concentration of 1 x 10
6
 
PBMCs were resuspended in 10ml of pre-warmed sterile PBS mixed with 5μM 
CFSE in dimethyl sulphoxide, which was further incubated for 8 minutes in a 
humidified 5% CO2 atmosphere at 37
o
C. Consequently, the reaction was stopped 
by the addition of 5 volumes of ice cold PBS and centrifugation at 400g (1800 
rpm) for 10 minutes. The washing step was repeated twice to remove any 
unbound CFSE. The cells were resuspended in culture medium, counted and 1 x 
10
6
 cells/well placed into 48-well culture plates.  
 
2.4.2.4.3 PBMC stimulation by CMV lysate and SEB 
To detect the ability of CD56+ T-cells to proliferate in response to CMV antigens, 
PBMCs labelled with CFSE were stimulated by 2 µl CMV lysate for 7 days. 
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Moreover, 1 µl SEB per 1X10
6
 cells/ml was used as a positive control and 
PBMCs labelled with CFSE were cultured in medium alone as a negative control.  
At day 7, PBMCs were harvested into FACs tubes, which were further centrifuged 
twice in sterile PBS at 400g (1800 rpm) for 10 minutes. PBMCs were stained for 
surface markers to identify CD56+ T-cells; CFSE is FITC conjugated therefore 
anti-CD3-PerCP-Cy5.5 and anti-CD56-APC were used for staining and cells were 
incubated for 20 minutes on ice in the dark. PBMCs were washed twice with 
sterile PBS to remove any unbound mAb and resuspended in 400 µl of PBS. They 
were then analysed in a FACSCalibur, usingWinMDI 2.9 software for analysis. 
The gating strategy used in the analysis of proliferated cells is identified in Figure 
2.4.  
 
Figure 2.4 Proliferation gating strategies. This figure illustrates the gating 
strategy followed in this study to identify proliferated cells. A. This figure shows 
the method followed to gate lymphocytes. B. This figure identifies the method of 
gating both NK cells and CD56+ T-cells. C. This figure shows the method of 
analysing proliferated cells at day 7. Cells to the left of the threshold had reduced 
CFSE staining and were regarded as having proliferated.   
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2.4.2.5 CD56+ T-cell CMV specificity detection 
T-cells are the essential part of cell-mediated immune responses toward antigens. 
CD8+ cytotoxic T-cells (CTL) recognize antigenic peptides bound to major 
histocompatibility complex class-I (MHC-I), which is expressed on all nucleated 
host cells and there are three HLA class-I loci, A, B and C; however, MHC-II is 
expressed on antigen presenting cells (APC). When host cells are under stress 
such as virus infection, the host cells start to degrade the foreign antigen to 
smaller peptide fragments and begin to present it on MHC-I to allow the 
recognition by CD8+ cytotoxic T cells of the host cell’s abnormal status. CTL 
initiate the release of cytotoxic mediators such as perforin and granzyme which 
induce the abnormal host cells to undergo apoptosis.  
To detect and enumerate the specific CD8+ T-cells recognizing target antigens, 
MHC-I Pentamers or tetramers can be used. These multivalent reagents, made up 
of several soluble class I MHC molecules bound to specific antigenic peptide, 
have sufficiently high avidity to bind to T cells with antigen receptors specific for 
the peptide. In this study CD56+T-cell specificity toward CMV peptides were 
investigated by using Pro5 MHC-I Pentamers (Proimmune, Oxford). The first step 
was to identify possible candidates who were CMV seropositive and of the 
appropriate HLA tissue type. In this study, three of the common European alleles 
were studied: HLA-A*02, HLA-B*07, and HLA-B*08. After that, the second step 
was to staining the cells by CMV Pro5 pentamers to detect their specificity toward 
CMV peptides. In Table 2.4, the list of reagent s used in this test is illustrated.  
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2.4.2.5.1 HLA tissue type 
PBMCs from healthy donors were isolated according to section 2.3.2, centrifuged 
twice in PBS and aliquoted into FACs tubes. Monoclonal antibodies against HLA-
A2, B7 and B8 (Table 2.5) were used to stain PBMCs for 20 minutes and left on 
ice in the dark. Both anti-HLA-A2 and anti-HLA-B7 are FITC conjugated 
therefore after the end of staining period the tubes were washed and left on ice. 
However, anti-HLA-B8 is conjugated to biotin therefore the tube was washed 
twice and stained with Streptavidin conjugated to FITC and left on ice for a 
further 20 minutes, then the tube was washed. The tubes were analysed by 
FACSCalibur, and gating strategy is explained in Figure 2.5.   
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Figure 2.5 Tissue typing gating strategy. These figures explain the gating 
strategy followed to identify the tissue type of CMV seropositive donors. 
Lymphocytes were gated in the scatter density plot and the tissue type was 
identified by using histograms of FITC staining. Representative positive and 
negative donors are shown the histograms are organised from the top as HL-A2 
positive, HLA-B7 positive, HLA-B8 positive and the last one as HLA-B8 
negative. 
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Reagents Manufacture 
PEPTIDE 
SEQUENCE 
EPITOPE 
ORIGIN 
Conjugated 
fluorochrome 
Anti-HLA A2 AbD Serotec - - FITC 
Anti-HLA B7 AbD Serotec - - FITC 
Anti-HLA B8 AbCam - - conjugated to 
biotin 
Streptavidin AbD Serotec - - FITC 
P
ro
5
 P
en
ta
m
er
s 
A*02:01 
 
Proimmune 
NLVPMVATV HCMV 
pp65 495-
504 
APC 
B*07:02 Proimmune TPRVTGGGA
M 
HCMV 
pp65 417-
426 
APC 
B*08:01 Proimmune QIKVRVDMV HCMV 
IE1 88-96 
APC 
Anti-CD8 clone 
LT8 
Proimmune - - FITC 
Anti-CD56 Coulter, 
Luton 
- - PE 
  
Table 2.4 Reagents used in pentamer labelling.    
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2.4.2.5.2 CD56+ T-cells Pro5 Pentamers staining  
PBMCs from CMV seropositive healthy donors who were tissue type positive for 
HLA-A2, HLA-B7 and HLA-B8 were isolated and washed according to section 
2.3.2. PBMCs were washed twice with sterile PBS then 1 x 10
6
 cells/ml were 
allocated into FACs tubes for staining. The cells were re-suspended in 50 μl 
sterile PBS before staining the cells using the appropriate pentamer. Pro5 
pentamers were centrifuged at 14,000g at 4
 o
C for 10 minutes. The purpose for 
this high-speed spin is removing any protein aggregates that reside in the vials, 
which can result in background and non-specific binding. Moreover, it is 
essentially to avoid pipetting the pentamers from the bottom of the vial. About 10 
µl were used from each pentamer vials to stain PBMCs for 10 minutes shielded 
from light and at room temperature. The tubes were washed twice in 2 ml sterile 
PBS at 400g (1800 rpm) for 10 minutes, supernatants from all tubes were 
discarded, tubes were stained with anti-CD8-FITC and anti-CD56-PE and the 
tubes left on ice shielded from light. Following the manufacturer’s 
recommendation, anti-CD19-PerCP-Cy5.5 was included to reduce the background 
due to the nonspecific binding of the pentamers to B cells. The tubes were washed 
twice, re-suspended in 400 μl PBS and the analysis was performed using a 
FACSCalibur and the data analysed with winMDI 2.9, gating for CD19- CD8
bright
 
cells.  
 
2.4.2.6 Identifying CD56+ T-cell gene expression profile in response to CMV 
This experiment was designed to identify the gene expression profile of CD56+ T-
cells in response to CMV lysate. The first step  was to select four CMV 
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seropositive candidates, then obtain enough peripheral blood to obtain sufficient 
CD56+ T-cells when sorting this type of cells from PBMCs. Next PBMCs were 
isolated from the blood samples according to section 2.3.2, after that, cells were 
counted according to section 2.3.3 to guarantee an adequate number of cells for 
the sorting step. The cells were divided into two groups, the first to be stimulated 
with CMV lysate and cultured overnight in a humidified 5% CO2 atmosphere at 
37
o
C, and the second group of cells to be cultured without stimulation overnight 
in a humidified 5% CO2 atmosphere at 37
o
C. The next day the two groups of cells 
were washed twice with sterile PBS at 400g (1800 rpm) for 10 minutes. Next, the 
cells were stained with anti-CD3 PerCP-Cy5.5 and anti-CD56-PE for 30 minutes 
and room temperature in the dark; following that, the cells were washed with 
sterile PBS twice and aliquoted in RPMI 1640 culture media to prepare them for 
the cell sorting step.  
 
2.4.2.6.1 CD56+ T-cell sorting  
CD56+ T-cell sorting was performed by Dr. Stuart Marshall-Clarke and Mrs. 
Natalie O’Hara, in the Technology Directorate FACS facility, Faculty of Health & 
Life Sciences. A FACSAria IIIu was used for cells sorting. In brief, the cells were 
stained by anti-CD56-PE and anti-CD3+-PerCP-Cy5.5 and the cells were sorted 
according to the mAb conjugated fluorochrome. Three groups of cells were sorted 
into RPMI1640 culture media: CD56+CD3- cells, CD56+CD3+ cells and CD56-
CD3+ cells. After that, the cells were washed with sterile PBS at 400g (1800 rpm) 
for 10 minutes, and prepared for immediate RNA extraction.         
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2.4.2.6.2 RNA extraction protocol  
After sorting of the cells, RNA extraction from sorted CD56+ T-cells was done 
instantly using an RNeasy mini kit (Qiagen). At the beginning, concentrated RPE 
buffer was diluted with 4 volumes of 96% ethanol to prepare the working 
solution. The samples were adjusted to a volume of 1ml by the addition of 100 μl 
RNase-free water plus 600 μl of buffer RLT and the mixtures resuspended 
thoroughly. Next, 250 μl of 96% ethanol was  added and each sample mixed 
thoroughly by pipetting. Then, 700 μl from each sample  was transferred to an 
RNeasy mini spin column placed into 2 ml collection tube and centrifuged for 15 
seconds at 8000g and the flow throughdiscarded. RNeasy columns were placed 
again into 2 ml collection tubes followed by the addition of 500 μl RPE buffer 
into the RNeasy mini spin columns and centrifuged for 15 seconds at 8000g. 
Again the flow through was discarded from all tubes and again 500 μl RPE buffer 
added into RNeasy mini spin columns, however this time the tubes were spun for 
2 minutes at 8000g. Next, the flow-through was discarded and RNeasy mini spin 
columns were centrifuged at 8000g for 1 minute to remove any traces of the 
ethanol. Then, RNeasy mini-spin columns were placed into 1.5 ml eppendorf 
tubes and 30 μl RNase-free water was added directly and carefully onto the gel-
membrane of the RNeasy mini-spin column without touching the gel-membrane 
and centrifuged at 8000g for 1 minute. The eluted RNA was measured by 
NanoDrop and placed in a -80
o
C freezer.     
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2.4.2.6.3 DNase-treatment of RNA   
This step was to remove any residual DNA remaining after the isolation of RNA. 
This was done by a RNase-Free DNase set (Qiagen, lot 79254). At the start, to 
prepare DNase I the stock was dissolved in 550μl RNase-free water using an 
RNase free needle, then the vials were inverted to mix the solution, which was 
stored at -20 
o
C. DNase-I incubation mix was prepared by diluting 10μl of DNase-
I stock solution in 70μl RDD buffer to constitute 80μl.  
The RNA eluate volume was brought up to 100μl by Rnase-free water. Then, 
about 350μl RLT buffer was added and mixed thoroughly. Next, 250μl 96%-
100% ethanol was added to dilute the RNA and mixed by pipetting gently. The 
whole quantity (about 700μl) was transferred to RNeasy-mini spin columns that 
were placed in 2 ml collection tubes, and the mixture centrifuged at 8000g for 15 
seconds. The flow-through was discarded and 350 μl RW-1 buffer was added and 
centrifuged at 8000g for 15 seconds. After this, the 80 μl incubation mix was 
added directly onto the membrane of the column and left at room temperature for 
15 minutes. This was followed by the addition of 350μl RW-1 buffer onto the 
membrane which was centrifuged at 8000g for 15 seconds, discarding the flow-
through. About 500μl of RPE diluted with ethanol was added to the column and 
centrifuged for 15 seconds at 8000g, discarding the flow-through. 50μl RPE 
buffer and centrifugation for 2 minutes at 8000g. Then, the RNeasy mini-spin 
columns were placed into 1.5 ml eppendorfs and 30 μl Rnase-free water added to 
elute the RNA, the tube was centrifuged for 1 minute at 8000g, then RNA was 
measured by NanoDrop and stored at -80
 o
C.      
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2.4.2.6.4 One-Colour Microarray-Based Gene Expression  
Microarrays were used to provide a comprehensive study of the gene expression 
profile of CD56+ T-cells in response to CMV stimulation. Agilent Human v2, 8 x 
60K arrays were purchased from Agilent Technologies. The experimental work 
with the arrays was done by Dr. Lucille Rainbow, Centre for Genomic Research, 
IIB. In brief, 8 total RNA samples (free from genomic DNA) were cleaned with 
Ampure RNA beads and quantified by NanoDrop. The quality of RNA was 
assessed using Agilent 2100 Bioanalyser RNA 6000 Pico chips. Samples were 
prepared for hybridisation onto Agilent Human genome v2 arrays. Approximately 
50ng of total RNA was used as initial input, and the Agilent Low-Input 
Amplification Kit was used for One-Colour target preparation for microarray 
expression analysis according to manufacturer’s instructions. 600ng of Cy3 
labelled aRNA (amplified RNA) was fragmented, and loaded onto the array which 
was hybridised for 17 hours at 65
0
C and 10rpm in an Agilent hybridisation oven. 
Following hybridisation the arrays were washed according to the manufacturer’s 
instructions and scanned using the Agilent Scanner (Figure 2.6).  
Downstream analysis of Agilent microarray data was processed by using Agilent 
technology software GeneSpring GX 9.0.  
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Figure 2.6 Microarrays workflow flow-charts. The workflow flow-charts is 
adapted from Agilent Technologies. The steps from cDNA synthesis to feature 
extraction were processed by Dr. Lucille Rainbow, Centre for Genomic Research, 
IIB. 
 
2.4.2.6.5 Data Analysis of microarrays using GeneSpring GX9.0  
The company recommended using Agilent technology default software for 
microarrays results; therefore, GeneSpring GX9.0 was used for this purpose. The 
software was developed by the company technology department and has the array 
design information and biological information about different entities of their 
array types. Data from Agilent single colour Expression data test were saved in 
text format (.txt). Steps for analysing the data are described as follows: 
 The text files containing microarrays results are loaded into GeneSpring 
GX9.0. 
 GeneSpring GX9.0 will automatically extract the gene expression data and 
perform standard normalisation and transformations by default, and these 
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are threshold all values to 5, median shift normalisation to the 75 
percentile and apply a baseline transformation by using the median of all 
samples.  
 Files were divided into two groups according to the conditions and they 
were the stimulated group and the un-stimulated group.  
 The two conditions of groups were compared together by using a 
Moderated T-test with cut-off of 0.05. 
 Multiple testing corrections were applied to remove any false-positive 
significantly expressed genes. The software default method for multiple 
testing corrections was applied and it is called Westfall and Young 
Permutation with cut-off 0.05 and fold changes was set to equal or more 
than 2 folds change. Next, the significantly expressed genes were exported 
into an excel file.   
 The results were clustered by hierarchical clustering to build a 
phylogenetic tree to cluster genes together that has similar properties. This 
step was also performed by GeneSpring GX9.0. 
 
 
 
2.4.2.6.6 Validation of Microarrays results 
 
RT-PCR analysis of gene expression was used for the validation of microarray 
experiments. Three genes of interest were picked for RT-PCR analysis: ISG-15, 
USP-18 and IFN-γ. Moreover, for positive control or housekeeping gene L-32 
was used. Both steps 2.4.2.6.7 and 2.4.2.6.8 were done with the help of Dr. Brian 
Flanagan in Department of Women’s and Children’s Health, ITM, University of 
Liverpool at Alder Hey Children’s Hospital.  
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2.4.2.6.7 Synthesis of cDNA (Reverse Transcription)  
RNA samples were placed on ice to avoid degradation.. High Capacity cDNA 
Reverse Transcription kit (Invitrogen catalogue number 4368814, UK) was used 
to reverse transcribe cDNA. First, 2 µl RT buffer, 2 µl dNTP nucleotides and 2 µl 
random primers were added into RNase-free eppendorfs. Then, 5 µl RNA 
(approximately 1µg) followed by 1 µl reverse transcriptase enzyme (stored at -
20
0
C) were added. The mixture was mixed gently by pipetting and incubated for 1 
hour at 37 
0
C in an AccuBlock™ Digital Dry Bath. After that, cDNAs were 
diluted with 180 µl sterile water and stored at -80
0
C.  
        
2.4.2.6.8 RT-PCR gene expression analysis  
Quantitative PCR analysis of the three candidate genes: IFN-γ, ISG-15 and USP-
18 were carried out by using RT-PCR. TaqMan® probes for gene expression 
assays were obtained from Applied Biosystems, UK. These TaqMan probes and 
the master mix details are identified in Table 2.5. The reaction was processed in 
an Applied Biosystems 7300 Real PCR system, and the software was also 7300 
Systems software. The principle behind TaqMan probes is explained as follows, 
an oligonucleotide probe has a quencher on the 3′ end that prevent the fluorescent 
dye attached to the 5′ end from emitting, which is also called reporter dye. 
However, when the target sequence is bound by the probe this will lead to 
cleavage of the reporter dye on the 5′ end by 5′ nuclease activity of the DNA 
polymerase. With the expansion of more complementary sequences there is 
cleavage of more reporter dye molecules from the TaqMan probes leading to the 
generation of more fluorescence. An increase in fluorescence is proportional to 
copy number of the target nucleic acid. Samples contain high levels of cDNA are 
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detected before those containing smaller amounts.  This results in a lower Ct, the 
cycle number at which fluorescence signal exceeds an arbitrary threshold. Hence, 
the Ct value, or cycle number is inversely proportional to the initial amount of 
target DNA. TaqMan probes are specific to their target sequence which makes 
them a better choice than conventional SYBR green methods.  
 
Reagent Lot number UniGene ID 
L32 TaqMan Probe 1093359 Hs.00388301_M1MRP 
IFN-γ TaqMan Probe 666419 Hs.0989290_g1 
ISG-15 TaqMan Probe 4331182 Hs00192713_m1 
USP-18 TaqMan Probe 4331182 Hs00276441_m1 
TaqMan Gene-Expression 
Master Mix 
1304177 - 
 
Table 2.5 Reagents used in RT-PCR analysis of gene expression. All the 
reagents were from Applied Biosystems, L32 TaqMan probe, IFN-γ TaqMan 
probe and TaqMan Gene-Expression Master Mix were provided by Dr. Brian 
Flanagan.   
 
The reaction mix for each probe was prepared as follow; first, four sterile 
eppendorfs were allocated in which each eppendorf was used for a single Taq-
Man probe. The quantity of probes and master mix were calculated by this method 
(12.5 µl of master mix X number of wells) and for the probes (1.25 µl TaqMan 
probe X number of wells). These quantities were aliquoted into each well and 
11.25 µl of cDNA of each sample were aliquoted into each of the 96 wells.  
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The thermal cycle conditions applied for the reaction was the same as 7300 
Applied Biosystems software default settings and the cycle is illustrated in Table 
2.6.   
Stage Steps Time and Temperature 
Initial prior PCR 
Activation AmpErase® UNG 2 minutes   50ᴼC 
Hot Start DNA Polymerase 
activation 
10 minutes  95ᴼC 
PCR cycles 
Melt 15 seconds  95ᴼC 
Anneal/Extend 1 minute 60ᴼC 
 
Table 2.6 RT-PCR thermal conditions. The thermal condition applied to the 
TaqMan gene expression assay was the same as 7300 Applied Biosystems 
software default, and the number of the cycles was 40 cycles. Activation 
AmpErase® UNG principle was to prevent re-amplification of PCR wastes from 
previous experiments. 
 
2.4.2.6.9 Protein expression analysis  
Two proteins were studied futher to validate microarray data, also, to compare 
between CMV healthy groups.  
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2.4.2.6.9. a CD38 surface staining of CD56+ T-cells  
Changes in CD56+ T-cell surface expression of CD38 in response to CMV lysate 
were further analyzed. Mononuclear cells were isolated according to step 2.3.2. 
The cells then were washed twice by using culture media RPMI 1640 (Sigma) 
containing (10% heat inactivated foetal calf serum + 2mM glutamine + 5000 unit 
Penicillin and Streptomycin). The cells were cultured in 48 well plates, in which 
some of the wells were treated as negative controls and other wells were 
stimulated using of 1:10 or 200 ng/ml (The Native Antigen Company, Upper 
Heyford) CMV lysate. The cells were incubated for three days in a humidified 5% 
CO2 atmosphere at 37
o
C. Each day, 1 µl/ml of cells Brefeldin-A (eBioscience) 
was added to some of the wells of the plate and it was further incubated in a 
humidified 5% CO2 atmosphere at 37
o
C for 4 hours. Next, the cells were washed 
twice with culture media (RPMI 1640) for 10 min, 400g (1800 rpm) and brake on. 
Then, 5 x 10
5
 cells were harvested into FACs tubes and surface stained by anti-
CD3, anti-CD56, anti-CD38 PE mAb (Biolegend, 356604) using the same steps as 
in section 2.4.1. The staining was analyzed using a FACSCalibur and 
subsequently analyzed by WinMDI 2.9 software. The expression of CD38 by 
CD56+ T-cells was measured by the same procedure explained in Figure 2.3.    
 
2.4.2.6.9. b ISG-15 intracellular staining of CD56+ T-cells  
PBMCs were intracellularly stained for the production of ISG-15 when induced 
by CMV lysate. Mononuclear cells were isolated according to 2.3.2. The cells 
were then washed twice using culture media RPMI 1640 (Sigma) containing (10% 
heat inactivated foetal calf serum + 2mM glutamine + 5000 unit Penicillin and 
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Streptomycin). The cells were cultured in 48 well plates, in which some of the 
wells were treated as negative controls with culture medium alone, some wells 
were stimulated using 1:10 (prepared in the laboratory) or 200ng/ml CMV extract 
(The Native Antigen Company, Upper Heyford). The cells were incubated 
overnight in a humidified 5% CO2 atmosphere at 37
o
C. The following day, 1 
µl/ml of Brefeldin-A (eBioscience, lot # 00-4506) was added to all wells of the 
plate and it was further incubated in a humidified 5% CO2 atmosphere at 37
o
C for 
4 hours. Next, the cells were washed twice with culture media (RPMI 1640) for 
10 min, 400g (1800 rpm) and brake on. Then, 5 x 10
5
 cells were harvested into 
FACs tubes and surface stained with anti-CD3 and anti-CD56 mAb using the 
same steps as in Section 2.4.1. After that, the cells were washed twice with sterile 
PBS and fixed using 100 µl IC Fixation buffer (eBioscience) for 20 minutes in the 
dark at room temperature. The cells were then permeabilize by washing with 2 ml 
of 1 X Permeabilization buffer (eBioscience) at 400g (1800 rpm) for 5 minutes 
with the brake on. Moreover, the permeabilization step was repeated three times. 
The cells were blocked by 10 µl goat serum (Sigma-Aldrich, G9023) fot 10 
minutes and room temperature, this followed by washing at 400g (1800 rpm) for 
10 minutes with the brake on. The cells were labeled by 1 µl ISG-15 polyclonal 
antibody (Thermo Fisher, PA5-17461), and the tubes were incubated for 30 
minutes at room temperature in the dark. Subsequently, the tubes were washed by 
PBS at 400g (1800 rpm) for 10 minutes. The cells were labeled by 1 µl secondary 
antibody Pierce Goat anti-Rabbit IgG, H+L-FITC (Thermo-scientific, 31583), and 
the tubes were incubated for 20 minutes at room temperature in the dark. 
Subsequently, the tubes were washed by PBS at 400g (1800 rpm) for 10 minutes.   
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The staining was analyzed using the FACSCalibur and subsequently analyzed by 
WinMDI 2.9 software. The production of these cytokines and expression of 
cytotoxic mediators by CD56+ T-cells was measured by the same procedure 
explained in Figure 2.3.    
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3. Frequency and phenotype of CD56+ T-cells in CMV seropositive and 
seronegative healthy subjects   
 3.1 CMV sero-status by applying IgG ELISA assay   
Sera from healthy subjects were analysed for the presence of IgG antibodies to 
CMV. The results were calculated as follows: the mean of the cut off wells’ 
absorbance value was calculated according to this equation: [the sum of cut off 
values / 2]. The sample was considered clearly positive if the mean of the 
antibody titres in two wells was more than 10 % above the cut off mean 
absorbance value. The sample was considered clearly negative if the mean of the 
antibody titres in two wells was lower than 10 % below the cut off mean 
absorbance value (Table 3.1). When the mean of the antibody titrers was equal or 
less than 10 % above or below the cut off mean this was considered a grey zone 
and samples should be repeated and if they gave the same value again the result 
was considered negative, however, no sample has fallen between this grey zone 
values. 
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 1 2 3 4 5 6 7 8 
A 0.062 2.164 0.500 0.170 0.134 1.654 0.100 0.106 
B 0.075 1.863 0.603 0.093 0.123 1.722 0.092 0.125 
C 0.074 0.144 1.021 1.607 1.555 2.299 1.410 1.047 
D 0.406 0.121 1.024 1.654 1.509 1.722 1.139 1.159 
E 0.361 1.126 0.217 0.992 0.073 0.166 1.033 1.396 
F 0.691 1.204 0.230 0.966 0.079 0.292 1.139 1.373 
G 0.138 0.142 1.582 1.213 0.076 0.106 1.410 0.093 
H 0.145 0.132 1.579 1.231 0.080 0.108 1.422 0.114 
 
Table 3.1 IgG ELISA detection. This table illustrates the CMV sero-status of 29 
healthy donors. Well A1 is the substrate blank. B1 and C1 are the negative 
control. D1 and E1 are the cut-off controls and their mean is 0.383. F1 is the 
positive control. Samples were allocated in duplicates, and any mean value more 
than 0.383+ 0.0383 (10%) was considered CMV seropositive. In addition, any 
sample less than 0.383- 0.0383 (10%) was considered CMV seronegative. No 
sample fell in the grey zone.  
.  
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3.2 Frequency of CD56+ T-cells in CMV seropositive and seronegative 
healthy subjects 
3.2.1 Introduction 
CD56+ T-cells numbers have previously been studied in groups of patients with 
different clinical conditions. Generally, the numbers are reduced in some 
autoimmune diseases such as psoriasis and rheumatoid arthritis when the relative 
numbers of CD56+ T-cells were compared to healthy controls (Koreck et al. 2002, 
Yanagihara et al. 1999). In addition, in patients infected with hepatitis E the 
numbers of CD56+ T-cells were also reduced (Srivastava et al. 2008). Moreover, 
chronic hepatitis C infected patients have reduced levels of CD56+ T-cells and 
they are also reported to be vulnerable to hepatic carcinoma (Kawarabayashi et al. 
2000). Also, the numbers are reduced in smokers and patients with chronic 
obstructive pulmonary disease (Urbanowicz et al. 2009).    
On other hand, CD56+ T-cell numbers have been reported to be expanded in 
infections conditions such as malaria, HIV and hepatitis B (Watanabe et al. 2003, 
Paiardini et al. 2005, Barnaba et al. 1994). These cells were also expanded in lung 
cancer patients with both non-small-cell and small-cell lung cancer when the 
levels were compared to healthy blood donors (Al Omar et al. 2012).  
The proportion of CD56+ T-cells was measured by collecting PBMCs from 
healthy donors, then double staining with anti-CD3 and anti-CD56 monoclonal 
antibodies. Relative number of CD3+CD56- T-cells and NK cells(CD56+CD3-) 
in CMV seropositive and CMV seronegative subjects were also measured and 
compared. During these analyses, the minimum number of accepted events using 
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the FACS-Calibur was 20,000 events. 68 healthy donors were used in these 
analyses, of which 34 were CMV seropositive and 34 CMV seronegative.  
The statistical analysis was performed by using Graph-Pad Prism and applying a 
Paired T-test and the results are shown in a vertical scatter plot.  
 
3.2.2 Aims  
The aim of this section of the study was to compare the relative levels of CD56+ 
T-cells in CMV seropositive and seronegative healthy individuals. Moreover, the 
comparison was made by using two different methods, the first in relation to the 
total number of lymphocytes and the second to the total number of CD3+ T-cells 
only. Both age and gender effects were analysed and compared to test for any 
significant differences. Following that, relative levels of CD3+CD56- T-cells cells 
and CD3-CD56+ NK cells were compared between CMV seropositive and 
seronegative healthy individuals.  
  
3.2.3 Results 
3.2.3.1 CD56+ T-cells relative numbers in healthy CMV seropositive and 
seronegative subjects  
Flow cytometric analysis of CD56+ T-cell population was applied to identify the 
relative numbers of these cells in healthy individuals. PBMCs were stained by 
anti-CD3 and anti-CD56 and expressed as a density plot. Numbers expressed as 
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percentages of total lymphocytes and T-cells (Figure 3.1) were collected into 
GraphPad prism; the two groups were compared by using a Paired T-test.  
In Figure 3.2, the percentage of CD56+ T-cells was calculated from total 
lymphocytes and T-cells. The mean value of CD56+ T-cells in CMV seronegative 
subjects was 3.292%, and for CMV seropositive subjects the mean was 8.380%. 
When these two groups were compared by applying a Paired t-test, there was a 
significant difference between them (P= <0.0001). This result indicates that 
CD56+ T-cells were expanded to higher levels in healthy chronic CMV 
seropositive individuals compared to the level of CD56+ T-cells in CMV 
seronegative individuals.    
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Figure 3.1 CD56+ T-cells level in representative CMV + and CMV- subjects. 
Density plots illustrate double staining of PBMCs by anti-CD3+ and anti-CD56+ 
with very clear-cut identification of these cells. Percentage of these cells was 
calculated from total lymphocytes and T-cells. The upper left density plot shows 
the percentage of CD56+ T-cells in a CMV seronegative healthy donor (1.8%). 
The upper right density plot shows the percentage of CD56+ T-cells in a CMV 
seropositive healthy donor (8.5%).  The lower left density plot shows the 
percentage of CD56+ T-cells from total T-cells in a different CMV seronegative 
healthy donor (1.6%). The lower right density plot shows the percentage of 
CD56+  T-cells from total T-cells in a CMV seropositive healthy donor (21.4%). 
CMV seronegative or seropositive plots were not obtained from the same donor. It 
is clear from the plots that all CD56+ T-cells are CD56+ dim and not bright.   
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Figure 3.2 Percentages of CD56+ T-cells in CMV+ and CMV- subjects. These 
vertical scatter plots compare the percentage of CD56+ T-cells obtained from total 
lymphocytes and CD3+ T-cells between CMV– and CMV+ subjects.  The mean of 
CD56+ T-cells in CMV seronegative subjects was 3.292± 0.3278, and in CMV 
seropositive subjects the mean was 8.380± 0.8006 (P <0.0001). Both scatter plots 
show clearly that CD56+ T-cells are expanded in CMV seropositive compared to 
CMV seronegative subjects. 
 
3.2.3.2 Relative numbers of CD56-CD3+ cells in healthy CMV seropositive 
and seronegative subjects 
Relative numbers of total CD3+CD56- T-cells in CMV seropositive versus 
seronegative subjects were also evaluated and compared. CD3+ T-cells were 
compared by two different methods, the first method was to calculate CD3+ T-
cells from the total lymphocytes and the second method was to calculate CD3+ T-
cells from total cells expressing CD3 after excluding CD56+ T-cells (Figure 3.3).  
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Figure 3.3 Percentages of CD56- T-cells in CMV+ and CMV- subjects. 
Frequency of CD56- T-cells was compared between CMV seropositive and 
seronegative healthy individuals. Both scatter plots showed more CD3+CD56-T-
cells in CMV seronegative than seropositive subjects. In the left plot, 
CD3+CD56- cells were evaluated from the total lymphocytes, the mean of 
CD3+CD56- T-cells in CMV seronegative subjects was 59.98% ± 2.034, which 
was more than the mean of CD3+CD56- T-cells in CMV seropositive subjects 
53.61% ± 1.475, although this was not quite statistically significant (P = 0.0516). 
In the right scatter plot CD3+ CD56- cells were evaluated from the total CD3+ T-
cells after subtracting CD56+ T-cells. The mean of CD3+CD56- T-cells in CMV 
seronegative subjects was 95.25% ± 0.4473, which was more than the mean of 
CD3+CD56- T-cells in CMV seropositive subjects 83.84% ± 0.7806 which was 
significant (P<0.0001). The number of donors was 68 healthy individuals of 
whom 34 were CMV seronegative and 34 were CMV seropositive. 
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 It is clear from Figure 3.3 that a higher percentage of CD56- T-cells was present 
in CMV seronegative than CMV seropositive healthy individuals.  
 
3.2.3.3 Relative numbers of NK cells (CD56+CD3-cells) in healthy CMV 
seropositive and seronegative subjects 
Relative numbers of total CD56+CD3- NK cells in CMV seropositive versus 
seronegative subjects were also evaluated and compared. NK cells were found to 
be present in roughly equal proportions in CMV seronegative and CMV 
seropositive healthy individuals (Figure 3.4).  
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Figure 3.4 Frequencies of CD56+CD3-NK cells in CMV+ and CMV- subjects. 
This figure shows the frequency of CD56+CD3-NK cells in CMV seropositive 
versus seronegative individual donors. There was no significant difference 
between numbers of NK cells present in CMV- healthy individuals 15.14± 0.9879 
compared with CMV seropositive 14.59± 0.7497 (P = 0.7873). 68 healthy donors 
were used of which 34 were CMV seronegative and 34 CMV seropositive. 
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3.2.3.4 CD56+ T-cell levels compared in different age groups 
Relative numbers of CD56+ T-cells were evaluated in three different age groups: 
20-34, 35-49 and >50 years. Relative CD56+ T-cell numbers were compared 
between each of these groups, then all groups were analysed by using One-way 
analysis of variance (Figure 3.5). It is clear that CMV seropositive subjects in all 
age groups have significantly expanded numbers of CD56+ T-cells than CMV 
seronegative healthy individuals.  
 
Figure 3.5 CD56+ T-cells compared by age group. This scatter plot illustrates 
the percentage of CD56+ T-cells present in the peripheral blood in 68 healthy 
donors; 34 were CMV seronegative and 34 were seropositive. It is clearly 
noticeable that more CD56+ T-cells were present in the PBMCs of CMV 
seropositive donors than CMV seronegative.  
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3.2.3.5 CD56+ T-cells compared according to gender  
CD56+ T-cell numbers were compared between males and females. Levels of 
CD56+ T-cells were compared between CMV seropositive and seronegative male 
donors and this was also done for female donors (Figure 3.6). After that, the levels 
of the cells were compared between CMV seropositive males and females, and 
CMV seronegative males and females to see if there are any significant 
differences between the two genders (Figure 3.7).  
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Figure 3.6 CD56+ T-cell levels according to gender. This figure shows the 
relative difference of CD56+ T-cells level within the same gender groups. Both 
male and female CMV seropositive subjects had significantly more than 
seronegative donors (P = 0.0001 and < 0.0001 respectively).    
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Figure 3.7 Levels of CD56+ T-cells in males and females with the same CMV 
sero-status. This figure shows the comparison between the levels of CD56+ T-
cells in males and females with the same CMV sero-status. No significant 
differences were detected between genders in either group.     
 
3.3 Characterisation of the phenotype of CD56+ T-cells in CMV seropositive 
and seronegative healthy subjects 
3.3.1 Introduction   
T-cell-mediated immunity has diverse characteristics in both function and 
phenotype. Both function and phenotype are adapted according to many factors. 
The previous section 3.2 has shown clearly that CD56+ T-cells were significantly 
(P <0.0001) expanded in CMV seropositive healthy donors.  
The potential characteristics of CD56+ T-cells were also investigated through the 
detection of markers on these cells in CMV seropositive and seronegative healthy 
donors, moreover, the levels of these markers between both sero-statuses were 
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compared to identify any significant variation. The expansion of these cells in 
CMV seropositive healthy donors would be expected to lead to characteristic 
phenotypic differences from CMV seronegative individuals. These variations may 
involve both surface markers as well as functional differences.  
Several markers were investigated in both CMV seropositive and seronegative 
healthy subjects. Naive T-cells are well known to express five markers CD45RA, 
CD62L, CCR7, CD27 and CD28 (Hamann et al. 1997). Memory T-cells have a 
phenotype distinct from that of naive T-cells, instead of the CD45RA memory T-
cells express CD45RO, however, a subtype of memory T-cells expresses high 
CD45RA with low CD45RO and these are called TEMRA (Libri et al. 2011). This 
type of memory cell is highly differentiated in the case of both CD4 and CD8 T-
cell compartments and starts to re-express CD45RA and increase in numbers in 
older individuals (Di Mitri et al. 2011). Moreover, memory T-cells are 
heterogeneous for marker expression and can be subdivided into functionally and 
phenotypically distinct subsets; first naive cells differentiate into central memory 
then effector memory and finally terminally differentiated effector memory TEMRA 
cells (Table 3.2). TCM or central memory cells express high CD45RO, CD62L and 
high CCR7, respond to CCL21 (secondary lymphoid tissue chemokine) and 
migrate centrally to lymph nodes; they secrete IL-2 after TCR triggering but not 
IFN-γ and IL-4, though, when they proliferate and become effector cells they start 
producing IFN-γ and IL-4 (Sallusto et al. 2004). Moreover, CD62L and CCR7 are 
two essential receptors involved in cell extravasation via high endothelial venules 
(HEV) toward T-cell areas in secondary lymphoid organ (Sallusto et al. 2004).  
Furthermore, TEM express CD45RO, though they are CCR7 negative and have 
chemokine receptors and adhesion molecule to assist TEM migration to inflamed 
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tissues. Moreover, they have the potential to secrete IFN-γ, IL-4 and IL-5 while 
CD8+ T cells have a large arsenal of perforin in response to antigenic stimulation 
(Sallusto et al. 2004).             
Many markers were evaluated according to their function and possible role 
regarding CMV infection. The background regarding their role and functions in 
the immune mechanism has been explained in Table 3.3. 
 TCM TEM TEMRA Naive T-cells 
CD45RA low low High High 
CD45RO High High low low 
CD28/CD27/ 
CCR-7/CD62L 
High High low High 
IL-2 High low low High 
IFN-γ Low High High low 
IL-4 Low High - Low 
TNF-α High High - low 
Table 3.2 Phenotypic characteristics of memory T-cells (Sallusto et al. 2004, 
Hamann et al. 1997). TCM = central memory; TEM = effector memory; TEMRA = 
effector memory cells expressing CD45RA.   
 
Another type of memory T-cell was identified and named TRM (tissue-resident 
memory T-cells). This type of memory T-cell is believed to remain at the site of 
infection after clearance of the pathogen. Moreover, the phenotype of these cells 
was found to be CD62L negative, CCR7 negative, CD11a high, CD44 high, CD69 
positive and CD103 positive (Mueller et al. 2013).   
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Table 3.3 Markers applied to phenotypic analysis of CD56+ T-cells in CMV 
seropositive and seronegative donors. 
Marker Immune related function during CMV infection 
CD4 
Interacts with MHC-II on APC via extracellular domain, therefore 
amplifying TCR signal to activate T-cells. Frequency of CD4+ T-
cells specific for HCMV was detected to be between 9-40% 
(Sylwester et al. 2005, Sester et al. 2002).   
CD8 
A co-receptor to TCR that targets MHC-I that is expressed on all 
nucleated cells. Foreign peptide expressed on MHC-I lead to T-cell 
activation leading to apoptosis of the cell under stress. Repeated 
CMV viremia in humans who are deficient in CD8+CMV specific 
T-cells (Crough and Khanna 2009).  
CD45RO 
Expressed on activated, memory T-cells, also on several other 
related immune cells. Improve TCR and BCR (B-cell receptor) 
signalling and activation.  
CD45RA 
Generally expressed on Naive T-cells. Also, it has been found to be 
expressed on highly on TEMRA memory T-cells (Libri et al. 2011).  
CD11a 
Also called Lymphocyte function-associated antigen-1 (LFA-1). It 
is a membrane glycoprotein that is involved in cell recruitment to 
site of infection (Hamann et al. 1997).   
CD58 
Also called Lymphocyte function-associated antigen-3 (LFA-3),it is 
up regulated due to CMV infection and assists in NK cells lysis of 
CMV infected cells (Fletcher et al. 1998).  
CD57 
NK cells expressing CD57+ were expanded during acute HCMV 
episodes (Lopez-Verges et al. 2011).  
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CD94/NKG2C 
A killer lectin-like receptor provides an alternative activation 
pathway for NK and CD8+ T-cells (Guma et al. 2005). 
CD94/NKG2C+ NK cells were found to expand in response to 
CMV infection (Ugolini et al. 2001, Andre et al. 2004, Monsivais-
Urenda et al. 2010, Foley et al. 2012).   
CD161 
Killer cell lectin-like receptor super family B. It has been identified 
that CD161 expression is up-regulated non-significantly on NK, 
CD56+ T-cells and CD3+ T-cells in CMV seropositive healthy 
donors  (Monsivais-Urenda et al. 2010).   
CD62L 
Cell adhesion molecule known also as L-selectin and involved in 
homing function of cells and also called lymph-node homing 
receptor (Hamann et al. 1997). TEMRA CD45RO+CD62L- cells were 
found to be protective against CMV reactivation (Luo et al. 2010). 
CD28 
Expressed on the surface of T-cells and is a receptor for CD80. It 
provides a co-stimulatory signal required for T-cell activation. 
Lower CD28 expression was found to be associated with CMV 
sero-positivity (Prelog et al. 2013, van Stijn et al. 2008).  
CD127 
Interleukin-7 receptor involved in development of lymphocyte 
activation. Involved in early viral-specific CTL becoming memory 
cells and down regulated in chronic viral infection such as CMV 
(van Stijn et al. 2008, Golden-Mason et al. 2006).  
CCR7 
CC Chemokine receptor type 7. Immune-suppressed patients have 
CMV specific CD8+CD45RO+CCR7-CD27- cells (Gamadia et al. 
2001). CCR7 expression is down regulated in CMV infection (van 
Stijn et al. 2008).  
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CD158a/h 
(KIR2DL1/DS1) 
CD158e 
(KIR3DL1) 
CD158f 
(KIR2DL5) 
KIR family expressed on NK cells and some other T-cells. They are 
named depending on the number of extracellular Ig-like domains. 
Also, on their cytoplasmic domain Long (L) which are inhibitory 
KIR or short (S) which are activating KIR. 
γδ-TCR 
γδ-T-cells were expanded in peripheral blood of renal transplant 
patients after few months due to CMV viremia (Dechanet et al. 
1999b). Non-significant increase was also found in seropositive 
healthy donors than sero-negative donors (Alejenef et al. 2014).       
TCRVα7.2 
Characteristic type of α TCR found mainly on MAIT cells. Using 
coloured conjugated antibodies for TCRVα7.2 and CD161 the 
MAIT cells can be identified (Gerart et al. 2013).     
CD25 
Activation marker also called α chain of IL-2 receptor generally 
found on activated T-cells and B-cells. CMV leads to activation of 
short term CD25+ CD4+ and CD8+ T-cells that produce cytokines 
and are capable of lysing pp65 of CMV (Samuel et al. 2014).  
CD69 
Activation marker of T-cells and NK cells. Up-regulation of CD69 
on T-cells occurs in response to CMV reactivation (Petersen et al. 
2011).  
CD16 
Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). CD16 is 
specifically upregulated on HCMV-induced γδ-T-cells (Couzi et al. 
2012). 
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3.3.2: Aims of this study  
The aims of this section of the study were to analyse and compare the phenotype 
of CD56+ T-cells in CMV seropositive and seronegative healthy individuals. 
Different memory, naive and activation markers described in Table 3.3 were 
investigated through staining CD56+ T-cells with a third monoclonal antibody. 
Moreover, the levels of these markers on CD56+ T-cells were compared between 
these two healthy groups by applying a Paired t-test.   
 
3.3.3 Results 
Overall, not all markers were evaluated from the same individual therefore the 
number of donors for each marker is different.    
3.3.3.1 Expression of CD4 and CD8 by CD56+ T-cells 
PBMCs from healthy  CMV seropositive and seronegative were labelled with 
three colour monoclonal antibodies in order to phenotype CD56+ T-cells. The 
cells were stained by anti-CD3 PerCP Cy5.5, anti-CD56 FITC and anti-CD4 PE 
or anti-CD8 PE. The percentage of CD56+ T-cells expressing CD4 or CD8 were 
calculated after applying only the CD56+CD3+ region of cells to density plots 
demonstrating CD4 or CD8 cells (Figure 3.8). A total of 32 healthy donors were 
tested, 16 CMV seropositive and 16 seronegative. CD56+ T-cells were identified 
to express CD4+, CD8+.  
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Figure 3.8 Expression of CD4 and CD8 by CD56+ T-cells. This figure shows 
representative plots of the percentage of gated CD3+CD56+ cells expressing CD4 
and CD8. 
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In this section, the question was asked whether the majority of CD56+ T-cells 
expressed CD4 or CD8 T-cell receptors among CMV+ or CMV- subjects. 
The mean of the expression of these two populations were compared by using 
Paired t-test which is shown in Figure 3.9.  
The results show that a mean of 74.79% of CD56+ T-cells in CMV seronegative 
healthy donors were CD8- (mean of CD8+CD56+T-cells 25.21 ± 3.316), while 
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87.12% of CD56+ T cells in seronegative donors were CD4- (mean of 
CD4+CD56+T-cells 12.83 ± 2.361). Although four-colour staining with anti-CD4, 
-CD8, -CD3 and -CD56 was not carried out, if no cells are double positive for 
CD4 and CD8,  this indicates that about 81% of CD56+ T-cells in CMV 
seronegative subjects were CD4- and CD8-. 
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Figure 3.9 Expression of CD4 and CD8 by CD56+ T-cells in CMV+/-. The 
percentage of CD8 and CD4 expressed on CD56+ T-cells was compared between 
CMV seronegative and seropositive subjects. Both CD4+ and CD8+ CD56+ T-
cells have expanded significantly (P= 0.0167 and <0.0001 respectively) in CMV 
seropositive than seronegative healthy subjects. 
 
When the percentage of CD8+ CD56+ T-cells from both CMV seronegative and 
seropositive subjects were compared with each other, the results show clearly a 
significant expansion (P<0.0001) of CD8+CD56+ T-cells in CMV seropositive 
(72.28% ± 3.619) compared to seronegative subjects (25.21%± 3.316; Figure 3.9).  
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CD4+CD56+ T-cells were also expanded significantly (P = 0.0167) in CMV 
seropositive (29.83% ± 2.361) compared to seronegative subjects (12.83% ± 
2.361).   
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Figure 3.10 Expression of CD4 vs CD8 by CD56+ T-cells. The figure show that 
a greater proportion of CD56+ T-cells expressed CD8 than CD4 in both 
seronegative and seropositive subjects (P = 0.0024 and <0.0001, respectively). 
 
A greater proportion of CD56+ T-cells were also found to express the CD8 
receptor than CD4. This was found in both CMV seronegative and seropositive 
healthy individuals. Generally, CD8+CD56+T-cells were significantly more 
abundant (P= 0.0024) than CD4+CD56+T-cells in CMV seronegative subjects. 
These CD8+CD56+T-cells were expanded significantly (P <0.0001) in the 
seropositive group more than CD4+CD56+T-cells (Figure 3.10).  
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3.3.3.2 CD56+ T-cells; naive and memory markers 
T-cell mediated immune responses toward pathogens result in the development of 
antigen-specific T lymphocytes to eliminate this pathogen. Antigenic specificity 
depends on T-cell recognition via TCR of the unique peptides expressed on the 
MHC molecules presented by APC. T-cell mediated immunity includes three 
aspects: the primary response via naïve T-cells, effector mechanisms via activated 
T-cells and memory response via memory cells, also, T cells induce other cells to 
participate in the immune response through their secretion of immune modulators. 
CD56+ T-cells were stained for naive and memory markers in CMV seropositive 
and seronegative healthy donors. The markers targeted were CD45RO, CD45RA, 
CD62L, CCR7, CD28 and CD127. Levels of expression of these markers were 
compared between CMV seropositive and seronegative subjects to identify any 
significant differences between these two groups. Density plots illustrating the 
levels of expression of these markers are shown in Figure 3.11.  
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Figure 3.11 Memory and naive markers expressed by CD56+ T-cells. 
Representative density plots illustrating levels of memory and naive markers 
expressed by CD56+ T-cells in CMV seronegative and seropositive healthy 
individuals. The levels of expression were identified after each plot was compared 
to a negative control.   
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Figure 3.12 Comparison of memory and naive markers expressed by CD56+ 
T-cells. Scatter plot illustrating the comparison between the percentage of each 
memory and naive marker between CMV seropositive (+) and seronegative (-) 
subjects. Numbers of donors were as follows: for CD45RO 14 seropositive and 14 
seronegative, CD45RA 19 seropositive and 19 seronegative, CD62L 14 
seropositive and 14 seronegative, CD28 14 seropositive and 12 seronegative, 
CD127 14 seropositive and 14 seronegative, and CCR7 5 seropositive and 7 
seronegative. 
 
- 135 - 
In Figure 3.12 the phenotypic analysis of CD56+ T-cells clearly showed 
significantly greater expression of CD45RO in seropositive (43.85% ± 4.733) than 
seronegative subjects (22.95% ± 3.066). Moreover, CD45RA showed almost the 
same level of expression between seropositive (98.88% ± 0.1436) and 
seronegative subjects (96.34% ± 2.189) clearly a substantial number of CD56+ 
cells from seropositive donors expressed both CD45RA and 45RO. CD62L was 
significantly expressed by more CD56+ T cells in seronegative (62.72% ± 4.611) 
than seropositive subjects (30.84% ± 6.150). Similarly, CD28 was also expressed 
on a significantly higher percentage of CD56+ T cells in seronegative (52.17% ± 
7.314) than seropositive subjects (22.10% ± 2.852). Likewise, CD127 was 
expressed by significantly more CD56+ T cells in seronegative (78.73% ± 4.191) 
than seropositive subjects (23.88 ± SE 3.858) as was CCR7 (64.21% ± 9.713 vs. 
20.23% ± 5.413). 
CD56+ T-cells from CMV seronegative subjects have been shown to express 
lower proportions of CD45RO+ cells but higher proportions of CD45RA+, 
CD62L+, CD28+ and CD127+ cells than CMV seropositive subjects. This pattern 
of surface marker expression is similar to that of naive and central memory T-
cells. However, in CMV seropositive healthy individuals the CD56+ T-cell 
phenotype of high CD45RO, re-expressed CD45RA, low CD62L, low CD28, low 
CD127 and low CCR7 was similar to that of TEMRA memory T cells and different 
from TEM in their re-expression of CD45RA as TEM do not re-express CD45RA.   
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3.3.3.3 CD56+ T-cell expression of Lymphocyte function-associated antigens 
CD56+ T-cells were phenotyped for their levels of expression of LFA-1 and LFA-
3 and CMV seropositive and seronegative healthy donors compared. CD11a or 
LFA-1 is involved in T-cell migration to the site of infection, CD58 or LFA-3 is 
upregulated in response to CMV infection and assists in NK cell lysis of CMV 
infected cells (Fletcher et al. 1998). In Figure 3.13 the proportions of CD56+ T 
cells expressing CD11a and CD58 are illustrated.  
CMV seronegative CMV seropositive 
  
  
Figure 3.13 LFA-1& 3 expressions by CD56+ T-cells. Representative density plots 
illustrating proportions of CD56+ T cells expressing CD11a/LFA-1 and CD58/LFA-3 in 
CMV seronegative and seropositive healthy individuals. The levels of expression were 
identified after each plot was compared to a negative control.   
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Figure 3.14 LFA-1& 3 expressions by CD56+ T-cells between CMV+/-. On the left 
levels of LFA-1 and -3 expressed by CD56+ T-cells were measured and compared 
between CMV seropositive and seronegative healthy individuals. Number of donors for 
CD11a were 19 seropositive and 19 seronegative, for CD58 the donors were 5 
seronegative and 7 seropositive. The right scatter plot represents MFI levels of CD11a, it 
was found clearly MFI of CD11a forCMV seropositive subjects were significantly 
greater (P= 0.0228) than for CMV seronegative subjects. 
 
Both CMV seropositive (98.85% ± 0.4308) and seronegative subjects (99.56% ± 
0.1519) expressed similar proportions of CD11a+ CD56+ T cells, moreover, when 
MFI levels of CD11a were compared, it was found that MFI of CD11a on cells 
from CMV seropositive subjects were significantly higher (P= 0.0228) than on 
those from CMV seronegative subjects. However, CD58 was expressed on a 
significantly lower proportion of CD56+ T cells (P = 0.0101) in CMV 
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seropositive (88.83% ± 5.049) than seronegative donors (40.70% ± 12.36; Figure 
3.14).  
  
 3.3.3.4 CD56+ T-cell expression of CD57, CD161, CD94/NKG2C and CD16 
 CD56+ T-cells were phenotyped for their expression of CD57, CD161, 
CD94/NKG2C and CD16 and levels of expression compared between CMV 
seropositive and seronegative healthy donors. In Figure 3.15 the proportions of 
cells expressing CD57, CD161, CD94/NKG2C and CD16 on CD56+ T-cells are 
illustrated.  
  
Figure 3.15 CD57, CD161, CD94/NKG2C and CD16 expression by CD56+ T-
cells. Density plots illustrating levels of CD57, CD161, CD94/NKG2C and CD16 
expressed by CD56+ T-cells in representative CMV seronegative and seropositive 
healthy individuals 
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Figure 3.16 CD57, CD161, CD94/NKG2C and CD16 expression by CD56+ T-
cells in CMV+ and CMV- subjects. Proportions of CD56+ T cells expressing 
CD57, CD161, CD94/NKG2C and CD16 were measured and compared between 
CMV seropositive and seronegative healthy individuals. Number of donors for 
CD57 were 5 seropositive and 7 seronegative, CD161 were 17 seropositive and 16 
seronegative, CD94 were 5 seropositive and 7 seronegative, NKG2C were 7 
seropositive and 18 seronegative, and CD16 were 15 seropositive and 12 
seronegative. 
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In figure 3.16 a significantly higher percentage of CD56+ T-cells expressed CD57 
in seropositive (77.43% ± 9.186) than seronegative subjects (29.30% ± 10.42). 
Additionally, seronegative subjects (21.86% ± 4.622) had a significantly (P = 
0.0022) higher proportion of CD161+ cells than seropositive subjects (6.857% ± 
2.451). Moreover, significantly more CD56+ T cells expressed CD94 in 
seropositive (62.84% ± 8.261) than seronegative subjects (31.44% ± 7.281), and 
NKG2C was also present on a significantly higher proportion of CD56+ T cells in 
seropositive (21.9% ± 4.94) than seronegative subjects (4.253% ± 1.496; P = 
0.0015). However, CD16 was not expressed on a significantly higher proportion 
of CD56+ T cells (P= 0.5067) in seronegative (21.76% ± 4.596) than seropositive 
subjects (21.27% ± 2.905; P = 0.5067). 
 
3.3.3.5 CD56+ T-cells expression of KIRs CD158 a/h, CD158e and CD158f 
CD56+ T-cells were phenotyped for their expression of killer-cell 
immunoglobulin-like receptors (KIRs) CD158a/h, CD158e and CD158f and CMV 
seropositive and seronegative healthy donors compared (Figure 3.17).  In figure 
3.18 the levels of CD158a/h, CD158e and CD158f expression on CD56+ T-cells 
are illustrated. 
Overall, no significant differences were found when CD56+ T-cells were 
compared between both CMV groups. Large variations were found in KIRs 
expression in all donor groups. 
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Figure 3.17 KIR expressions by CD56+ T-cells. Plots illustrating expression of 
KIRs CD158a/h, CD158e, and CD158f by CD56+ T-cells in representative CMV 
seronegative and seropositive healthy individuals. 
CMV seronegative CMV seropositive 
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Figure 3.18 KIR expressions by CD56+ T-cells in CMV+ and CMV- subjects. 
Proportions of CD56+ T cells expressing CD158a/h, CD158e and CD158f 
compared between CMV seropositive and seronegative healthy individuals. 
Number of donors for CD158a/h were 5 seropositive and 7 seronegative, CD158e 
were 5 seropositive and 7 seronegative, CD158f were 5 seropositive and 7 
seronegative. 
 
3.3.3.6 CD56+ T-cell expression of CD25 and CD69 
CD56+ T-cells were phenotyped for their expression of CD25 and CD69 and 
compared between CMV seropositive and seronegative healthy donors. In Figure 
3.19 the proportions of CD56+ T cells expressing CD25 and CD69 are illustrated.  
Overall, no significantly differences were detected in CD56+ T-cell phenotype 
when CMV seronegative was compared to seropositive healthy individuals. 
However, CD56+ T-cells were expressing more CD69 in seropositive (2.375% ± 
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0.5830) than seronegative (2.845% ± 0.5092). Also, CD25 were expressed slightly 
more by seronegative (1.995% ± 0.4212) than seropositive (1.548% ± 0.3290) 
healthy donors (P= 0.5037).  
 
Figure 3.19 CD69 and CD25 expression by CMV+/-. Proportions of CD56+ T 
cells expressing CD69 and CD25 in representative CMV seronegative and 
seropositive healthy individuals. 
CMV seronegative CMV seropositive 
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Figure 3.20 CD69 and CD25 expression by CD56+T-cells in CMV+ and 
CMV- subjects. Proportions of CD56+ T cells expressing CD69 and CD25 were 
measured and compared between CMV seropositive and seronegative healthy 
individuals. Numbers of donors for CD69 were 19 seropositive and 19 
seronegative and for CD25 were 18 seropositive and 16 seronegative. Both 
markers were not tested from the same individual.  
 
 
3.3.3.7 CD56+ T-cell expression of TCRVα7.2 and γδ-TCR 
CD56+ T-cells were phenotyped for their expression of two different types of 
TCRs and compared between CMV seropositive and seronegative healthy donors. 
In Figure 3.21 the proportions of CD56+ T cells expressing TCRVα7.2 and γδ-
TCR in representative donors are illustrated. 
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Figure 3.21 TCRVα7.2 and γδ-TCR expression by CD56+ T-cells. Plots 
illustrating levels of TCRVα7.2 and γδ-TCR expressed by CD56+ T-cells in 
representative CMV seronegative and seropositive healthy individuals. 
CMV seronegative CMV seropositive 
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Figure 3.22 TCRVα7.2 and γδ-TCR expression by CD56+ T-cells in CMV+ 
and CMV- subjects. The scatter plot shows the proportions of CD56+ T cells 
expressing γδ TCR and Vα-7.2 TCR in healthy CMV seronegative and 
seropositive subjects. Overall, no significant difference was found between the 
two CMV groups. The numbers of donors for each group were 19 seropositive 
and 20 seronegative for γδ-TCR and 9 seropositive and 12 seronegative for Vα7.2 
TCR.  
 
In figure 3.22 γδ TCR expression on CD56+ T-cells was compared between CMV 
seropositive (21.39% ± 4.052) and seronegative subjects (21.15% ± 2.927) no 
significant difference resulted.  
V α 7.2 TCR expressions by CD56+ T cells also did not differ significant when 
between seropositive (16.07% ± 3.463) and seronegative subjects were compared 
(15.68% ± 3.626).  
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3.3.3.8 CD56+ T-cell expression of exhaustion markers 
CD56+ T-cells were phenotyped for their expression of PD-1, CTLA-4 and 
KLRG1 and compared between CMV seropositive and seronegative healthy 
donors. Proportions of CD56+ T cells expressing PD-1, KLRG1 and CTLA-4 in 
representative donors are illustrated in Figure 3.23. Moreover, the levels of 
expression In CMV seropositive and seronegative donors are illustrated in density 
plots (Figure 3.24).  
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Figure 3.23 PD-1, CTLA-4 and KLRG-1 expression by CD56+ T-cells in 
CMV+ and CMV- subjects. The scatter plot shows the proportions of CD56+ T 
cells expressing PD-1, CTLA-4 and KLRG-1 in healthy CMV seronegative and 
seropositive. Only KLRG-1 has shown significant difference between CMV 
seropositive and seronegative healthy donors. 
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Figure 3.24 PD-1, CTLA-4 and KLRG-1 expression by CD56+ T-cells in 
CMV+ and CMV- subjects. Plots illustrating levels of CD56+ T cells expressing 
PD-1, KLRG1 and CTLA-4 in representative CMV seronegative and seropositive 
healthy individuals. 
CMV seronegative             CMV seropositive 
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Overall, no significant difference was found between the two CMV groups in PD-
1 (seronegative 8.187% ±2.064, seropositive 13.2% SE± 6.056) and CTLA-4 
(seronegative 74.68% ±4.949, seropositive 74.25% ±4.777). However, KLRG-1 
expression was significantly more in CMV seropositive (12.23% ±3.994) than 
seronegative (10.83% ±2.424) (P= 0.0435). Number of donors for seronegative 7 
and seropositive 11 (Figure 3.23). 
 
3.3.4 Discussion 
In this part of the study relative numbers of the distinct subset of CD3+ T-cells 
that express the NK receptor CD56 (NCAM) were evaluated. This type of 
lymphocyte is also named CD56+ T-cells, CIK, NKT and CD56+CD3+ cells. 
This part of the study aimed to identify any difference in levels of this subset of 
lymphocytes between CMV seropositive and seronegative healthy individuals, 
also, to evaluate both NK cell and CD3+CD56- T-cell levels between the same 
healthy individuals. A secondary aim was to identify if the levels were 
significantly different between age groups and gender groups. Section 3.2.3.1 has 
clearly identified that CD56+ T-cells were significantly expanded in CMV 
seropositive healthy donors compared to seronegative donors. Additionally, the 
mean levels of CD56+ T-cells in CMV seropositive subjects (8.38%) were 2.5 
folds higher than the mean of CD56+ T-cells in CMV seronegative subjects 
(3.29%).         
Section 3.2.3.2 tested for differences in the levels of CD3+ CD56- T-cells 
between CMV seropositive and seronegative healthy donors. When comparing the 
levels of CD3+ CD56- T-cells as a proportion of total lymphocytes it was shown 
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that CMV seronegative subjects had relatively more CD3+CD56- T-cells than 
seropositive subjects although this was not statistically significant (P=0.0516). 
However, when CD3+CD56- T-cells has been compared between these two 
healthy groups after excluding CD56+T-cells there was clearly a significant 
difference (P<0.0001).   
Any differences in NK cell levels between CMV seropositive and seronegative 
subjects were also evaluated and compared in section 3.1.3.3. NK cells were 
identified as cells that only express CD56 but without CD3. Mean levels of NK 
cells were the almost the same between CMV seropositive and seronegative 
healthy donors (P=0.7873).   
Data were subdivided into different age groups which were compared in section 
3.1.3.4. It was clear that CMV seropositive subjects had more CD56+ T-cells than 
CMV seronegative subjects in all age groups. What is more, those healthy donors 
who were 50 years and over and CMV seropositive had more expanded CD56+ T-
cells than the rest of the seropositive age groups. All CMV seronegative groups 
expressed similar levels of CD56+ T-cells. Comparing the levels of CD56+ T 
cells between genders in section 3.1.2.5 showed no significant difference between 
males and females.   
All the previous sections clearly identified that CMV seropositive subjects had 
accumulated more CD56+ T-cells in their peripheral blood than CMV 
seronegative healthy individuals, which implies a role of these cells in response to 
chronic CMV carriage.   
For the phenotypic analysis of this part of the study CD56+ T-cells were 
investigated. This was done through three colour surface staining of CD56+ T-
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cells in two groups of healthy donors; CMV seropositive and seronegative. The 
surface receptors that were targeted were: CD4, CD8, CD45RA, CD45RO, 
CD62L, CCR7, CD28, CD127, CD11a/LFA-1, CD58/LFA-3, CD57, CD161, 
CD94/NKG2C, CD16, CD158a/h, CD158e, CD158f, CD25, CD69, TCRVα7.2 
and γδ-TCR. Percentage expression was calculated by density plot after the levels 
were compared to negative controls. Any differences in the percentage expression 
between CMV seronegative and seropositive subjects were compared by applying 
a Paired t-test. CMV status was determined by using ELISA as mentioned earlier 
in section 3.1.  
CD56+ T-cells in CMV seropositive subjects were found to comprise a higher 
proportion of CD8+ and CD4+ cells than in seronegative subjects. Although four 
color staining with anti-CD3, CD56, CD4 and CD8 was not conducted, in some 
CMV+ subjects the total % of CD56+ T cells expressing CD4 or CD8 was >100% 
suggesting that some expressed both CD4 and CD8. The higher incidence of CD8 
expression on CD56+ T-cells was also found in several studies that identified that 
CD8+ T-cells provide protection against CMV infection in both human and mice 
(Crough and Khanna 2009). Moreover, HCMV detected to be reactivated in 
individuals who were deficient in CMV-specific CD8+ T-cells (Crough and 
Khanna 2009). The proportionate increase in  CD4+ CD56+ T-cells was also 
found in other studies in which HCMV-specific CD4+ T-cells increased between 
9% to 40% (Sylwester et al. 2005, Sester et al. 2002). 
Overall, CD8 was expressed significantly more by CD56+ T-cells than CD4 in 
both seronegative and seropositive subjects. This was also explained by other 
studies who found that CD8+ T-cells can expand to 17 folds to give rise to CD56+ 
T-cells, however, CD4+ cells failed to do so and even the generated cells were 
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CD56 negative (Franceschetti et al. 2009). Both CD4 and CD8 tend to be stable 
markers of post-thymic T cells so any increases in response to CMV infection are 
presumably a result of expansion of CD4+ or CD8+ CD56+ T cells.  
On other hand, some studies stated that CD56 acquisition is correlated with 
increased cytotoxicity of these cells. CD56 was acquired by lymphocytes in an ex 
vivo environment that already expressed the phenotype CD4+CD8+, CD4-CD8- 
and CD4-CD8+ after the cells were cultured with IL-2 and anti-CD3 mAb (Lu 
and Negrin 1994). However, it is not clear whether CMV infection in vivo leads to 
expansion of T cells already expressing CD56 or induction of CD56 expression by 
previously CD56- cells. 
The phenotype of CD56+ T-cells in CMV seronegative subjects was found to be 
similar to that of naïve T cells, as low numbers expressed CD45RO, while high 
numbers expressed CD45RA, CD62L, CD28 and CD127. They only differed 
from TCM in their low expression of CD45RO while TCM  have adequate 
expression of CD45RO (Sallusto et al. 2004). Furthermore, in analysis of CMV 
seropositive subjects it was found that numbers of CD56+T-cells expressing 
CD45RO was increased significantly, together with a reduction in numbers of 
cells expressing CD62L, CD28, CD127 and CCR7. This surface expression is 
similar to TEMRA and different from TEM in re-expression of CD45RA as TEM do 
not re-express CD45RA (Sallusto et al. 2004). CD45RA re-expression was 
explained in several studies as an outcome of persistent chronic viral infection 
(Henson et al. 2012).  
CD11a is a component of the integrin LFA-1 and levels of expression on CD56+ 
T-cells were the same between each CMV group. However, MFI levels were 
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increased significantly in CMV seropositive compared to seronegative subjects. 
CD11a is essential in homing of immune cells to an infection site and also in 
extravasation and activation (E. Jiang et al. 2014). CD58, the ligand for 
CD2/LFA-2 and essential in cell adhesion, was significantly increased in CD56+ 
T-cells in CMV seropositive compared to seronegative healthy individuals. This 
was also found in other studies indicating up-regulation of CD58 in response to 
CMV infection, also, a strong correlation was found between NK cell lysis of 
CMV-infected cells and the surface expression of CD58 (Fletcher et al. 1998). 
CD57, CD94 and NKG2C were expressed by significantly more CD56+ T-cells in 
CMV seropositive than seronegative healthy individuals. This is also consistent 
with another investigation that showed expansion of a CD94/NKG2C and CD57 
expressing NK cell population during CMV infection (Lopez-Verges et al. 2011). 
The ligand for NKG2C is HLA-E, which is expressed by CMV-infected cells and 
bound by the CMV encoded protein UL40. Also, HLA-E has a high affinity for 
the inhibitory receptor NKG2A, however this study identified that high 
CD57/NKG2C NK cells lacked expression of NKG2A (Lopez-Verges et al. 2011) 
and another study has shown that culturing PBMCs with CMV-infected cells 
resulted in selective expansion of NK cell expressing the activation receptor 
CD94/NKG2C over cells expressing CD94/NKG2A (Guma et al. 2006).  
The significantly reduced numbers of CD161+ CD56+ T-cells in CMV 
seropositive subjects  argued against any virus-associated expansion of Th17 
cells, iNKT cells or MAIT cells, all of which are CD161+ (Cosmi et al. 2008, 
O'Reilly et al. 2011, Dusseaux et al. 2011). Also, in CMV seropositive children 
CD161 was expanded on NK cells (Monsivais-Urenda et al. 2010), however 
CD161 was absent from CMV-specific CTL (Northfield et al. 2008). CD16 is 
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expressed in the form of the Fc receptor FcγRIIIa (CD16a) on lymphocytes while 
FcγRIIIb (CD16b) is expressed on neutrophils. CD16 expressing cells were found 
to be expanded in HCMV-induced γδ-T-cells (Couzi et al. 2012) while in this 
study CD56+ T-cells from CMV seronegative subjects did not have significantly 
less CD16 than in seropositive subjects. There were no significant differences in 
expression of KIRs CD158a/h, CD158e and CD158f on CD56+ T-cells from 
CMV seronegative and seropositive subjects.  
CD69 is an activation marker of T-cells and NK cells. Up-regulation of CD69 on 
T-cells occurs in response to CMV reactivation (Petersen et al. 2011). However, 
this study has shown that levels of CD69 expression were almost the same 
between both seropositive and seronegative subjects and no significant difference 
resulted. CD25 is an activation marker of activated T-cells and B-cells and CMV 
leads to activation of short term CD25+ CD4+ and CD8+ T-cells that produce 
cytokines capable of lysing CMV pp65 expressing cells (Samuel et al. 2014). 
However, no significant difference in CD25 expression was found between CMV 
seropositive and seronegative groups. About 21% of CD56+ T-cells in PBMCs 
were γδ-TCR positive however when CMV seropositive and seronegative donors 
were compared there was no significant difference, this argues against a study that 
had observed an expansion in γδ-T-cells in PBMCs in renal allograft patients due 
to CMV infection (Dechanet et al. 1999b). However, it in a recent paper from this 
group, a selective expansion of Vδ1+ γδ T cells in CMV positive healthy donors 
with increasing age was reported (Alejenef et al, 2014). It is possible that overall 
levels of γδ T cells remain unchanged following CMV infection as the normally 
more abundant Vδ2+ cells may not be expanded. Numbers of cells expressing Vα-
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7.2 TCR, a marker of iNKT cells, also showed no significant differences between 
seropositive and seronegative subjects.  
Overall, Figure 3.25 illustrates significantly increased while Figure 3.26 illustrates 
significantly decreased surface markers between CD56+ T cells from CMV 
seropositive and seronegative groups.  
 
Figure 3.25 Phenotypic differences between CD56+ T cells from CMV 
seropositive and CMV seronegative healthy subjects. Cell surface markers that 
were mostly increased in CMV seropositive subjects. Results are expressed as 
mean percentage of CD56+ T cells with p values above indicating levels of 
significance between CMV seronegative and CMV seropositive subjects. 
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Figure 3.26 Phenotypic differences between CD56+ T cells from CMV 
seropositive and CMV seronegative healthy subjects. Cell surface markers that 
were mostly decreased in CMV seropositive subjects. Results are expressed as 
mean percentage of CD56+ T cells with p values above indicating levels of 
significance between CMV- and CMV+ subjects. 
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CD56+ T-cell phenotypic characteristics in CMV seropositive subjects were 
consistent with memory cells (TEMRA) and different from TEM in their re-
expression of CD45RA. While, in CMV seronegative subjects the phenotypic 
characteristic of CD56+ T-cells were similar to naïve T cells and different from 
TCM in having low expression of CD45RO.  
Exhaustion markers were included to validate the responsive functions of CD56+ 
T-cells. In chronic viral status the cells that are virus-specific such as CD8+ T-
cells lose their cytotoxicity and acquire a non-functional exhausted status, starting 
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by losing IL-2 production then followed by TNF-α and IFN-γ (Wherry et al. 
2004). PD-1 (Programmed cells death) and PD-1-Ligands play a role in immuno-
regulatory functions for T-cells activation and tolerance (Jin et al. 2011). No 
differences were noted in CD56+ T-cells between seropositive and seronegative 
healthy donors. KLRG-1or killer lectin-like receptor G1 recognizes the classical 
cadherin family (Grundemann et al. 2010). CD56+ T-cells in seropositive subjects 
expressed significantly more KLRG-1 than seronegative groups. This was also 
reported as KLRG-1 expression was induced in virus specific CD8+ T-cells 
against repetitive activation of chronic CMV, HIV, EPV infection which 
influences the function of these cells (Thimme et al. 2005). Also, another study 
showed that T-cells that express KLRG-1 preserve their function, however they 
demonstrate deprived proliferation capability (Voehringer et al. 2002), increase 
KLRG-1 up-regulation of virus-specific CD8+ T-cells is an evidence of T-cell 
differentiation (Bengsch et al. 2010). On the other hand, CTLA-4 levels were 
roughly the same between sero-groups and no significant variation detected. 
Surprisingly, levels of KLRG-1 and CTLA-4 were elevated, however, PD-1 was 
not which contradicts another study which claimed that PD-1 and KLRG-1 but not 
CTLA-4 were elevated in virus specific CD8+ T-cells (Bengsch et al. 2010).              
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4. Functional responses in CD56+ T cells from CMV seropositive and CMV 
seronegative healthy subjects 
4.1 Cytokine responses of CD56+ T-cells  
4.1.1 Introduction 
It has been found that relative numbers of CD56+ T-cells have been expanded in 
CMV seropositive healthy subjects. The next step was involving the evaluation of 
the capability of CD56+ T-cells to recognise and respond to CMV lysate. The 
cells were stimulated and evaluated for the immune expression of IFN-γ, TNF-α, 
IL-2, Perforin, Granzyme A and Granzyme B.  
IFN-γ is a type II interferon and involved in immune responses to viral infection. 
The interferon were subtyped according to their sequence homology and receptor 
specificity (Schroder et al. 2004). Both IFN-γ and TNF-α (tumour necrosis factor- 
alpha) have been found to be expressed by CD8+ and CD4+ T-cells when induced 
by viral lysate (Radha et al. 2005). IL-2 is naturally produced in response to 
infection, and it is essential in several biological functions involving growth, 
differentiation and proliferation of cells. Moreover, TCR stimulation leads to 
production of IL-2 (Stern and Smith 1986). Perforin and Granzyme are part of one 
of the pathways of apoptosis induced by lymphocytes in response to virally 
infected or transformed cells. Both these molecules work in cooperative method in 
order to induce target cell apoptosis (Trapani and Smyth 2002).    
PBMCs from both CMV seropositive and seronegative subjects were incubated 
overnight in culture medium in a humidified 5% CO2 atmosphere at 37
o
C. CD56+ 
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T-cell response was assessed by their content of IFN-γ, TNF-α, IL-2, Perforin, 
Granzyme-A and -B as described in section 2.4.2.1.  
 
4.1.2 Aims  
This section is part of the functional investigations of the capabilities of CD56+ 
T-cells when stimulated by CMV lysate. Levels of cytokine expression from 
CD56+ T-cells will be compared between cells from CMV seropositive and 
seronegative subjects. Also, CD56+ T-cell cytokines expression will be compared 
to NK cells and CD56- T-cells.  
 
4.1.3 Results 
PBMCs were incubated for 24 hours in 48 well plates; each well contained 1 X 
10
6
 cells/ ml. The cells were stimulated by CMV lysate at 2 µl/ml and SEB 
(Staphylococcal enterotoxin B) at 1µl/ml. Moreover, un-stimulated cells were 
used as background and an isotype control was also applied to remove non-
specific binding of monoclonal antibodies. Cells were labelled with anti-CD3 and 
anti-CD56 to identify CD56+CD3- NK cells, CD56+ T-cells and CD56- T-cells, 
the cells were further stained intracellularly as explained in section 2.4.2.1 for 
IFN-γ, TNF-α, IL-2, Perforin, Granzyme A and B.  Both results from CMV 
seropositive and seronegative donors were compared by using a Paired T-test, 
p<0.05 being regarded as statistically significant.  
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SEB was used as a preferred positive control for intracellular staining for 
cytokines in response to CMV lysate and examples of the results are illustrated in 
Figure 4.1.  
 
Figure 4.1 SEB as a positive control for CD56+T-cells. Examples of the cells’ 
response to overnight stimulation with SEB on IFN- γ expression.   
 
4.1.3.1 IFN-γ expression following stimulation with CMV lysate 
IFN-γ expression by NK cells, CD56+ T-cells and CD56- T-cells after cells were 
stimulated overnight with CMV lysate. The levels of expression are illustrated by 
density plot in Figure 4.2.  
Generally, PBMCs from healthy CMV seropositive donors expressed more IFN-γ 
in response to CMV lysate when incubated overnight in a humidified 5% CO2 
atmosphere at 37
o
C.  Following that, levels of IFN-γ expression were compared 
between CMV seropositive and seronegative by using a Paired T-test. The results 
are illustrated in Figure 4.3.  The three groups of cells expressed significantly 
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more IFN-γ in seropositive donors than seronegative subjects. IFN-γ expressed by 
NK cells was significantly more (P = 0.002) in CMV seropositive (5.937% 
±1.049, N=18) than seronegative subjects (2.332% ±0.4045, N=23).  Also, IFN-γ 
expressed by CD56+ T-cells was significantly more (P = 0.0042) in CMV 
seropositive (5.482% ±0.6093, N=18) than seronegative subjects (2.585% 
±0.3664, N=23). Moreover, IFN-γ expressed by CD56- T-cells was significantly 
more (P = 0.0399) in CMV seropositive (3.843% ±0.7222, N=18) than 
seronegative subjects (1.976% ±0.2981, N=22). 
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 Seronegative Seropositive 
 Figure 4.2 Levels of IFN-γ expression. In the  representative populations of NK 
cells, CD56+ T-cells and CD56- T-cells after overnight stimulation with CMV 
lysate.. 
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Figure 4.3 Levels of IFN-γ expression in CMV+ and CMV- subjects. Paired T-
tests were used to compare levels of IFN-γ expression by NK cells, CD56+ T-
cells and CD56- T-cells after overnight stimulation with CMV lysate. IFN-γ was 
expressed by significantly more NK cells (P = 0.002) in CMV seropositive than 
seronegative subjects.  Also, IFN-γ was expressed by significantly more CD56+ 
T-cells (P = 0.0042) in CMV seropositive than seronegative subjects. Moreover, 
IFN-γ was expressed by more CD56- T-cells (P = 0.0399) in CMV seropositive 
than seronegative subjects. 
 
4.1.3.2 TNF-α expression following stimulation with CMV lysate 
Levels of TNF-α expression by NK cells, CD56+ T-cells and CD56- T-cells were 
studied after cells were stimulated by CMV lysate. The levels of expression were 
illustrated by density plot in Figure 4.4. TNF-α expressed by NK cells was not 
significantly different in CMV seropositive (3.008% ±0.6572, N=23) than 
seronegative subjects (2.264% ±0.4835, N=12). TNF-α expressed by CD56+ T-
cells was significantly more (P = 0.0088) in CMV seropositive (3.912% ±0.6010, 
N=23) than seronegative subjects (1.936% ±0.2648, N=20). Moreover, TNF-α 
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expressed by CD56- T-cells was not significantly different (P = 0.3810) in CMV 
seropositive (1.926% ±0.2671, N=26) than seronegative subjects (1.369% 
±0.3660, N=22), these results are illustrated in Figure 4.5.  
 
 Seronegative Seropositive 
 
Figure 4.4 Levels of TNF-α expression. In a representative NK cells, CD56+ T-cells 
and CD56- T-cells from representative subjects after overnight stimulation with CMV 
lysate.. 
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Figure 4.5 A Levels of TNF-α expression in CMV+ and CMV- subjects. Paired T-
test was used to compare levels of TNF-α expression by NK cells, CD56+ T-cells and 
CD56- T-cells after overnight stimulation with CMV lysate. TNF-α expressed by NK 
cells was not significantly different in CMV seropositive than seronegative subjects. 
TNF-α expressed by CD56+ T-cells was significantly more (P = 0.0088) in CMV 
seropositive than seronegative subjects. Moreover, TNF-α expressed by CD56- T-
cells was not significantly different (P = 0.3810) in CMV seropositive than 
seronegative subjects. 
 
4.1.3.3 IL-2 expression following stimulation with CMV lysate 
IL-2 expression by NK cells, CD56+ T-cells and CD56- T-cells was also studied 
after cells were stimulated by CMV lysate. The levels of expression are illustrated 
by density plot in Figure 4.6. IL-2 expressed by NK cells was not significantly 
different (P = 0.4086) in CMV seropositive (1.303% ±0.2354, N=14) than 
seronegative subjects (1.143% ±0.2076, N=17). Neither was IL-2 expressed by 
CD56+ T-cells significantly different (P = 0.1151) in CMV seropositive (2.170% 
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±0.3907, N=10) than seronegative subjects (1.528% ±0.4528, N=17). Moreover, 
IL-2 expressed by CD56- T-cells was also not significantly different (P = 0.1272) 
in CMV seropositive (0.6831% ±0.1183 N=25) than seronegative subjects 
(1.401% ±0.3729, N=11), as illustrated in Figure 4.7. 
 Seronegative               Seropositive 
 
Figure 4.6 Levels of IL-2 expression. In NK cells, CD56+ T-cells and CD56- T-
cells from representative subjects after overnight stimulation with CMV lysate. 
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Figure 4.7 Levels of IL-2 expression in CMV + and CMV- subjects. Paired T-
test was used to compare levels of IL-2 expression by NK cells, CD56+ T-cells 
and CD56- T-cells after overnight stimulation with CMV lysate. IL-2 expressed 
by NK cells was not significantly different (P = 0.4086) in CMV seropositive than 
seronegative subjects. IL-2 expressed by CD56+ T-cells was not significantly 
different (P = 0.1151) in CMV seropositive than seronegative subjects. Moreover, 
IL-2 expressed by CD56- T-cells was not significantly different (P = 0.1272) in 
CMV seropositive than seronegative subjects. 
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4.1.3.4 Perforin content following stimulation with CMV lysate 
Perforin expression by NK cells, CD56+ T-cells and CD56- T-cells was tested 
after cells were stimulated by CMV lysate. The levels of expression are illustrated 
by the density plots in Figure 4.8. Perforin expression by NK cells was not 
significantly different (P = 0.6524) in CMV seropositive (90.43% ±2.094, N=10) 
than seronegative subjects (90.06% ±4.062, N=7). Perforin expression by CD56+ 
T-cells was not significantly different (P = 0.2335) in CMV seropositive (71.49% 
±5.503, N=10) than seronegative subjects (54.90% ±11.28, N=7). Moreover, 
perforin expression by CD56- T-cells was not significantly different (P = 0.6592) 
in CMV seropositive (43.44% ±9.476, N=10) than seronegative subjects (30.03% 
±7.742, N=7), these results are illustrated in Figure 4.9.  
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Figure 4.8 Levels of perforin.  Within NK cells, CD56+ T-cells and CD56- T-
cells from representative subjects after overnight stimulation with CMV lysate. 
                   Seronegative Seropositive 
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Figure 4.9 Levels of perforin in CMV+ and CMV- subjects. Paired T-test was 
used to compare perforin expression by NK cells, CD56+ T-cells and CD56- T-
cells after overnight stimulation with CMV lysate. Perforin expression by NK 
cells was not significantly different (P = 0.6524) in CMV seropositive than 
seronegative subjects. Perforin expression by CD56+ T-cells was not 
significantly different (P = 0.2335) in CMV seropositive than seronegative 
subjects. Moreover, perforin expression by CD56- T-cells was not significantly 
different (P = 0.6592) in CMV seropositive than seronegative subjects.   
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4.1.3.5 Granzyme A expression following stimulation with CMV lysate 
Granzyme A expression by NK cells, CD56+ T-cells and CD56- T-cells was 
tested after cells were stimulated by CMV lysate. The levels of expression were 
illustrated by density plots in Figure 4.10. 
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Granzyme A expression by NK cells was not significantly different (P = 0.5976) 
in CMV seropositive (47.43% ±10.61, N=12) than seronegative subjects (38.44% 
±11.78, N=7). Granzyme A expression by CD56+ T-cells was not significantly 
different (P = 0.3053) in CMV seropositive (49.25% ±6.776, N=12) than 
seronegative subjects (25.26% ±9.815, N=7). Moreover, perforin expression by 
CD56- T-cells was not significantly different (P = 0.1830) in CMV seropositive 
(19.98% ±7.183, N=12) than seronegative subjects (6.343% ±3.253, N=7), these 
results are illustrated in Figure 4.11.  
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Figure 4. Levels of Granzyme A expression.  In a representative NK cells, 
CD56+ T-cells and CD56- T-cells from representative subjects after overnight 
stimulation with CMV lysate 
                      Seronegative Seropositive 
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Figure 4.11 Levels of Granzyme A expression in CMV + and CMV- subjects. 
Paired T-test was used to compare levels of Granzyme A expression by NK cells, 
CD56+ T-cells and CD56- T-cells after overnight stimulation with CMV 
lysate.Granzyme A expressed by NK cells was not significantly different (P = 
0.5976) in CMV seropositive than seronegative subjects. Granzyme A expression 
by CD56+ T-cells was not significantly different (P = 0.3053) in CMV 
seropositive than seronegative subjects. Moreover, perforin expression by CD56- 
T-cells was not significantly different (P = 0.1830) in CMV seropositive than 
seronegative subjects. 
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4.1.3.6 Granzyme B expression following stimulation with CMV lysate 
Granzyme B expression by NK cells, CD56+ T-cells and CD56- T-cells was 
tested after cells were stimulated by CMV lysate. The levels of expression are 
illustrated by density plots in Figure 4.12. 
Granzyme B expressed by NK cells was not significantly different (P = 0.1416) in 
CMV seropositive (78.35% ±3.897, N=8) than seronegative subjects (68.33% 
±4.356, N=7). Granzyme B expression by CD56+ T-cells was significantly higher 
(P = 0.0015) in CMV seropositive (65.66% ±3.034, N=8) than seronegative 
subjects (24.11% ±7.468, N=7). Moreover, Granzyme B expression by CD56- T-
cells was significantly higher (P = 0.0037) in CMV seropositive (26.53% ±2.038, 
N=8) than seronegative subjects (15.09% ±1.422, N=7), these results are 
illustrated in Figure 4.13.  
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Figure 4.12 Levels of Granzyme B expression. In a representative NK cells, 
CD56+ T-cells and CD56- T-cells from representative subjects after overnight 
stimulation with CMV lysate 
 Seronegative Seropositive 
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Figure 4.13 Levels of Granzyme B expression in CMV + and CMV- subjects. 
Paired T-test was used to compare levels of Granzyme B expression by NK cells, 
CD56+ T-cells and CD56- T-cells after overnight stimulation with CMV lysate. 
Granzyme B expression by NK cells was not significantly different (P = 0.1416) 
in CMV seropositive than seronegative subjects. Granzyme B expression by 
CD56+ T-cells was significantly higher (P = 0.0015) in CMV seropositive than 
seronegative subjects. Moreover, perforin expression by CD56- T-cells was also 
significantly higher (P = 0.0037) in CMV seropositive than seronegative subjects. 
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4.2 Degranulation assay of CD56+ T-cells; detection by LAMP-1 (CD107a) 
expression 
CD107a is a marker for NK cell and CD8+ T-cell degranulation as part of the 
perforin-dependent cytotoxic process therefore it was investigated whether 
CD56+ T-cells express this marker after their induction by CMV lysate and the 
standard NK cell target K562, and if there were any significant differences 
between healthy CMV seropositive and seronegative subjects.     
 
4.2.1 Aim 
To assess levels of CD107a surface expression in NK, CD56+ T-cells and CD56- 
T-cells in response to exposure to K562 and CMV lysate in CMV seropositive 
and seronegative healthy subjects.  
 
4.2.2 Cell surface exposure of CD107a in response to stimulation  
PBMCs were stimulated with K562 or CMV lysate in culture medium in a 
humidified 5% CO2 atmosphere at 37
o
C, following that the cells were labelled 
with anti-CD3, anti-CD56 and anti-CD107a. The levels of CD107a expression on 
the cells after exposure to K562 are illustrated in figure 4.14 and after exposure to 
CMV lysate in figure 4.16.   
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In Figures 4.15 and 4.17 proportions of cells expressing CD107a were compared 
between CMV seropositive and seronegative healthy subjects after exposure to 
CMV lysate and K562.  
When PBMCs were stimulated by K562 cells, levels of CD107a expression were 
found to be significantly more in NK cells (P = 0.0061) and CD56+ T-cells (P = 
0.0202) in seropositive (15.00% ±2.653, 12.26% ±1.501 respectively) than 
seronegative (8.006% ±1.567, 7.186% ±1.138 respectively) healthy subjects after 
stimulation with K562 cells. However, CD56- T-cells did not express high levels 
of CD107a and the comparison between both CMV groups was non-significant (P 
= 0.7089) (seronegative 0.7722% ±0.2411, seropositive 0.76% ±0.1676). The 
number of participants was for NK cells 11 seronegative and 15 seropositive, 
CD56+ T-cells 12 seronegative and 12 seropositive, and for CD56- T-cells 9 
seronegative and 18 seropositive   
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 Seronegative Seropositive 
 
Figure 4.14 Levels of CD107a expression after PBMCs pulsed with K562. 
Levels of CD107a expression on NK cells, CD56+ T-cells and CD56- T-cells 
from healthy subjects after exposure to K562 cells. 
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Figure 4.15 Levels of CD107a expression after PBMCs pulsed with K562 in 
CMV + and CMV- subjects. CD107a levels of expression were found to be 
significantly more in NK (P = 0.0061) and CD56+ T-cells (P = 0.0202) in CMV 
seropositive than seronegative healthy subjects after stimulation with K562 cells. 
However, CD56- T-cells did not express high levels of CD107a and the 
comparison between both CMV groups was non-significant (P = 0.7089). 
 
When PBMCs were stimulated by CMV lysate CD107a positive cells were found 
to be significantly more in NK (P = 0.0236) and CD56+ T-cells (P = 0.0376) in 
seropositive (5.742% ±1.185, 4.757% ±0.6900 respectively) than seronegative 
(1.963% ±0.4527, 2.353% ±0.3082 respectively) healthy subjects after stimulation 
with CMV lysate. However, very few CD56- T-cells express high levels of 
CD107a and the comparison between both CMV groups was non-significant (P = 
0.1392) (seronegative 0.5750% ±0.1493, seropositive 1.467% ±0.4072). Numbers 
of healthy participants was 6 CMV seropositive and 6 seronegative subjects.    
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             Seronegative     Seropositive 
  
Figure 4.16 Levels of CD107a expression after PBMCs stimulated with CMV.  
Representative plots of proportions of cells expressing CD107a on NK cells, 
CD56+ T-cells and CD56- T-cells from healthy subjects after exposure to CMV 
lysate. 
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Figure 4.17 Levels of CD107a expression after PBMCs stimulated with CMV 
in CMV + and CMV- subjects. Proportions of cells expressing CD107a were 
found to be significantly more in NK (P = 0.0236) and CD56+ T-cells (P = 
0.0376) in seropositive than seronegative healthy subjects after stimulation with 
CMV lysate. However, CD56- T-cells did not express high levels of CD107a and 
the comparison between both CMV groups was non-significant (P = 0.1392). 
Numbers of healthy participants was 6 CMV seropositive and 6 seronegative 
subjects.    
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4.3 Proliferative responses of CD56+ T cells to CMV antigens 
PBMCs from CMV seropositive healthy donors were labelled with CFSE 
according to section 2.4.2.4.2. CSFE labelled PBMCs were incubated for 7 days 
in 48 wells culture plate in culture medium in a humidified 5% CO2 atmosphere at 
37
o
C. PBMCs were incubated at three different conditions; PBMCs un-stimulated, 
PBMCs with CMV lysate and PBMCs with SEB as a positive control. Cells 
proliferation was calculated for three different groups, NK cells, CD56+ T-cells 
and CD56- T-cells.  
 
4.3.1 Aims 
To detect the proliferative response of CD56+ T-cells from CMV seropositive 
subjects in response to stimulation with CMV. 
 
4.3.2 Proliferative responses of CD56+ T cells to CMV antigens 
Percentages of proliferated CD56+ T-cells at day 7 of the incubation period in 
response to CMV was compared by using a Paired T-test compared to un-
stimulated cells. Representative density plots illustrating the percentage of 
proliferated cells are presented in Figure 4.18. Moreover, the percentage 
proliferation was compared in Figure 4.19. The percentage of proliferated cells in 
un-stimulated and CMV stimulated wells from the 5 CMV seropositive donors 
was compared by Paired T-test. Differences in NK cell proliferation did not quite 
reach statistical significance (P = 0.059) (seronegative 4.804% ±1.614, 
seropositive16.76% ±3.460). CD56+ T-cells (P = 0.0173) (seronegative 4.860% 
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±2.319, seropositive 21.32% ±5.539) and CD56- T-cells (P = 0.0203) 
(seronegative 6.7% ±2.239, seropositive 21% ±4.170) proliferated significantly 
more in response to CMV than un-stimulated cells.     
 
Figure 4.18 Representative plots of CFSE labelled PBMCs.  PBMCs were 
stained by anti-CD56 and anti-CD3 to identify CD56+ T-cells, NK cells and 
CD56- T-cells. CD56+ T-cells proliferated by 1.9% in the un-stimulated well, 
7.1% in response to CMV lysate and 70.3% in response to SEB. NK cells 
proliferated by 2.5% in the un-stimulated well, 12.5% in response to CMV lysate 
and 52.1% in response to SEB. Last CD56- T-cells (CD3+CD56-) proliferated by 
2% in the un-stimulated well, 15% in response to CMV lysate and 70.7% in 
response to SEB. Numbers of healthy CMV+ participants was 5.   
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Figure 4.19 The percentage of proliferated cells.  Levels compared between  
un-stimulated and CMV stimulated wells from the 5 CMV seropositive donors 
were compared by Paired T-test. CD56+ T-cells (P = 0.0173) and CD56- T-cells 
(P = 0.0203) significantly proliferated in response to CMV compared to un-
stimulated cells. 
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4.4 Antigen specificity of CD8+CD56+ T cells in CMV+ subjects 
Healthy CMV seropositive subjects were tissue typed for HLA-A2, -B7 and B8 
according to section 2.3.2.5.1. Following that, HLA Pro5 Pentamers comprising 
these three common HLA tissue types loaded with immuno-dominant 9mer or 
10mer CMV peptides (illustrated in Table 2.5) were used.  
 
4.4.1 Aims 
To study CD56+ T-cell (CD8
bright+
 CD56+) CMV antigen specificity toward CMV 
compared to CD8+ CD56- T-cells.  
 
4.4.2 CD56+ T-cells Pro5 pentamer staining 
PBMCs from CMV+ volunteers were labelled by Pro5 pentamers according to 
section 2.3.2.5.2. Lymphocytes were gated for CD8
bright+
 cells and both CD56+ 
and CD56- populations analysed for HLA pentamer staining. Pentamer-specific 
CD8+ cells were detected in CD56+ and CD56- cells. Examples of Pentamer-
labelled CD8+
bright
CD56+ T-cells and CD8+CD56- from candidates positive for 
either HLA-A2, -B7 and –B8 are illustrated in Figure 4.20.  
The percentage of pentamer labelled CD8+
bright
CD56+ T-cells and CD8+ CD56- 
cells were compared by Paired T-test and the results are illustrated in Figure 4.21. 
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Figure 4.20 Representative plots of Pro5 CMV pentamer-labelleing. Both 
CD8
bright
+ CD56+ and CD8
bright
+ CD56- cells were targeted in subjects positive 
for one of three different class I HLA types A2, B7 and B8. Some CD56+ T-cells 
showed specificity toward CMV peptides loaded on the pentamers, which can be 
visualised by the percentage of CD8+ CD56+ cells.    
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Figure 4.21 Comparison of the percentage of pentamer labelled cells in 
CD56- and CD56+ T cells. Pentamer staining was compared between CD8
 
bright+
CD56- and CD8
bright+
CD56+ T-cells. The lines join results from the same 
subjects. HLA-A2 and B7 pentamers labelled similar percentages of cells between 
CD8
bright+
CD56- and CD8+
bright+
CD56+ T-cells. However, HLA-B8 pentamer 
labelled more CD8
bright+
CD56+ T-cells than CD8
 bright+
CD56- cells. No significant 
differenece detected.  
 
4.5 Discussion  
In Chapter 3, expansion of CD56+ T-cells in CMV seropositive healthy donors 
was detected. Also, these cells were shown to express memory surface markers in 
CMV seropositive subjects while in CMV seronegative donors were more likely 
to express naive surface markers. Overall, this study has provided evidence that 
CD56+ T-cells have dual functions where they preserved TCR specificity against 
CMV and expanded in response to CMV stimulation while also performing NK-
like cytotoxicity against MHC negative K562 cells. Additionally, this ex-vivo 
study aimed to analyse CD56+ T-cells’ potential immunological functions in 
response to CMV in CMV seropositive and seronegative PBMCs and to compare 
the results between them. Several experiments studied their capability of 
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expressing intracellular cytokines IFN-γ, TNF-α and IL-2 and the cytotoxic 
mediators Perforin, Granzyme A and B. CD107a surface expression was also 
studied following stimulation with CMV lysate and K562. Moreover, CFSE 
labelling was used to detect proliferation in response to CMV and the polyclonal 
stimulator SEB. To study these functional properties, PBMCs from both sero-
groups were incubated with CMV lysate and SEB as a positive control overnight. 
Isotype and un-stimulated PBMCs were applied to remove any formed 
background. Paired t-tests were used to compare the mean of both sero-groups 
and the results were displayed as scatter plots. Also, the cells’ specificity to CMV 
was investigated by labelling the cells with Pro5 CMV Pentamers. The remaining 
possibility of cells response can be due to other part of the host cells (fibroblast) 
where CMV lysate were extracted.  
CMV is life-long and latent virus and even though it is pathologically not risky in 
healthy seropositive subjects, however, it has been reported to disrupt the immune 
system and results in high levels of cytokine expression (Dunn et al. 2002). 
CD56+ T-cells responded to CMV lysate by producing significantly more IFN-γ, 
TNF-α, Granzyme B in seropositive than seronegative healthy donors. However, 
CD56+ T-cell production of IL-2 and expression of Perforin and Granzyme A, 
when compared between sero-groups, were not significantly different and these 
results are illustrated in Table 4.1. The phenotype of CD56+ T-cells in CMV 
seropositive healthy subjects revealed memory characteristics therefore the 
significantly elevated proportions of cells expressing IFN-γ, TNF-α and granzyme 
B can be argued as evidence of an immunological memory response of CD56+ T-
cells against CMV. Even though perforin and granzyme A have not shown any 
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significant variation from CMV seronegative donors however the levels are less 
than what have been detected in seropositive donors.    
 
 
NK CD56+ T-cells CD56- T-cells 
- + - + - + 
IFN-γ 2.332 5.937* 2.585 5.482* 1.976 3.483* 
TNF-α 2.264 3.008 1.936 3.912* 1.369 1.926 
IL-2 1.143 1.303 1.528 2.170 1.401 0.6831 
Perforin 90.06 90.43 54.90 71.49 30.03 43.44 
Granzyme A 38.44 47.43 25.26 49.25 6.343 19.98 
Granzyme B 68.33 78.53 24.11 65.66* 15.09 26.53* 
Table 4.1 Cytokine and cytotoxic mediator detection. This table illustrates the 
mean proportions of cytokine and cytotoxic mediator expressing NK, CD56+ T-
cells and CD56- T-cells in response to overnight stimulation with CMV lysate.  ( 
* ) = Significantly more than seronegative group. + = CMV seropositive and - = 
seronegative.       
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Among the differences between healthy subjects of different CMV sero-status 
were that a higher proportion of CD56+ T-cells produced IFN-γ in CMV+ 
subjects, the same as was found for NK cells and CD56- T-cells. Moreover, for 
TNF-α significant production by CD56+ T-cells contrasted with data for NK cells 
and CD56- T-cells which showed no significant differences between both CMV 
sero-statuses. In addition, granzyme-B was expressed by a significantly higher 
proportion of both CD56+ CD56- T-cells from CMV+ subjects while NK cells 
showed no significant differences between both CMV sero-statuses.   
CD56+ T-cell production of significant levels of IFN-γ has also been reported in 
other studies. CD56+ T-cells were reported to produce Th1 cytokines when 
stimulated non-specifically using PMA (Doherty et al. 1999). This was also found 
in patients with hepatitis B-associated liver disease (Barnaba et al. 1994). 
CD56+T-cells were reported to produce significantly more IFN-γ when stimulated 
with K562 in chronic HIV-infected individuals and long-term non-progressor HIV 
infected patients than healthy donors (Y. Jiang et al. 2014). Significant levels of 
TNF-α were also reported in CD56+ T-cells isolated from the human liver when 
they were stimulated by PMA and ionomycin (Doherty et al. 1999).  
TEMRA and TEM both pre-store the serine protease Granzyme B and the pore-
forming perforin, however this normally does not occur in TCM and naive cells 
(Sallusto et al. 2004). Granzyme B was present in significantly more CD56+ T-
cells and CD56- T-cells from CMV+ subjects, while perforin  was not expressed 
by significantly more cells in CMV seropositive than seronegative subjects. This 
finding contrasts with a study that mentioned reduced levels of granzyme B and 
perforin in PBMCs of smokers and chronic obstructive pulmonary disease 
(COPD) patients, however this study also reported reduced numbers of CD56+ T-
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cells in those individuals (Urbanowicz et al. 2009). However, this group have also 
measured CD56+ T-cells in induced sputum of both smokers and COPD patients 
and reported a significant increase in numbers and cytotoxicity of CD56+ T-cells 
in COPD patients than both smokers and healthy non-smokers; also smokers have 
significant more CD56+ T-cells than healthy non-smokers. Moreover, levels of 
granzyme B and perforin were significantly more in COPD patients than smokers 
and healthy non-smokers, also smokers have significant more granzyme B and 
perforin than healthy non-smokers (Urbanowicz et al. 2010). These increases may 
result from the greater incidence of pulmonary infections in COPD patients and 
smokers. CD56+ expression on CD8+ cells has been correlated with CD8+ 
effector functions and the cells were found to be enriched with perforin and 
granzyme B (Pittet et al. 2000, Santin et al. 2001).   
CD107a or LAMP-1 is a marker for NK cell and CD8+ T-cell degranulation as 
part of the perforin-dependent cytotoxic pathway; CD107a can work as an 
activation marker as upon stimulation CD107a is transported to the surface of the 
cells. Significantly greater proportions of CD56+ T-cells and NK cells were found 
to express CD107a upon stimulation with K562 and CMV lysate in CMV 
seropositive than seronegative healthy donors. Increased expression of CD107a 
was also reported in CD56+ T-cells when stimulated by K562 and 
PMA/ionomycin in chronic HIV-infected individuals and HIV long-lerm non-
progressors (Y. Jiang et al. 2014). Moreover, the same was reported when hepatic 
CD56+ T-cells collected from liver graft perfusates were stimulated with K562 
and the SNU398 human hepatocellular carcinoma cell line leading to significantly 
greater expression of CD107a than in healthy PBMCs (Kim et al. 2013). In this 
study CD56- T-cells failed to express significant levels of CD107a which was also 
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reported in a study on CD3+CD8+ levels of CD107a in response to CMV in 
females with recurrent abortions (Tarokhian et al. 2014).  
PBMCs were labelled by CFSE and incubated for 7 days with CMV antigens and 
SEB as positive control to detect the proliferation of NK cells, CD56+ T-cells and 
CD56- T-cells. Levels of proliferated NK cells, CD56+ T-cells and CD56- T-cells 
were significantly more than un-stimulated cells. TEMRA have a defect in their 
proliferative capacity, however, CD56+ T-cells proliferated in response to CMV 
and SEB. This contrasts with a study which showed that CD56+ T-cells generated 
in vitro have no proliferative capacity (Franceschetti et al. 2009). In the present 
study, CD56+ T-cells proliferated to a similar extent as CD56- T cells in response 
to CMV antigens so it is clear that they do not lose their capability to proliferate in 
response to viral antigens as what have been reported in a study illustrated that T-
EMRA proliferate to some levels  (Geginat et al. 2003). 
CD8
bright+
CD56+ T-cells’ antigenic specificity was studied towards three common 
immuno-dominant 9mer or 10mer CMV peptides in healthy subjects of the 
appropriate HLA types. This was to reveal if TCR expressed by CD8
bright+
CD56+ 
T-cells can mediate specific binding and recognition towards CMV common 
peptides, and to compare their immuno-specificity with that of CD8+CD56- T-
cells. The labelling with HLA-A*02:01-NLV that represents HCMV pp65 495-
503 showed no significant difference between CD8
bright+
CD56+ T-cells and 
CD56-CD8
 bright+
 T-cells, the specificity of CD8
bright+
CD56+ T-cells and CD56-
CD8
bright+
 T-cells were both ranging between 0.2-0.3% up to 7.1%. Moreover, 
staining with a pentamer for HLA-B*07:02-TPR which is HCMV pp65 417-426 
showed no significant difference between CD8
bright+
CD56+ T-cells and CD56-
CD8
bright+
 T-cells, the specificity of CD8
bright+
CD56+ T-cells was ranging from 
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0.5% up to 1.9% and CD56-CD8
bright+
 T-cells was ranging from 0.5% up to 2.5%. 
Staining with the pentamer HLA-B*08:01-QIK 88-96 which is HCMV IE1 
showed no significant difference between CD8
bright+
CD56+ T-cells and CD56-
CD8
bright+
 T-cells, the specificity of CD8
bright+
CD56+ T-cells was ranging from 
1.9% up to 15.1% and for CD56-CD8
bright+
 T-cells was from 1.5% up to 6.2%. 
CD8
bright+
CD56+ T-cells showed higher specificity toward QIK-HLA-B*08:01 
than CD56-CD8
bright+
 T-cells, and this was also higher than both pp65 peptides 
NLV-HLA-A*02:01 and TPR-HLA-B*07:02. The expression of CD56 (NCAM) 
has been correlated with anti-CD3 induced cytotoxic functions of CD8+ T cells in 
healthy subject (Pittet et al. 2000), and in human papilloma virus specific CD8+ 
T-cells (Santin et al. 2001). Moreover, these cells have been found to be effectors 
in protection against HIV, hepatitis C virus and Japanese encephalitis virus 
(Sooryanarain et al. 2012, Hou et al. 2012, Doskali et al. 2011) as well as the 
autoimmune inflammatory condition Behçet’s disease (Ahn et al. 2005). Also, 
CD4+CD28-CD56+ cells were expanded in patients with chronic hepatitis B virus 
infection (Wang et al. 2009) and mast cell stimulation by reovirus was found to 
lead to recruitment of CD56+ T cells in vitro (McAlpine et al. 2012). Overall, the 
results of Chapter 4 support the concept that CD56+ T cells are an important 
component of the anti-CMV response in healthy subjects.   
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5. Frequency and phenotype of CD56+ T-cells in CMV seropositive and 
seronegative Renal Transplant Patients 
5.1 Introduction 
CMV replication leading to viraemia is one of the major clinical infections 
leading to rejection, morbidity and mortality in kidney graft recipients. To prevent 
these complications the recipients are given prophylactic therapy where they 
receive antiviral medications such as valganciclovir (De Keyzer et al. 2011).  
All patients studied had received a renal transplant at the Royal Liverpool and 
Broadgreen University Hospital Trust Transplant Unit. They were receiving 
maintenance immunosuppression comprising tacrolimus or, in the case of older 
patients, cyclosporine. All patients are monitored regularly for post-transplant 
CMV infection using standard PCR techniques. Since 2008, all patients who were 
CMV- are given a kidney from a CMV+ donor and also any patients given 
Campath 1 induction were given prophylactic treatment with valganciclovir for 90 
days post transplantation. Prior to 2008, pre-emptive antiviral therapy was given 
to patients in whom CMV became detectable by PCR.   
The risk of CMV viremia in transplant patients is correlated with the CMV sero-
status of the donor and recipient. Moreover, the high risk group are those with D 
(donors) CMV positive and recipients (R) CMV negative. Recognition of 
alloantigen by T-cells either directly or through indirect allo-recognition of donor 
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peptide leads to activation of T-cells toward the graft and the expansion of allo-
specific T-cells toward the graft, increasing the risk of acute or chronic rejection 
(Issa et al. 2010).  
5.2 Aim 
The aim of this section of the study was to compare the relative levels and 
phenotype of CD56+ T-cells in Kidney transplant patients (KTPs) and to compare 
the results to what has been found in healthy donors. 
 
5.3 Results 
5.3.1 Frequency of CD56+ T-cells in CMV seropositive and seronegative 
renal transplant patients 
Flow cytometric analysis of CD56+ T-cell populations was applied to identify the 
relative numbers of these cells in kidney transplant patients (KTP). PBMCs were 
stained with anti-CD3 and anti-CD56 and expressed as a density plot in the same 
way as in Figure 3.1. Numbers were expressed as percentages of both total 
lymphocytes and T-cells and were analysed using GraphPad prism; the CMV+ 
groups were compared with the D-/R- group by using a paired T-test. In Figure 
5.1, the percentage of CD56+ T-cells was calculated from total lymphocytes and 
T-cells. When the mean value of CD56+ T-cells from total lymphocytes was 
calculated, the D+R- patient group (mean 5.42% ±1.01) had significantly 
(P=0.0247) more than in the D-R- group (mean 1.9% ±0.35). Moreover, in the R+ 
group (mean 5.11% ±0.69) levels were significantly higher (P < 0.0001) than in 
the D-R- group.  
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When the CD56+ T-cell percentage was calculated from total CD3+ T-cells, the 
mean value of CD56+ T-cells from total CD3+ T-cells for D+R- patients (mean 
9.74% ±1.12) was significantly (P=0.0037) more than for D-R- patients (mean 
4.91% ±0.76). Moreover, levels for the R+ group (mean 9.72% ±0.97) were 
significantly (P=0.0003) higher than for the D-R- group.   
  
  
Figure 5.1 Scatter plots comparing the percentage of CD56+ T-cells between 
different KTP groups. These scatter plots compare the percentage of CD56+ T-
cells obtained from total lymphocytes and T-cells between different KTP groups, 
D-R-, D+R- and R+. Clearly, D+R- (n=26) and R+ (n=26) KTP have significantly 
more CD56+ T-cells than D-R- (n=20) when CD56+ T-cells where calculated 
from total lymphocytes (P=0.0247 and < 0.0001 respectively) and when 
calculated from total CD3+ cells (P=0.0037 and 0.0003 respectively).   
 
 
5.3.2 CD56+ T-cell levels during CMV viraemia  
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Levels of CD56+ T-cells were investigated and compared between KTPs with or 
without CMV viraemia, as detected by the Medical Microbiology Laboratory, 
Royal Liverpool University Hospital. In Figure 5.2, CD56+ T-cells from KTPs 
who have had a previous episode of viremia were compared to the levels of the 
cells in KTPs who have never had viraemia. When all patients were analysed 
together, those who had one or more episodes of viraemia had significantly more 
CD56+ T cells than those who did not. Figure 5.3 shows levels of CD56+ T-cells 
in viraemic D+R- KTPs compared to non-viraemic D+R- KTPs. In those eight 
patients sampled after the episode of viraemia (pre-viraemia) levels were 
increased compared to patients without viraemia and this was statistically 
significant (P = 0.024). In the six D+/R- patients who had a viraemic episode after 
sampling (post-viraemia) CD56+ T cell levels were not significantly different 
from those in the group without viraemia (Fig. 5.3); no significant differences 
were found between other KTP groups.       
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Figure 5.2 KTPs studied who had an episode of viraemia. All KTPs studied 
who had an episode of viraemia (5.2% ±0.99) had significantly more CD56+ T-
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cells than KTPs without viraemia (4.3% ± 0.58; P=0.003).   
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Figure 5.3 D+R- patients studied who had an episode of viraemia. D+R- KTPs 
who had one or more episodes of viraemia (8.13% ±1.63) and pre-viraemia 
(9.92% ±2.1) had significantly more CD56+ T-cells than KTPs without viraemia 
(3.22% ± 1.20; P=0.03).  
 
5.3.3 Relative numbers of CD56-CD3+ cells in KTPs 
Relative numbers of total CD56- T-cells in KTPs were also evaluated and 
compared. CD3+ T-cells were compared by two different methods, the first 
method was to calculate CD3+ T-cells from the total lymphocytes and the second 
method was to calculate CD3+ T-cells from total cells expressing CD3 (Figure 
5.4). No clear differences were observed between any of the groups. Frequency of 
CD56- T-cells was compared between KTP groups. When evaluated from total 
lymphocytes the mean of CD56- T-cells in D-R- (N=20) was 42.49± 5.4, which 
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was less than the mean of CD56- T-cells in D+R- (N=26) of 46.54% ± 4.85, 
although this was not quite statistically significant (P = 0.276). Moreover, The R+ 
group (N=26) at 49.10% ± 3.05 was at a similar level as the D-R- group 
(P=0.3825).  When CD56- T-cells were evaluated from the total T-cells, the mean 
of CD56- T-cells in the D-R- group was 94.34% ±0.95 which was greater than the 
mean of CD56- T-cells in the D+R- (N=26) of 91.34% ± 1.079, although this was 
not statistically significant (P=0.52). Moreover, the R+ group (N=26) at 90% 
±0.95 was at a similar level as the D-R- group (N=20; P=0.24).  
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Figure 5.4 Scatter plots comparing the percentage of CD56- T-cells between 
different KTP groups. Frequency of CD56- T-cells was compared between KTP 
groups. In the left plot, CD56- T-cells were evaluated from the total lymphocytes, 
the mean of CD56- T-cells in D-R- was less than the mean of CD56- T-cells in 
D+R- and this was not quite statistically significant (P = 0.276). Moreover, The 
mean of R+ group was at a similar level as the D-R- group (P=0.3825). In the 
right plot, CD56- T-cells were evaluated from the total T-cells, the mean of 
CD56- T-cells in the D-R- group was greater than the mean of CD56- T-cells in 
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the D+R-, although this was not statistically significant (P=0.52). Moreover, the 
mean of R+ group was less than the D-R- group (P=0.2438).   
5.3.4 Relative numbers of CD56+CD3- NK cells in KTPs 
Relative numbers of total CD56+CD3- NK cells in KTPs were also evaluated and 
compared. NK cells were found to be present in roughly equal proportions in all 
three groups (Figure 5.5) which did not differ significantly from CMV 
seronegative and CMV seropositive healthy individuals (Figure 3.4).  
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Figure 5.5 Frequency of CD56+CD3-NK cells in KTPs. This figure shows the 
frequency of CD56+CD3-NK cells in KTPs. There were no significant differences 
between numbers of NK cells in any of the three groups. P values between groups 
are shown. 
 
5.4 Characterisation of the phenotype of CD56+ T-cells in KTPs  
Chapter 3 of this thesis investigated CD56+ T-cells in healthy CMV seropositive 
and seronegative donors. Many CD56+ T-cells were shown to express a memory 
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phenotype in CMV seropositive healthy donors and in seronegative healthy 
donors most cells expressed naïve cell markers. In this section, CD56+ T cells 
were phenotyped in KTP groups D-R-, D+R- and R+.  
 
5.4.1 Aims  
The aims of this section of the study were to analyse and compare the phenotype 
of CD56+ T-cells in KTPs according to CMV status and also to compare the 
results with the CD56+ T cell phenotype in healthy CMV+ and CMV- donors.  
 
5.4.2 Results 
5.4.2.1 Expression of CD4 and CD8 by CD56+ T-cells in KTPs 
PBMCs from KTPs were stained with three colours in order to phenotype CD56+ 
T-cells for their expression of CD4+ and CD8+. In Figure 5.6 the percentage of 
CD4+ and CD8+ cells within the CD56+ T-cell population in KTPs groups is 
shown. In the D-/R- group, most CD56+ T cells were CD4-8- whereas in both 
D+/R- and R+ groups almost all were either CD8+ or CD4+. This is quite similar 
to the pattern seen in healthy CMV- and CMV+ subjects. To determine if there 
were any significant differences between the surface expression of CD8 and CD4 
on CD56+ T-cells in the different KTP groups the proportions were compared by 
paired t-test.    
The percentage of CD8+ and CD4+ CD56+ T-cells was compared between KTP 
groups. CD8+ CD56+ T-cells were significantly more in D+R- (59.25% ± 6.36) 
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and R+ (60.77% ± 4.55) than D-R- (26.32% ± 1.89; P=0.0011 and 0.0002 
respectively). CD4+ CD56+ T-cells were significantly more in D+R- (42.83% ± 
3.77) and R+ (38.57% ± 4.72) than D-R- (24.36% ± 2.61; P=0.0008 and 0.0434 
respectively). Moreover, CD8 was expressed on significantly more cells than CD4 
on CD56+ T-cells in both D+R- (P=0.025) and R+ (P=0.0335) groups.  
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Figure 5.6 The percentage of CD8+ and CD4+ CD56+ T-cells compared 
between KTP groups. CD8+ CD56+ T-cells were significantly more in D+R- 
and R+ than D-R- (P=0.0011 and 0.0002 respectively). CD4+ CD56+ T-cells 
were significantly more in D+R- and R+ than D-R- (P=0.0008 and 0.0434 
respectively). Moreover, CD8 was expressed on significantly more cells than CD4 
on CD56+ T-cells in both D+R- (P=0.025) and R+ (P=0.0335) groups. 
 
5.4.2.2 CD56+ T-cells; naive and memory markers in KTPs 
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CD56+ T-cells were stained for naive and memory markers in KTPs. The markers 
used were CD45RO, CD45RA, CD62L, CD28 and CD127. Levels of expression 
of these markers were compared between KTP groups to identify any significant 
differences between these groups and in Figure 5.7 the results are illustrated.  
Proportions of CD4RO+ cells were significantly more in the D+R- group (44.07% 
SE± 7.619, N=15) and R+ group (41.78% SE± 4.467, N=12) than the D-R- group 
(18.60% SE± 2.146, N=14) (P 0.0117 and 0.0007 respectively). Mean proportions 
of CD45RA+ cells were significantly (P 0.0341) more in D-R- (88.07% 
SE±1.562, N=10) than R+ patients (78.47% ±3.197, N=15), however, there was 
no significant difference between D-R- and D+R- groups (85.88% ±2.539). 
Proportions of CD62L+ cells were significantly more in D-R- (72.36% ±3.592, 
N=10) than in D+R- (55.69% ±2.544, N=15) and R+ patients (45.14% ±4.904, 
N=14) (P 0.0079 and 0.0001 respectively). Proportions of CD28+ cells were 
significantly more in the D-R- group (58.72% ±7.835, N=10) than in D+R- 
(22.65% ±5.682, N=13) and R+ patients (21.66% ±4.463, N=19) (P 0.0192 and 
0.0001 respectively). Finally, proportions of CD127+ cells were significantly 
more in D-R- (64.6% ±4.173, N=10) than D+R- (31.99% ±5.113, N=17) and R+ 
patients (33.50% ±4.820, N=13) (P 0.0035 and 0.0005 respectively). These 
differences are similar to those found between CDM- and CMV+ healthy subjects.  
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Figure 5.7 Memory and naive markers expressed by CD56+ T-cells in KTPs. 
This dot plot illustrates differences in proportions of CD56+ T-cells expressing 
memory markers in different KTP groups. Bar indicate levels of significance 
between groups (t-test). 
 
5.4.2.3 CD56+ T-cells; CD11a, NKG2C and CD161 in KTPs 
Percentages of CD56+ T cells expressing CD11a, NKG2C and CD161 were 
evaluated by using three colour staining. The results are illustrated in Figure 5.8, 
showing percentage positive cells and mean fluorescence intensity of CD11a 
expression in each group. No significant difference was found in proportions of 
CD11a+ cells or MFI in all KTP groups. Proportions of NKG2C+ cells were 
significantly more in D+R- (32.96% ±8.522, N=7) and R+ (10.28% ±1.732, N=8) 
than D-R- patients (3.070 ± 1.017, N=6). Proportions of CD161+ cells were 
significantly more in D-R- (29.24% ±5.230, N=11) than D+R- (10.96% ±2.608, 
N=18) and R+ groups (9.553% ± 3.579, N=11).   
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Figure 5.8 CD11a, NKG2C and CD161 expression on CD56+ T-cells from 
KTPs.This dot plot illustrates the expression of CD11a, NKG2C and CD161 on 
CD56+ T-cells from KTPs. No significant difference was found in proportions of 
CD11a+ cells (left) or MFI (right) in all KTP groups. Bars show levels of 
significance between groups (T-test). 
 
5.4.2.4 CD56+ T-cells; CMV HLA Pentamer labelling  
PBMCs from KTPs of appropriate HLA type were labelled with Pro5 pentamers 
according to section 2.3.2.5.2. Lymphocytes were gated for CD8
bright+
 cells and 
both CD56+ and CD56- populations analysed for HLA pentamer staining. 
Pentamers-specific CD8+ cells were detected in both CD56+ and CD56- cell 
populations. Representative examples of pentamer-labelled CD8+
bright
CD56+ T-
cells and CD8+CD56- from patients positive for either HLA-A2, -B7 or -B8 are 
illustrated in figure 5.9. A total of four KTPs who were of HLA-A2 tissue type 
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were tested, three who were HLA-B7 but only one who was HLA-B8 was tested. 
The percentage of pentamer labelled CD8+
bright
CD56+ T-cells and CD8+ CD56- 
cells were compared by paired T-test and the results are illustrated in figure 5.10. 
However, sample sizes were too small for adequate statistical comparison. 
 
 
 
Figure 5.9 Representative density plots of HLA-pentamer-labelleing. Both bright 
CD8
bright+
 CD56+ and CD8
bright+
 CD56- cells from D+/R- renal transplant patients of 
three different HLA tissue types, HLA-A2, -B7 and -B8. Upper panels, 
CD56+CD8+ cells, lower panels CD56-CD8+ cells. 
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Figure 5.10 Comparision of HLA-pentamer-labelled cells. The percentages of 
HLA pentamer staining was compared between CD8
bright+ 
CD56- and 
CD8
bright+
CD56+ T-cells in KTPs. The lines join results from the same patients. 
 
5.5 Discussion 
CMV reactivation in immuno-suppressed KTPs can lead to serious medical 
consequences such as graft damage, dysfunction, rejection and death. The level of  
danger behind CMV reactivation is correlated with the CMV status type of donors 
and recipients, as the high-risk group is D+R- patients. The previous chapters 
have revealed significant expansions in numbers of CD56+ T-cells in healthy 
CMV seropositive compared to sero-negative subjects, this expansion being 
associated with increased immuno-functional activities against CMV. This 
chapter aims to identify the characteristic phenotype of CD56+ T-cells in KTPs 
and study their antigenic specificity against three common HLA immuno-
dominant 9mer or 10mer CMV peptides. The comparison between CD56+ T-cell 
numbers in healthy subjects and KTPs is illustrated in Figure 5.11.  
Levels of CD56+ T-cells when calculated from total lymphocytes or T-cells 
showed D+R- patients had significantly more than in the D-R- group. Moreover, 
in the R+ group levels were significantly higher than in the D-R- group. CD56+ 
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T-cell mean levels were more in healthy seropositive subjects than seropositive 
KTPs, also healthy seronegative subjects had significantly more CD56+ T-cells 
than the KTP D-R- group. This could be explained as KTPs are under 
immunosuppression leading to reduced numbers of immune-effector cells. As 
cells were quantified as ‘percent total lymphocytes or T cells’, without knowing 
absolute lymphocyte numbers it is not possible to assess whether total cell 
numbers were different in different patient and healthy groups. Regarding NK and 
CD56- T-cells, no significant differences were found between KTP groups and 
healthy subjects, while CD56- T-cells when calculated as a percentage of total 
CD3+ cells in healthy subjects showed significant variation.  
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Figure 5.11 Levels of CD56+ T-cells in healthy subjects and KTPs.This graph 
compares levels of CD56+ T-cells in healthy subjects and KTPs. The lowest mean 
level was found in D-R- KTPs. Proportions of CD56+ T-cells were significantly 
more in CMV seronegative healthy subjects than in D-R- KTPs (P=0.0043). Also, 
healthy CMV+ subjects had significantly higher proportions of CD56+ T-cells 
than D+R- and R+ KTP groups (P 0.0018 and 0.0012 respectively) * indicates 
significant P value as shown in Chapter 3 and 5 section 5.3.1. 
 
CD56+ T-cell levels were significantly expanded more in KTPs with than without 
viraemia. This was noted in specifically in the D+R- group where the cells 
significantly expanded more in patients with viraemia and who had viraemia after 
sampling than without viraemia. However, differences in levels in patients who 
had viraemia before sampling was not quite statistically significant. CD8+ CD56+ 
T-cells had reduced expression of CD56 when HIV patients were treated with 
prolonged antiviral therapy, however,  in patients who were not receiving this 
prolonged therapy, CD56 expression was restored along with high perforin 
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content (Poonia and Pauza 2014). This finding together with what has been 
detected in this study indicates that CD56+ T-cells expand and are involved in 
antiviral activity to control viraemia.  
Relative numbers of CD56+ T-cells in healthy subjects have illustrated higher 
proportions of CD8+ and CD4+ cells in seropositive than sero-negative subjects. 
Generally, proportions of CD56+ T-cells expressing CD8 were significantly more 
than those expressing CD4. Similar results were also detected in KTPs where 
significantly more CD56+ T-cells expressed CD8 in D+R- and R+ than D-R- 
groups, also, CD4 was expressed by significantly more cells in D+R- and R+ 
groups than in the D-R- group. CMV-sepcific-CD8+ and CMV-specific-CD4+ T 
cells have been reported to have protective roles against CMV in solid organ 
transplantation; deficiency of these CMV-specific cells resulted in clinical 
complications in lung, renal and BMT transplantation (Riddell et al. 1992a, Sester 
et al. 2002, Sester et al. 2005).      
The characteristic surface phenotype of CD56+ T cells in KTPs was similar to 
what has been found in healthy subjects; more CD56+ T-cells tend to express 
memory markers in CMV+ than D-R- patients. In the case of CD11a no 
significant differences in MFI were detected although the mean in D-R- patients 
was higher, but not significantly more than in D+R- and R+ KTPs which is in 
contrast to what has been detected in healthy groups. This may be a result of the 
continuing immunosuppression in KTPs which may prevent up-regulation of 
activation molecules in T cell populations. 
It has been reported in renal transplant patients that CMV-specific-CD8+T-cells 
provide a protective role against CMV activation (Radha et al. 2005, Reusser et al. 
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1999). CD8
bright+
 CD56+ T-cells were evaluated for their TCR specificity toward 
CMV lysate and compared to CD8
bright+
CD56- cells in KTPs. For HLA-B*08:01 
QIK unfortunately only one KTP was tested. PBMCs from four KTPs were 
labelled with HLA-A*02:01-NLV that represents HCMV pp65495-504 and showed 
no significant differences between CD8
bright+
CD56+ T-cells and CD8
bright+
CD56- 
T-cells, the percent of peptide-specific CD8+
bright
CD56- T-cells ranging from 
0.2% up to 3.8%, and CD8+
bright
CD56+T-cells between 0.5% up to 1.7% which is 
higher, but not significantly, in CD8+
bright
CD56-T-cells. However, these levels are 
less than in healthy CMV+ subjects, although levels are highly variable. Three 
KTPs were labelled with HLA-B*07:02-TPR which is HCMV pp65417-426 and 
showed no significant difference between CD8
bright+
CD56+ T-cells and 
CD8
bright+
CD56- T-cells, moreover, CD8
bright+
CD56- T-cells range between 0.2% 
up to 6.5% while CD8
bright+
CD56+ T-cells 0.1% up to 3.9%, reflecting a higher, 
but not significantly higher, percentage in CD8+
bright
CD56-T-cells, however these 
tended to be higher for both cell types than in healthy CMV+ subjects. The only 
HLA-B*08:01 KTP showed 3.1% CD8
bright+
CD56- T-cells and 1.57% 
CD8
bright+
CD56+ T-cells, and it is reported that reactivation of CMV in solid 
organ transplant patients triggered the induction of CMV-immediate early gene 
transcription (Reinke et al. 1999). Moreover, this specificity for CMV-IE-QIK can 
enhance CMV reactivation as CD56+ T-cells produce TNF-α in response to CMV 
(Figure 4.5) and TNF-α can play a role in reactivation of CMV. This occurs 
through TNF-α indirect stimulation of surface expression of MIEP (major IE 
enhancer/promoter) via the activation of NF-kB (De Keyzer et al. 2011). 
Additionally, the role of MIEP activation of CMV is not well understood 
(DeMeritt et al. 2004). However, others reported CD8+ T-cells specific for CMV-
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IE-1 peptides provide a protective role against reactivation in lung and heart 
transplantation (Bunde et al. 2005). These data identified that CD8
bright+
CD56+ T-
cells possess specificity toward CMV in KTPs, the levels of specificity are 
variable in healthy subjects and KTPs.  
This chapter identified expansion of CD56+ T-cells in CMV positive KTPs as 
well as healthy donors. Also, CD56+ T-cells were more expanded in D+/R- KTPs 
with viraemia than those without viraemia. CD56+ T-cells tended to express 
memory markers in CMV positive and naïve markers in CMV negative KTPs as 
was also shown in healthy donors. TCR specificity of CD56+ T-cells also showed 
binding of pentamers labelled with common CMV epitopes. CMV antigen-
specific CD56+ T cells were not selectively enriched when compared to the 
majority CD56- T cell population but still made up a significant proportion of the 
antigen-specific CD8
bright+
 T cell population. 
Chapters 3 and 4 showed increased numbers and function of CD56+ T cells in 
healthy CMV+ subjects. Additionally, out of 72 KTPs evaluated in this study 25 
had post-transplant viraemia (35%), followed by significant expansion of CD56+ 
T-cells in their PBMCs. This also was significant when levels of CD56+ T-cells in 
the high risk group D+R- were tested. With many CD56+ T-cells in CMV positive 
KTPs expressing memory markers and keeping their TCR specificity, this can 
indicate that CD56+ T-cells, particularly CD8+ cells,  are involved in immune 
responses towards suppressing CMV reactivation in KTPs. Mononuclear cells, 
especially CD8+ and CD4+ T-cells, spread and surround the tubules in kidney 
transplants and these cells are loaded with perforin, granzyme A and B (Colvin 
RB 2006, Cornell et al. 2008), also, they express Fas-L (Robertson et al. 1996, 
Cornell et al. 2008). Moreover, effector cells during acute rejection produce high 
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levels of IFN-γ and TNF-α (Hoffmann et al. 2005) similar to CD56+ T-cell 
cytokine responses to CMV antigens in healthy subjects as found in this study. In 
D+/R- patients in whom donor and recipient are matched for class I HLA, there is 
the possibility that some of these cells represent CMV-specific cytotoxic T cells.       
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6. Study to identify CD56+ T-cell gene expression profile in response to CMV 
6.1 Introduction  
In Chapters 3-5, evidence was provided for increased numbers and levels of 
activation of CD56+ T cells in healthy CMV+ subjects. When stimulated with 
CMV antigens, CD56+ T cells proliferated and showed increased levels of both 
proinflammatory cytokines and molecules involved in cytotoxic function. The 
aims of this chapter were to conduct a wider investigation into the response of 
purified CD56+ T cells from healthy CMV+ subjects to antigenic stimulation.    
Microarrays were used to provide a comprehensive study of the gene expression 
profile of CD56+ T-cells in response to CMV stimulation. This is a hybridization 
method in which nucleic acids from stimulated and unstimulated cells are 
screened against a large set of oligonucleotide probes to identify changes in levels 
of gene expression. Moreover, SurePrint G3 Human Gene Expression 
Microarrays provide a comprehensive coverage of genes and transcripts with the 
most up-to-date content. Moreover, SurePrint G3 Human Gene Expression 8x60K 
MicroarrayKit has 96 x 10 ERCC control probes and 10 x 32 E1A spike-in 
control probes. Both these controls are incorbrated into microarrays to improve 
performance assessment for platforms of gene expression.    
PBMCs from healthy CMV+ subjects were stimulated overnight by CMV lysate,  
cells were then labelled by conjugated monoclonal antibodies anti-CD3 and anti-
CD56 then washed and sorted to isolate CD56+ T-cells. Following this, RNA was 
extracted and analysed by microarrays for gene expression. The results for some 
genes were validated by qPCR and protein expression methods. This part of the 
study aimed to detect differences in up-regulated and down-regulated expressed 
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genes in CD56+ T-cells incubated under two different conditions. It was decided 
that gene expression have to be more than two-fold changed; the fold change is 
calculated by dividing the two detected intensities to give a ratio that is log 2 
transformed.        
 
6.2 Aim 
To identify changes in the pattern of genes expressed by enriched CD56+ T-cells 
when stimulated by CMV lysate using microarray analysis. The results will be 
validated first by qPCR and second by detection of protein expression. 
 
6.3 Results 
6.3.1 One-Colour Microarray-Based Gene Expression 
Agilent Human v2 8x60K arrays were purchased from Agilent Technologies. The 
experimental work with the arrays was done by Dr. Lucille Rainbow, Centre for 
Genomic Research, IIB. The analysis was done according to section 2.4.2.6.5 and 
the 8X slide after the visualization is presented in Fig. 6.1. Analysis was 
performed by using a moderated t-test and Westfall-Young multiple testing 
corrections with cut off of p<0.05 as explained in the manufacturer’s reference 
guide.  
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Figure 6.1 Microarrray chips. Image showing Agilent Human v2 8x 60K arrays 
chip after the hybridization of cy3 labelled RNA from purified CD56+ T cells to 
the probes of the slide. Samples from four healthy CMV+ subjects were tested 
following stimulation with CMV antigens (upper row) or without stimulation 
(lower row). Colours were inverted inside the regions from black to white to 
clearly illustrate those regions.     
 
Normalisation of baseline signal levels was carried out between samples. This  
transformation of the gene signals  ensure those which have not significantly 
changed to be around the area of zero is presented in Figure 6.2. The 
normalization was performed to minimize differences from non-biological sources 
such as technical variations, different RNA concentrations, hybridization, 
differences between the 8 areas of the chip and labelling the samples with Cy3 
colour.  
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Figure 6.2 Gene normalization. All gene intensities of the samples were rescaled 
to the same relative abundance level centering on zero. S represents the stimulated 
CD56+ T-cells and U for un-stimulated CD56+ T-cells, Red for up-regulated 
while blue for down-regulated genes. 
 
Overall, 131 genes passed the statistical tests; genes with values less than or equal 
to a 2 fold change (FC) were removed to emphasize the aim of only detecting 
highly significantly changed genes (Figure 6.3). Out of these 131 the controls and 
duplicates were excluded to identify a total of 106 genes whose levels were 
significantly changed. The results are shown in Table 6.1 to indicate the genes and 
the level of significant change in expression.  
Several gene banks such as Gene Cards (www.genecards.org) were used to 
analyse these 106 genes to identify their functions, as shown in the appendix.     
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Figure 6.3 Significantly expressed genes using the filtration method. In the 
upper volcano plot 131 Entities (red colour) passed the P-value multiple testing 
correction cut-off of 0.05 and FC ˃ 2 when comparing S= stimulated cells vs. U= 
un-stimulated cells. The table illustrates a summary of the results of the 
comparison between S and U cells. Clearly, 9610 entities have passed FC ˃ 2 
while only 131 entities have shown to have a P-value cut off < 0.05.      
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Table 6.1 Detailed information about genes whose expression significantly 
changed. This table shows the details of genes whose levels of expression were 
significantly altered in CD56+ T cells stimulated with CMV antigens after 
analysing microarrays results using gene spring. Up-regulated in pink and down-
regulated in light blue. Log FC = fold change, X = Unknown. 
Gene Symbol Gene Name Probe Name p. value Log FC Ensemble ID 
X Unknown A_24_P15502 2.24E-04 3.1195118 Control 
X Unknown A_33_P3246995 0.001442 4.4135036 Control 
APOL6 apolipoprotein L, 6 A_24_P941167 0.001453 2.2074013 ENST00000409652 
BST2 bone marrow stromal cell 
antigen 2 
A_23_P39465 0.001407 2.6559215 ENST00000533098 
C1orf173 chromosome 1 open reading 
frame 173 
A_24_P522998 4.39E-04 5.088724 ENST00000433746 
CACNA1A calcium channel, voltage-
dependent, P/Q type, alpha 
1A subunit 
A_33_P3275846 9.76E-04 3.5303764 ENST00000357018 
CD38 CD38 molecule A_23_P167328 2.10E-04 5.3847494 ENST00000540195 
CIB2 calcium and integrin 
binding family member 2 
A_33_P3308914 5.46E-04 2.5931766 ENST00000539011 
CMPK2 cytidine monophosphate 
(UMP-CMP) kinase 2, 
mitochondrial 
A_33_P3401826 3.58E-05 3.621748 ENST00000478738 
CNP 2',3'-cyclic nucleotide 3' 
phosphodiesterase 
A_23_P21838 0.001426 2.5997334 ENST00000393892 
CPSF7 cleavage and 
polyadenylation specific 
factor 7, 59kDa 
A_33_P3309039 2.86E-04 3.7240167 ENST00000439958 
CREM cAMP responsive element 
modulator 
A_23_P201979 6.44E-04 3.1300871 ENST00000460270 
CYP2J2 cytochrome P450, family 2, 
subfamily J, polypeptide 2 
A_23_P103486 5.78E-04 3.0702367 ENST00000469406 
DDX58 DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 58 
A_33_P3418170 3.34E-04 3.6301575 ENST00000379882 
DDX60 DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 60 
A_23_P41470 2.82E-04 2.6578708 ENST00000393743 
DDX60L DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 60-like 
A_23_P30069 7.00E-04 2.754306 ENST00000511577 
DHX58 DEXH (Asp-Glu-X-His) 
box polypeptide 58 
A_23_P38346 3.01E-04 2.8720646 ENST00000423748 
ECE1 endothelin converting 
enzyme 1 
A_24_P396375 2.70E-04 3.0791154 ENST00000415912 
EIF2AK2 eukaryotic translation 
initiation factor 2-alpha 
kinase 2 
A_23_P142750 1.83E-04 3.1597533 ENST00000395127 
EPSTI1 epithelial stromal 
interaction 1 (breast) 
A_23_P105794 1.34E-04 2.8132715 ENST00000476830 
ETV7 ets variant 7 A_23_P42353 6.35E-04 3.7648585 ENST00000339796 
FRMD3 FERM domain containing 3 A_33_P3363425 9.14E-04 3.2037926 ENST00000304195 
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FTSJD2 FtsJ methyltransferase 
domain containing 2 
A_23_P374149 0.001427 2.3990216 ENST00000491004 
GALM galactose mutarotase 
(aldose 1-epimerase) 
A_33_P3273436 8.58E-04 3.285547 ENST00000272252 
GBP1P1 Guanylate Binding Protein 1, 
Interferon-Inducible 
Pseudogene 1 
A_19_P00808588 9.75E-04 3.7079072 ENST00000513638 
GBP3 guanylate binding protein 3 A_21_P0010536 0.00109 3.8230472 ENST00000461384 
GBP4 guanylate binding protein 4 A_24_P45446 0.001079 2.820499 ENST00000471938 
GCH1 GTP cyclohydrolase 1 A_33_P3311439 6.30E-04 3.102622 ENST00000395524 
GCH1 GTP cyclohydrolase 1 A_24_P167642 2.98E-04 3.2402992 ENST00000254299 
GMPR guanosine monophosphate 
reductase 
A_24_P277657 4.36E-04 3.7887647 ENST00000540478 
HERC5 hect domain and RLD 5 A_23_P110196 5.90E-06 4.295132 ENST00000502913 
HERC6 hect domain and RLD 6 A_23_P250358 6.59E-04 3.5208874 ENST00000511939 
HES4 hairy and enhancer of split 
4 (Drosophila) 
A_33_P3342628 2.23E-05 6.210292 ENST00000304952 
HRASLS2 HRAS-like suppressor 2 A_23_P105012 4.36E-04 2.7677798 ENST00000255695 
IFI35 interferon-induced protein 
35 
A_23_P152782 0.001172 2.7933698 ENST00000538473 
IFI44 interferon-induced protein 
44 
A_23_P23074 9.08E-04 3.1116233 ENST00000485662 
IFI44L interferon-induced protein 
44-like 
A_23_P45871 5.49E-05 3.8292685 ENST00000476521 
IFI6 interferon, alpha-inducible 
protein 6 
A_23_P201459 4.59E-05 4.0179195 ENST00000362020 
IFIH1 interferon induced with 
helicase C domain 1 
A_23_P68155 4.96E-05 3.7843661 ENST00000543192 
IFIT1 interferon-induced protein 
with tetratricopeptide 
repeats 1 
A_23_P52266 7.29E-05 4.3839293 ENST00000546318 
IFIT2 interferon-induced protein 
with tetratricopeptide 
repeats 2 
A_23_P24004 2.02E-05 4.486988 ENST00000371826 
IFIT2 interferon-induced protein 
with tetratricopeptide 
repeats 2 
A_24_P304071 2.14E-05 4.2640696 ENST00000371826 
IFIT3 interferon-induced protein 
with tetratricopeptide 
repeats 3 
A_33_P3283611 2.26E-05 4.9602613 ENST00000543062 
IFIT5 interferon-induced protein 
with tetratricopeptide 
repeats 5 
A_24_P30194 0.001185 2.4392035 ENST00000371795 
IFITM1 interferon induced 
transmembrane protein 1 
(9-27) 
A_23_P72737 0.001419 3.144174 ENST00000452428 
IFITM2 interferon induced 
transmembrane protein 2 
(1-8D) 
A_24_P287043 0.001107 2.621654 ENST00000527146 
IFITM4P interferon induced 
transmembrane protein 4 
pseudogene 
A_24_P16124 2.07E-04 3.1359797 ENSG00000130487 
IFNG interferon, gamma A_23_P151294 1.22E-07 6.0913982 ENST00000229135 
IGFBP7 insulin-like growth factor 
binding protein 7 
A_23_P353035 9.03E-05 4.926652 ENST00000295666 
IL15RA interleukin 15 receptor, 
alpha 
A_23_P138680 5.43E-04 5.288265 ENST00000379972 
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IL2RA interleukin 2 receptor, alpha A_24_P230563 4.74E-04 2.9039214 ENST00000447847 
IRG1 immunoresponsive 1 
homolog (mouse) 
A_33_P3319925 3.60E-05 5.714017 ENST00000449753 
ISG15 ISG15 ubiquitin-like 
modifier 
A_23_P819 2.79E-06 5.015381 ENST00000379389 
ISG20 interferon stimulated 
exonuclease gene 20kDa 
A_23_P32404 6.85E-05 3.4611702 ENST00000546338 
KLHDC7B kelch domain containing 7B A_24_P117410 0.001145 2.7272 ENST00000395676 
KLHDC7B kelch domain containing 7B A_23_P6535 4.02E-04 2.5850372 ENST00000395676 
LAG3 lymphocyte-activation gene 
3 
A_23_P116942 7.74E-04 3.5425837 ENST00000203629 
LAP3 leucine aminopeptidase 3 A_23_P18604 0.001421 3.3443398 ENST00000226299 
LOC79015 uncharacterized LOC79015 A_23_P254181 7.04E-04 3.0117376 ENST00000415889 
MOV10 Mov10, Moloney leukemia 
virus 10, homolog (mouse) 
A_23_P161125 0.001265 2.8278618 ENST00000471160 
MT1B metallothionein 1B A_23_P37983 2.07E-04 3.828361 ENST00000334346 
MT1L metallothionein 1L 
(gene/pseudogene) 
A_23_P427703 0.001424 2.4807048 ENSG00000260549 
MX1 myxovirus (influenza virus) 
resistance 1, interferon-
inducible protein p78 
(mouse) 
A_23_P17663 2.92E-04 3.1825523 ENST00000455164 
MX2 myxovirus (influenza virus) 
resistance 2 (mouse) 
A_23_P6263 0.001207 2.9111667 ENST00000330714 
NEXN nexilin (F actin binding 
protein) 
A_23_P200001 3.39E-04 3.1112146 ENST00000480732 
NT5C3 5'-nucleotidase, cytosolic III A_33_P3393836 3.74E-05 3.8463078 ENST00000409467 
NT5C3 5'-nucleotidase, cytosolic III A_23_P59547 3.97E-05 3.4802923 ENST00000405342 
OAS1 2'-5'-oligoadenylate 
synthetase 1, 40/46kDa 
A_23_P64828 7.94E-04 2.9598832 ENST00000377508 
OAS2 2'-5'-oligoadenylate 
synthetase 2, 69/71kDa 
A_23_P204087 2.40E-04 2.9682827 ENST00000392583 
OAS2 2'-5'-oligoadenylate 
synthetase 2, 69/71kDa 
A_33_P3225522 7.10E-04 3.9064493 ENST00000449768 
OAS3 2'-5'-oligoadenylate 
synthetase 3, 100kDa 
A_33_P3402489 1.44E-04 3.648745 ENST00000228928 
OAS3 2'-5'-oligoadenylate 
synthetase 3, 100kDa 
A_24_P335305 1.73E-05 4.2969465 ENST00000323881 
OASL 2'-5'-oligoadenylate 
synthetase-like 
A_23_P139786 2.53E-05 3.466197 ENST00000257570 
PARP10 poly (ADP-ribose) 
polymerase family, member 
10 
A_24_P340853 8.34E-04 2.2641857 ENST00000527262 
PARP12 poly (ADP-ribose) 
polymerase family, member 
12 
A_23_P111804 0.001137 2.4642165 ENST00000488726 
PARP9 poly (ADP-ribose) 
polymerase family, member 
9 
A_23_P69383 8.58E-04 2.6494117 ENST00000452457 
PGAP1 post-GPI attachment to 
proteins 1 
A_33_P3312735 4.22E-05 3.343388 ENST00000422382 
PI4K2B phosphatidylinositol 4-
kinase type 2 beta 
A_23_P18598 4.27E-04 2.6377878 ENST00000537420 
PLSCR1 phospholipid scramblase 1 A_23_P69109 4.13E-04 3.2515664 ENST00000448205 
PML promyelocytic leukemia A_23_P358944 0.001168 2.2871413 ENST00000435786 
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PML promyelocytic leukemia A_23_P334664 9.43E-04 2.3369055 ENST00000395132 
PML promyelocytic leukemia A_24_P207139 4.88E-04 3.865312 ENST00000268058 
PNPT1 polyribonucleotide 
nucleotidyltransferase 1 
A_23_P154488 4.71E-05 3.2472057 ENST00000402246 
PRIC285 peroxisomal proliferator-
activated receptor A 
interacting complex 285 
A_33_P3400374 1.69E-04 2.9332774 ENST00000427522 
RGS16 regulator of G-protein 
signaling 16 
A_23_P217845 9.38E-04 2.9532652 ENST00000367558 
RNF43 ring finger protein 43 A_33_P3213029 7.71E-04 3.0697901 ENST00000407977 
RRAGC Ras-related GTP binding C A_23_P97623 0.001363 4.112468 ENST00000474456 
RTP4 receptor (chemosensory) 
transporter protein 4 
A_23_P166797 5.34E-05 3.0634089 ENST00000259030 
SAMD9L sterile alpha motif domain 
containing 9-like 
A_33_P3264846 1.49E-04 3.316527 ENST00000394472 
SLC27A2 solute carrier family 27 
(fatty acid transporter), 
member 2 
A_23_P140450 6.37E-04 2.9749262 ENST00000544960 
SLC38A5 solute carrier family 38, 
member 5 
A_23_P84929 3.03E-04 2.8301091 ENST00000462359 
SOCS1 suppressor of cytokine 
signaling 1 
A_23_P420196 3.66E-04 3.0243402 ENST00000332029 
SP140 SP140 nuclear body protein A_33_P3268555 7.23E-04 2.5678482 ENST00000544128 
STAG3 stromal antigen 3 A_33_P3317058 8.01E-04 2.9011881 ENST00000379577 
TMEM140 transmembrane protein 140 A_24_P372134 0.001084 2.490767 ENST00000456488 
TNFSF10 tumor necrosis factor 
(ligand) superfamily, 
member 10 
A_23_P121253 4.23E-05 4.3497934 ENST00000241261 
TNFSF10 tumor necrosis factor 
(ligand) superfamily, 
member 10 
A_33_P3226810 8.06E-05 3.9121034 ENST00000241261 
TRIM5 tripartite motif containing 5 A_23_P356526 5.88E-04 2.5912266 ENST00000465634 
USP18 ubiquitin specific peptidase 
18 
A_23_P132159 9.73E-07 5.2692184 ENST00000215794 
USP41 ubiquitin specific peptidase 
41 
A_32_P54553 4.42E-07 5.602893 ENST00000454608 
XLOC_000755 Uncharacterised  A_21_P0001111 2.48E-04 3.4425192 ENST00000440492 
XLOC_001609 Uncharacterised A_21_P0001893 2.51E-04 3.4356153 ENST00000452037 
XLOC_001966 Uncharacterised A_21_P0002006 0.001414 3.5555193 ENST00000414795 
XLOC_l2_000
233 
Uncharacterised A_21_P0010531 7.63E-04 2.5990458 ENST00000438195 
ZC3HAV1 zinc finger CCCH-type, 
antiviral 1 
A_23_P20122 0.001103 2.571025 ENST00000471652 
ZNFX1 zinc finger, NFX1-type 
containing 1 
A_24_P23034 0.001044 2.2538695 ENST00000537431 
X Unknown A_33_P3303742 0.001369 -2.6417236 ENST00000439905 
BAIAP2 BAI1-associated protein 2 A_23_P315836 8.57E-04 -2.668449 ENST00000435091 
C15orf52 chromosome 15 open 
reading frame 52 
A_23_P163467 0.001095 -2.8513255 ENST00000397535 
EGR3 early growth response 3 A_23_P216225 0.001465 -2.7386675 ENST00000317216 
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FLJ40288 uncharacterized FLJ40288 A_21_P0014767 0.001468 -2.2612228 ENSG00000183470 
FRY furry homolog (Drosophila) A_33_P3223488 2.19E-04 -2.8213084 ENST00000436046 
GAS7 growth arrest-specific 7 A_24_P82466 0.001099 -3.479138 ENST00000323816 
HSD17B1 hydroxysteroid (17-beta) 
dehydrogenase 1 
A_23_P15542 9.83E-04 -2.394454 ENST00000225929 
LOC1005057
46 
uncharacterized 
LOC100505746 
A_21_P0000759 5.88E-04 -3.36895  
LOC388242 coiled-coil domain 
containing 101 pseudogene 
A_32_P135336 2.26E-05 -3.503117 ENST00000549950 
MUC5B mucin 5B, oligomeric 
mucus/gel-forming 
A_24_P102650 0.00107 -2.7954655 ENST00000349637 
MYLK4 myosin light chain kinase 
family, member 4 
A_33_P3252939 0.001104 -2.545482 ENST00000274643 
NAV2 neuron navigator 2 A_23_P52727 0.001392 -2.4784532 ENST00000396085 
NRARP NOTCH-regulated ankyrin 
repeat protein 
A_33_P3337272 0.001073 -2.4398358 ENST00000356628 
PLIN5 perilipin 5 A_23_P39251 9.74E-04 -2.6129234 ENST00000381848 
PTGFRN prostaglandin F2 receptor 
negative regulator 
A_33_P3307197 8.48E-04 -2.9451718 ENST00000544471 
SIGLECP3 sialic acid binding Ig-like 
lectin, pseudogene 3 
A_32_P128258 6.71E-04 -3.44869 ENSG00000171101 
UBXN11 UBX domain protein 11 A_24_P239811 7.93E-04 -3.1068769 ENST00000486658 
VCAN versican A_23_P144959 2.76E-04 -5.141041 ENST00000512590 
XLOC_001338 Uncharacterised A_21_P0002164 0.001206 -3.0045128  
XLOC_011215 Uncharacterised A_21_P0008616 0.001288 -2.5846038  
XLOC_011218 Uncharacterised A_21_P0008619 0.001492 -2.333941  
XLOC_012522 Uncharacterised A_21_P0009199 0.001353 -2.5692058 ENST00000514726 
XLOC_l2_012
135 
Uncharacterised A_21_P0012998 0.001168 -2.9539542 ENST00000505712 
XLOC_l2_015
033 
Uncharacterised A_21_P0013601 5.38E-04 -2.766016  
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Figure 6.4 
Hierarchical 
clustering of the 
genes. Significant 
changes in gene 
expression between 
activated and 
inactivated CD56+ T 
cells were illustrated by 
using heat maps. A 
Hierarchical clustering 
approach joins genes by 
dendrograms that have 
similar gene expression 
patterns between them. 
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A comparison between CD56+ T-cells under stimulated and un-stimulated 
conditions revealed 131 probes that were significantly changed, hower, out of 
these probes only 106 genes were significantly changed. Hierarchical clustering of 
these genes was performed (Figure 6.4).       
Overall, genes are arranged according to FC levels in Table 6.2. Two genes have 
FC levels more than 6 and they are IFN-γ and HES4, and only VCAN was down-
regulated to less than -5 folds between CMV-stimulated and un-stimulated CD56+ 
T-cells.  
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FC Gene Symbol 
6 ≤ 
 
HES4, IFNG 
5 to 5.99 
 
IRG1,USP41,CD38, IL15RA, USP18, C1orf173, ISG15 
4 to 4.99 
 
IFIT3, IGFBP7, IFIT2, IFIT1, TNFSF10, OAS3, HERC5, IFIT2, RRAGC 
IFI6 
3 to 3.99 
 
TNFSF10, OAS2, PML, NT5C3, IFI44L, MT1B, GBP3, GMPR, IFIH1, ETV7, 
CPSF7, GBP1P1, OAS3, DDX58, CMPK2, XLOC_001966, LAG3 
CACNA1A, HERC6, NT5C3, OASL, ISG20, XLOC_000755, XLOC_001609, 
LAP3, PGAP1, SAMD9L, GALM, PLSCR1,PNPT1, GCH1 FRMD3, MX1, 
EIF2AK2, IFITM1, IFITM4P, CREM, IFI44, NEXN, GCH1 ECE1, CYP2J2, 
RNF43, RTP4, SOCS1, LOC79015 
 
2 to 2.99 
 
SLC27A2, OAS2, OAS1, RGS16, PRIC285, MX2, IL2RA, STAG3, DHX58 
SLC38A5, MOV10, GBP4, EPSTI1, IFI35, HRASLS2, DDX60L, KLHDC7B, 
DDX60, BST2, PARP9, PI4K2B, IFITM2, CNP, XLOC_l2_000233, CIB2, 
TRIM5, KLHDC7B, ZC3HAV1, SP140, TMEM140, MT1L, PARP12, IFIT5, 
FTSJD2, PARP10, ZNFX1،APOL6 
 
-2 to -2.99 
 
FLJ40288, XLOC_011218, HSD17B1, NRARP, NAV2, MYLK4, 
XLOC_012522, XLOC_011215, PLIN5, BAIAP2, EGR3, XLOC_l2_015033, 
MUC5B, FRY, C15orf52, PTGFRN, XLOC_l2_012135 
-3 to -3.99 
 
XLOC_001338, UBXN11, LOC100505746, SIGLECP3, GAS7, LOC388242 
-5 ≥ VCAN 
Table 6.2 Significantly up- or down-regulated genes expressed by CD56+ T-
cells in response to CMV categorised according to fold change (FC).   
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Up-regulated genes grouped according to biological processes expressed by 
CD56+ T-cells in response to CMV lysate are illustrated in bar charts with the FC 
levels of the genes shown. In Figure 6.5 the genes that are normally regulated by 
IFN are illustrated.    
 
Figure 6.5 Genes normally regulated by IFNs and up-regulated in CD56+ T 
cells following CMV stimulation. The bar chart shows more genes were 
regulated by IFN-γ than both α and β. 
Genes expressed by CD56+ T-cells were sorted according to the effect of CMV 
lysate; these are shown in Figure 6.6. The biological processes involved are 
negative regulation of viral processing and genome replication, detection of the 
virus and response to the virus.   
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Figure 6.6 Genes upregulated according to function by CD56+ T-cells due to 
an anti-CMV response. Three functions were included response to virus, 
detection and virus and negative regulaytion of viral process and genome 
replication.   
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Genes upregulated by CD56+ T-cells due to immune response and defence 
response are shown in Figure 6.7.  
 
 
Figure 6.7 Genes upregulated according to immune and defence response by 
CD56+ T-cells due to an anti-CMV response. These two charts show genes 
upregulated in CD56+ T-cells in response to CMV lysate; TNFSF10 is involved 
in immune response, while SP140, PLSCR1 and EIF2AK2 in defence response.   
 
According to the Gene Ontology Normal Usage Tracking System (GONUTS; 
http://gowiki.tamu.edu/wiki/index.php/Main_Page) the defence response is 
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reactions triggered due to the incidence of a foreign body or due to an injury, 
while immune response is any immune system process in response to internal or 
external pathogen. Therefore, defence response is a wider definition.   
Genes whose expression in CD56+ T-cells changed due to stress are shown in 
Figure 6.8. Stress is due to the CMV lysate and other cell signalling processes 
leading to disturbance of metabolic or signalling processes and variation in 
temperature and pH; controlling stress is essential for cell homeostasis  (Kultz 
2005).      
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Figure 6.8 Genes upregulated according to stress by CD56+ T-cells due to an 
anti-CMV response. Changes in expression of stress regulated genes in CD56+ 
T-cells.  VCAN was the only gene that was down-regulated due to stress inCD56+ 
T-cells.   
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6.3.2 Validation of microarrays results 
Results of microarray gene expression were validated by two methods, RT-PCR 
and protein expression by using flow cytometry. Three transcripts were quantified 
by RT-PCR in Dr. BF Flanagan’s laboratory (Women’s and Children’s Health, 
ITM, Alder Hey Hospital) and they were IFN-γ, ISG-15 and USP-18. Two were 
analysed by detecting their protein expression by FACs analysis and they are ISG-
15 and CD38.  
 
6.3.3 RT-PCR gene expression analysis  
The experiment was described in section 2.3.2.6.8. The detected expression of 
these genes will be calculated and compared to microarrays. Quantitative RT-PCR 
is an accurate method to utilise and quantify the expression levels of genes by 
using Taq-man.  
The protein ISGylation and de-ISGylation cycle involves ISG-15, USP18, E1 
activating enzyme, E2 conjugating enzyme and E3 ligase (TRIM5, HERC5 and 
HERC4). ISGylation is briefly explained as the covalent attachment of ISG-15 to 
proteins which is induced by IFN, while removal of ISG-15 is called de-
ISGylation via USP-18 (Schneider et al. 2014); this is similar to the ubiquitination 
pathway (Figure 6.9).       
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Figure 6.9 Ubiquitination cycle. Labelling proteins with ubiquitin or ubiquitin-like 
 modifier render them to be targeted for degradation within the 26s proteasome. The reaction 
is  catalysed by E1, E2 and E3 (adapted from www.biochemie.charite.de) 
 (Takeuchi and Yokosawa 2008).  
 
 
As monoclonal antibodies are available for IFN-γ, ISG-15 and USP-18, these 
were picked for quantification by RT-PCR and flowcytometry to validate 
microarrays results. In figure 6.10an illustration of two samples amplification blot 
is attached. 
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Figure 6.10 Amplification plot showing curves by RT-PCR. Samples were run 
in duplicates; the amplification blot shows curves of same products amplified at 
the same time. Delta (Δ) Rn used to show the magnitude of the signal produced 
when samples amplified. The green threshold line identifies the Ct value during 
the PCR exponential phase.    
    
The results of RT-PCR of IFN-γ gene expression analysis are illustrated in Table 
6.3, and for ISG-15 gene expression analysis are illustrated in Table 6.4, and for 
USP-18 gene expression analysis are illustrated in Table 6.5.  
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Table 6.3 RT-PCR results for IFN-γ. Av= average, L32 housekeeping gene, Ct= 
threshold cycle and the difference between stimulated and unstimulated was 
calculated by this equation (Ct s- Ct us), 2^Ct = 2 delta Ct to calculate relative 
gene expression and is expressed as fold change between non stimulated and 
stimulated cells.   
 
 
   
 
 
S
am
p
le
 
L32 Av IFN-γ Av 
L32 - 
IFN- γ 
Ct 2^Ct 
S-1 
26.3208 26.3934 26.3571 25.6838 25.8338 25.7588 0.5983 
7.532 
 
185. 
 
US-
1 
25.8969 25.4654 25.6812 32.7122 32.5192 32.6157 -6.9345 
S-2 
27.6131 27.2341 27.4236 26.6391 28.1414 27.3903 0.03335 
4.310 
 
19.8 
 
US-
2 
30.8165 30.6321 30.7243 34.925 35.0782 35.0016 -4.2773 
S-3 
29.3997 29.2063 29.303 27.9552 28.2704 28.1128 1.1902 
6.087 
 
68.0 
 
US-
3 
36.7006 36.8294 36.765 41.5109 41.8144 41.6627 -4.8976 
S-4 
33.9122 33.8688 33.8905 30.7599 30.9006 30.8303 3.06025 
7.177 144. US-
4 
36.786 38.1902 37.4881 42.7882 40.423 41.6056 -4.1175 
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Table 6.4 RT-PCR results for ISG-15. Av= average, L32 housekeeping gene, 
Ct= threshold cycle and the difference between stimulated and unstimulated was 
calculated by this equation (Ct s- Ct us), 2^Ct = 2 delta Ct to calculate relative 
gene expression.  Expressed as fold change between non stimulated and 
stimulated cells.  .   
 
S
am
p
le
 
L32 Av ISG-15 Av 
L32 - 
ISG-15 
Ct 2^Ct 
S-1 
26.3208 26.3934 26.3571 21.0772 20.9384 21.0078 5.3493 
4.234 
 
18.8 
 
US-
1 
25.8969 25.4654 25.6812 24.4557 24.6773 24.5665 1.11465 
S-2 
27.6131 27.2341 27.4236 22.2968 21.5766 21.9367 5.4869 
 
5.931 
 
61.3 US-
2 
30.8165 30.6321 30.7243 31.3468 31.0041 31.1755 -0.4512 
S-3 
29.3997 29.2063 29.303 26.5472 26.3905 26.4689 2.83415 
5.137 
 
35.2 
 
US-
3 
36.7006 36.8294 36.765 38.7396 39.3974 39.0685 -2.3035 
S-4 
33.9122 33.8688 33.8905 30.4878 30.3916 30.4397 3.4508 
6.118 69.4 US-
4 
36.786 38.1902 37.4881 39.6427 40.6693 40.156 -2.6679 
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Table 6.5 RT-PCR results of USP-18. Av= average, L32 housekeeping gene, 
Ct= threshold cycle and the difference between stimulated and unstimulated was 
calculated by this equation (Ct s- Ct us), 2^Ct = 2 delta Ct to calculate relative 
gene expression expressed as fold change between non stimulated and stimulated 
cells.   
.  
S
am
p
le
 
L32 Av USP-18 Av 
L32 - 
USP-18 
Ct 2^Ct 
S-1 
26.3208 26.3934 26.3571 24.8248 24.817 24.8209 1.5362 
3.8107 
 
14.04 
 
US-1 
25.8969 25.4654 25.6812 27.9286 27.9826 27.9556 -2.2745 
S-2 
27.6131 27.2341 27.4236 24.1246 24.1243 24.1245 3.29915 
5.7899 
 
55.33 
 
US-2 
30.8165 30.6321 30.7243 33.2039 33.2261 33.215 -2.4907 
S-3 
29.3997 29.2063 29.303 26.7736 26.9293 26.8515 2.45155 
4.4915 
 
22.49 
 
US-3 
36.7006 36.8294 36.765 39.1202 38.4896 38.8049 -2.0399 
S-4 
33.9122 33.8688 33.8905 32.5595 33.0314 32.7955 1.09505 
4.5467 23.38 
US-4 
36.786 38.1902 37.4881 41.7594 40.1202 40.9398 -3.4517 
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The means of the gene expression values were compared to microarrays levels 
and illustrated in Figure 6.11.  
 
Figure 6.11 Comparison between means of gene expression in RT-PCR and 
Microarrays. Only USP-18 level of expression in microarrys were higher than 
RT-PCT.  
 
 
6.3.4 ISG-15 and CD38 protein expression analysis by FACs  
Monoclonal antibodies were only available for a few of the gene products found 
to be upregulated by microarray analysis. ISG-15 and CD38 protein expression 
were validated by flow cytometry. The samples from CMV negative and positive 
subjects were compared to analyse any possible significant differences.  
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6.3.4.1 ISG-15 protein expression by CD56+ T-cells      
The method for detecting ISG-15 protein is described in section 2.3.2.6.9. A total 
of 10 CMV positive and negative subjects were analysed.  ISG-15 expression 
levels were compared between three different cells groups: NK cells, CD56+ T-
cells and CD56- T-cells after incubating PBMCs overnight with CMV lysate.  
Results are illustrated in figure 6.12. The levels were calculated by density plot 
and presented in Figure 6.13. 
 
 
 
 
 
 
 
Figure 6.12 Levels of ISG-15 protein expression. ISG-15 in response to CMV 
extract in NK cells, CD56+ T-cells and CD56- T-cells were compared between 
CMV positive and negative healthy donors.   
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Figure 6.13 Levels of ISG-15 protein expression by density blot. Density plots 
illustrating the levels of ISG-15 in different cell populations before and after 
overnight stimulation with CMV lysate. Results from a representative CMV+ 
subject are shown. 
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Proportions of NK cells expressing ISG-15 following stimulation with CMV 
extract were significantly more in CMV positive (46.69% ± 9.179) than negative 
subjects (16.68% ± 3.371) (P=0.0248; Fig. 6.8), moreover proportions of CD56+ 
T-cells expressing ISG-15 were significantly more in CMV positive (47.550% ± 
9.476) than negative subjects (14.64% ± 4.304) (P=0.0152). However, proportions 
of CD56- T-cells expressing ISG-15 were not significantly more in CMV positive 
(36.67% ± 10.88) than negative subjects (11.74% ± 2.331) (P=0.0648).  
 
6.3.4.2 CD38 protein expression by CD56+ T-cells      
CD38 is an ectoenzyme and a marker of cell activation found on the surface of 
several immune cell types and functions in cell adhesion, signal transduction and 
calcium signalling. Ectoenzyme is situated on the outer surface of cells membrane 
and released upon stimulation. CD38 gene expression was found to increase 
significantly in CMV lysate stimulated CD56+ T-cells. Expression of CD38 
protein was evaluated in NK cells, CD56+ T-cells and CD56- T-cells and 
compared between CMV sero-groups (figure 6.14).  
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Figure 6.14 CD38 expressions. CD38 expression by cells from CMV+ and 
CMV- donors; no significant differences were found. The right scatter plot shows 
NK cells to have the highest MFI for CD38 expression among the cell groups but 
no significant differences were seen between CMV groups.     
 
6.4 Discussion  
This part of the study aimed to identify changes in the gene expression of CD56+ 
T-cells in response to overnight CMV stimulation. The first step was to obtain 
purified CD56+ T cells which was performed using fluorescence activated cell 
sorting of double labelled cells. Although purities of sorted cell populations were 
>90% but there was still some slight contamination, most likely with CD56- T 
cells. The possibility remains that these contaminating cells contributed in such a 
way that they significantly altered the pattern of changes in gene expression by 
CD56+ T cells.  
The gene expression experiments were done by using Agilent Human v2 8 x 60K 
arrays. The results were validated through RT-PCR and flow cytometric analysis 
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of protein expression. Overall 106 genes were significantly changed following 
CMV antigen stimulation of CD56+ T-cells. IFN-γ gene expression significantly 
increased and it is clear that most of the genes significantly changed were 
interferon stimulated genes; therefore, before proceeding to discuss their role it is 
essential to consider how the IFN antiviral response works. While the Type I 
interferons IFN-α and IFN-β are part of the innate immune response, IFN-γ is the 
sole representative Type II interferon (Schneider et al. 2014). In brief, the Type I 
IFN mediated response is part of the innate immune response and participates in 
activation of the adaptive immune response. When a cell is invaded or detects the 
presence of a pathogen such as a virus, bacterium or parasite, there is consequent 
production of IFN that binds cell surface receptors and triggers a series of signal 
transducers also called Janus kinase signal transducer and activator of 
transcription pathway (JAK-STAT). This leads to transcriptional regulation of 
IFN-regulated genes and preparation of the cells into an anti-pathogenic status 
(Schneider et al. 2014), inducing the transcription of 500 to 1000 IFN-stimulated 
genes (ISGs) that encode proteins with several functions including resisting 
infection and shaping the immune response (Diamond and Farzan 2013).  
Family groups of significantly changed ISGs are IFN-induced proteins with 
tetratricopeptide (IFIT) repeat domains which include IFIT1 (ISG-56), IFIT2 
(ISG-54), IFIT3 (ISG-60) and IFIT5 (ISG-58) and also IFN-induced 
transmembrane proteins (IFITM) which include IFITM1, IFITM2 and IFITM4P 
(Pseudogene) and Interferon induced with helicase C domain 1 (IFIH1). The latter 
exists in the cytoplasm and senses viral nucleic acid, induces the production of 
IFN-α and β and is effective in triggering the innate immune response and NK cell 
activation (Cocude et al. 2003, Bamming and Horvath 2009) which in consistent 
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with this study where it was found to increase in response to CMV lysate (Figures 
6.6-6.8). This study showed IFIT1 and 2 to be upregulated in response to CMV 
which participate in negative regulation of viral processes and genome replication 
(Figure 6.6).  IFIT 1, 2 and 3 also participate in response to stress (Figure 6.8). 
While IFIT5 is an essential enhancer for the innate immune system response 
against viral infection (Zhang et al. 2013), the IFIT family encodes proteins that 
are contained in the cytoplasm with no known enzymatic functions and are also 
named viral stress-inducible genes. Additionally, they contain tetratricopeptide 
repeats (TPR) that can participate in functions such as cell cycle progression, 
transcription, protein folding and transport (D'Andrea and Regan 2003, Diamond 
and Farzan 2013).  
This family under normal condition are not expressed, however, during virus 
infection they are expressed rapidly (Sarkar and Sen 2004) and after ~2 hours of 
IFN-α induction (Diamond and Farzan 2013) and were upregulated here (Figure 
6.5). Their antiviral functions include suppression of translation initiation, binding 
of viral RNA and sequestering viral RNA and proteins in the cytoplasm; 
furthermore, studies suggest they can play roles in immune responses (Diamond 
and Farzan 2013). The IFITM family are similar to IFIT in lacking enzymatic 
functions, and they have effective antiviral functions against enveloped viruses. 
IFITM proteins are found abundantly in late endosomes and lysosomes of the cell, 
and they function to block virus migration into the cells which make them 
effective against viruses which require entry into late endosomes and lysosome 
for their effective invasion, such as SARS-coronavirus and filovirus. However, 
they have no effect on HIV against which IFTIM2 is effective, this indicate 
selectivity for the virus they inhibit (Schneider et al. 2014). IFITM4P has been 
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identified as a pseudo-gene (Diamond and Farzan 2013), which is known to be an 
outcome of accumulation of multiple mutations and their product is not required 
to perform biological functions. 
2', 5'-oligoadenylate synthetase OAS genes 1, 2, 3 and L are induced by IFN-γ and 
are involved in generating immune and defence responses while OAS1 is induced 
by α as well (Figures 6.5 and 6.7). Also, OAS 1 and 3 are involved in negative 
regulation of viral processing and genome replication, and were found to be 
upregulated in response to CMV lysate (Figure 6.6). The OAS/RNase L system 
inhibits viral infection and is part of the innate immune pathway to degrade viral 
and cellular RNA (Silverman 2007). Mx1 is involved in response to viruses, 
immune and defence responses and response to stress (Figures 6.6, 6.7 and 6.8). 
Myxovirus resistance (Mx) genes 1 and 2 are involved in inhibiting virus entry 
into cells, and are IFN-induced. Moreover, Mx1 acts at an early step of the virus 
cycle where it prevents viruses from reaching their cellular destination (Levy et al. 
1986). Mx2 traps reverse-transcribed genomes from attaining a nuclear 
destination and is found to be effective against HIV and influenza-A (Silverman 
2007). SOC1 is also induced by IFN-γ (Figure 6.5) and is involved in immune and 
defence responses and stress (Figures 6.7 and 6.8). It encodes SOCS protein that 
increases on early response to IFN induction and regulates IFN through JAK-
STAT (Schneider et al. 2014).  LAG-3 is expressed by activated NK and T-cells 
and blocking LAG-3 and PD-1 at the same time induces T cell activation which 
reveals the inhibitory effects  of these gene products on T-cells during chronic 
viral infection (Triebel et al. 1990, Blackburn et al. 2009).  
Putative RNA helicases DEAD-box DDX58, DDX60, DDX60L and DEAH-box 
DHX58 were up-regulated significantly in the response to CMV (Figure 6.6). 
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DDX58 and DHX58 both involved in immune and defence responses and 
response to stress (Figures 6.7 and 6.8). DEAD-box and DEAH-box play roles in 
binding nucleic acids and unwinding  RNA structure, also, in cell differentiation 
and are distinguished by their amino acids of the helicase 4-mer motif-II 
(Abdelhaleem et al. 2003). PNPT1 and PLSCR1 are both induced by IFN-β and in 
response to stress (Figures 6.5 and 6.8), PLSCR1 is involved also in negative 
regulation of viral processing, genome replication and response (Figures 6.6 and 
6.7).The IFN-induced Phospholipid scramblase 1 (PLSCR1) is involved in 
antiviral responses and cells with low levels of PLSCR1 are weakly responsive to 
antiviral-IFN responses (Dong et al. 2004). PNPT1 is an IFN-induced gene that 
encodes a  protein involved in RNA processing and degradation  (G. Wang et al. 
2012). TNFSF10 encodes a protein of the TNF ligand family which induces 
apoptosis in transformed cells; this gene is involved in the immune response 
(Figure 6.7).          
VCAN was the only gene whose expression was found to be significantly 
decreased in response to CMV antigens and has been reported to be reduced due 
to stress (Figure 6.8). This gene encodes the extracellular matrix glycoprotein 
versican which is involved in cell adhesion, proliferation, migration and 
angiogenesis and plays a central role in tissue morphogenesis and maintenance. 
Versican can bind L and P-selectin and CD44 (Wight 2002) and studies indicated 
T-cells struggle to migrate in versican enriched media, while blocking of versican 
in this media induced cell migration (Evanko et al. 2012, Wight et al. 2014).  
ISG-15, TRIM5 and HERC5 were all upregulated in response to CMV (Figure 
6.6); these genes are involved in immune and defence responses and stress 
response (Figure 6.7 and 6.8).  
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Figure 6.11 shows that expression levels of ISG-15, USP-18 and IFN-γ between 
RT-PCR and microarrays correlated quite closely.I It is expected that RT-PCR 
would be more sensitive than microarrays and this was found for IFN-γ and ISG-
15, however, USP-18 microarrays expression levels was 10 folds higher than RT-
PCR. Moreover, genes involved in the innate immune response to viral infection 
Type-I IFN responses; OAS, MX-1, MDA5 and TRIM5 were also increased in 
CMV-specific-CD4+ T-cells (Hu, 2013).  
In addition, ISG-15 and CD38 were further studied to validate microarrays and 
RT-PCR results and to compare protein expression between CMV positive and 
negative healthy donors in response to CMV antigens. Figure 6.13 shows 
comparison between levels of ISG-15 after overnight stimulation. Clearly, CMV 
positive donors showed higher ISG-15 levels than CMV negative healthy donors 
and this was statistically significantly in NK cells and CD56+ T-cells although not 
quite for CD56- T cells.  
However, CD38 was highly expressed among all cell groups with no significant 
differences between CMV- and CMV+ donors (figure 6.14). Mean fluorescence 
intensities (MFI) were increased in NK cells and CD56+ T-cells from CMV+ 
compared to CMV- donors, although this did not reach statistical significance. 
CD38 functions as a signalling molecule and is expressed widely on several cell 
types; it is type II transmembrane glycoprotein and detected on activated T and B-
cells. It has been argued in HIV patients that high levels of CD38 on CD8+ T-
cells can be a negative prognostic marker (Liu et al. 1996). In EBV-induced 
infectious mononucleosis numbers of CD38 antigenic sites were higher than in 
CMV-induced infectious mononucleosis, however, both were higher than in 
healthy control groups (Zidovec Lepej et al. 2003).  
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To conclude this part of the study, CD56+ T-cell gene expression studies 
indicated high expression of genes involved in immune responses toward CMV. 
Some genes were identified in the literature to be involved in responses against 
other viruses but not CMV such as DDX60, ISG15,ISG, MX1, MX2, OASL and 
TRIM5 etc (Schoggins and Rice 2011). This is consistent with cellular studies in 
previous chapters indicating that CD56+ T-cells respond to CMV lysate and share 
some properties with NK cells and T-cells.      
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7. General conclusions and future work 
CMV is a common asymptomatic persistent infection and prevalence ranges 
between 30-90% in developed countries (Crough and Khanna 2009). HCMV 
infection is a potential threat leading to failure in graft adaptation in recipients 
sometimes leading to graft rejection. Moreover, CMV induces the immune system 
via triggering inflammation, immune cell infiltration, expression of adhesion 
molecules in the transplanted organ, the release of cytokines and chemokines, and 
growth factors connected to the process of acute rejection of the graft (Koskinen 
et al. 1999). Kidney rejection may be promoted via re-activation of CMV in the 
blood followed by fever, muscle pain, leucopenia, hepatitis, gastroenteritis, 
pneumonitis and thrombocytopenia (Hartmann et al. 2006, Weikert and Blumberg 
2008). 
CD56+ T-cells were first described by Lanier et al   (Lanier et al. 1986) but 
shown by Schmidt-Wolf et al (1991) to be generated in vitro after the addition of 
anti-CD3, IFN-γ and IL-2 to PBMCs and incubation for 28 days. These cells were 
shown both to exert TCR specificity and to have NK cell function (Pievani et al. 
2011). This study aimed to investigate any relationship between CD56+ T-cells 
and CMV both in healthy subjects and kidney transplant patients. CD56+ T-cells 
have the potential to promote cytopathic effects against transplanted kidneys upon 
CMV activation.  
CD56+ T-cell prevalence and function between CMV seropositive and 
seronegative healthy and KTPs were evaluated. Both healthy subjects and KTPs 
have significantly higher levels of CD56+ T-cells in seropositive than 
seronegative groups. In Figure 5.11 both healthy subjects and KTPs were 
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compared to identify any significant differences between the groups studied. 
Proportions of CD56+ T-cells were significantly higher in healthy CMV+ subjects 
than both CMV+ KTP groups, D+R- and R+. Additionally, healthy CMV- donors 
had significantly higher proportions of CD56+ T-cells than D-R- KTPs. This 
indicates that CD56+ T-cells expanded in response to the presence of CMV in 
CMV + healthy and patient groups, and the significant lower levels in D+R- and 
R+ KTPs than the healthy seropositive donors may be due to immune-suppression 
therapy consisting of Cyclosporine, Campath-1 or Tacrolimus; this was also found 
in CMV- healthy subjects and KTPs where the healthy subjects had significantly 
higher levels than D-R- patients. Still, with this immune-suppressive therapy the 
CMV+ KTPs showed significantly higher levels of CD56+ T-cells than the D-R- 
patient group. If infection with viruses other than CMV induces expansion of 
CD56+ T cells, in the case of D-/R- KTPs this may have been prevented by 
immunosuppressive drug treatment, giving rise to lower levels than in healthy 
CMV- subjects. Other viruses such as HHV-6 and BK virus can also be re-
activated in KTPs. Future work could examine CD56+ T cell levels and functional 
activity in KTPs in which donor and recipient were both negative for CMV but 
mismatched for these other viruses. This would show whether CMV is unique in 
inducing expansion of CD56+ T cells.  
Both patients and healthy positive donors had increased CD4 and CD8 surface 
expression on CD56+ T-cells than in CMV- groups and  CD8 was expressed on 
significantly more cells than CD4 in both seropositive healthy and KTP groups. 
Furthermore, characterization of CD56+ T-cells in both CMV+ healthy subjects 
and KTPs revealed that these cells become memory cells with T-EMRA like 
phenotype and pre-store granzyme B as this study detected. The only difference 
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detected was that in healthy donors MFI for CD11a was significantly higher in 
CMV+ than CMV- subjects while in KTPs this was not statistically significant. 
This also can be a result of administration of immune-suppressive therapy. 
Overall, the results indicated that CD56+ T-cell prevalence and memory 
phenotype are almost the same between healthy subjects and KTPs depending on 
the sero-status of the individual.  
The functional capacity of CD56+ T-cells was evaluated in Chapter 4 of this 
study. CD56+ T-cell populations have dual functions where some preserved TCR 
specificity against CMV and expanded in response to CMV stimulation while also 
performing NK-like cytotoxicity against MHC negative K562 cells. CD56+ T-
cells from CMV+ donors reacted to CMV lysate by producing Th1 like cytokines 
IFN-γ and TNF-α and Granzyme B in significantly greater proportions than in 
CMV – donors (Table 4.1). Th1 cells promote an alloresponse to a kidney graft 
and graft rejection via the activation and recruitments of CD8+ T-cells, B-cells 
release IgG2a that activates complement and CD8+ T-cells also promote 
macrophage dependent delayed-type hypersensitivity. Additionally, CD8+ T cells 
also may express Fas-L that promotes CD8+ T-cell cytotoxicity (Issa et al. 2010).  
Moreover, the CD107a degranulation assay showed that CD56+ T-cells from 
CMV+ subjects express significantly more CD107a than CMV- donors after being 
pulsed by K562 and CMV lysate. KLRG-1 was expressed by significantly more 
CD56+ T-cells in CMV+ than CMV- subjects, this marker was argued to increase 
on cells lacking proliferation capability (Voehringer et al. 2002).  
However, this study showed that CD56+ T-cells obtained from CMV+ donors 
were able to proliferate in response to CMV stimulation which is consistent with 
another study (Geginat et al. 2003). TCR specificity was preserved by CD56+ T-
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cells obtained from both healthy subjects and KTPs, CD8
bright+
 CD56+ T-cells 
reacted specifically to pentamers loaded with common CMV peptides HLA-
A*02:01-NLV, HLA-B*07:02-TPR and HLA-B*08:01-QIK. CD8
bright+
CD56+ T-
cell reactivity to these pentamers were compared to CD56-CD8
 bright+
 T-cells. 
Furthermore, CD8
bright+
CD56+ T-cells from one HLA-B8+ healthy donor showed 
a higher proportion of HLA-B*08:01-QIK binding cells than CD8
bright+
CD56- T-
cells. Comprehensive cellular work conducted in Chapters 3-5 and showed 
increased proportions and function of CD56+ T cells in CMV+ healthy subjects 
and KTPs, also CMV-specific cytotoxic T cells were found, which might indicate 
involvement toward the immune rejection of the kidney graft via CMV antigens 
on the graft especially in high risk groups D+R-. In future work, pentamer+ cells 
could be purified and tested for cytotoxic activity against both CMV-infected 
target cells and NK cell targets. This would indicate whether CD56+ T cells can 
retain both antigen-specific and non-MHC restricted cytotoxic function. This 
might be relevant to transplant rejection in D+/R- patients.  
Gene expression profile of CD56+ T-cells purified from CMV+ PBMCs was 
evaluated as illustrated in Chapter 6. This study detected 106 genes that 
significantly changed following CMV antigen stimulation. The technique applied 
was Microarrays and in three cases was validated via RT-PCR and Flow-
cytometry. CMV can trigger activation of signalling pathways that prime mRNA 
expression which in turn can be detected by Microarrays to provide quantitative 
study of the results of CMV lysate activation on CD56+ T-cells. The functions of 
these genes are involved in innate and adaptive immune responses. Interferon 
stimulated genes were significantly upregulated in CD56+ T-cells upon overnight 
stimulation with CMV lysate. Significantly expressed genes were sorted 
 
- 259 - 
according to their biological process in Figures 6.5-6.8. Validation of microarrays 
has been processed by RT-PCR on IFN-γ, ISG-15 and USP-18.  
However, a drawback of these studies is that there was some contamination with 
CD56- T cells. This was not the case in flow cytometric studies as single cell 
expression could be investigated. CD38 and ISG-15 proteins expression and 
levels between CMV- and CMV+ healthy donors were studied via flow 
cytometry. Overall, ISG-15 was discovered in 1992 (Loeb and Haas 1992) and it 
is one of the early genes that response to viral stimulation and interferon 
induction, moreover, more than158 conjugation targets for ISG-15 have been 
detected; these targets are involved in several processes such as RNA splicing, 
stress response, transcription and translation (Zhao, 2005, Giannakopoulos, 2005). 
ISG-15 was argued as essential in IFN-α/β induced antiviral response via 
maintaining antiviral protein stability, activity, localisation and association with 
other proteins during the antiviral response (Lu, 2006). ISG-15 knockout mice 
show increased susceptibility to viral infection (Lenschow, 2005, Lenschow, 
2007), while CD56+ T-cells expressed more ISG-15 in CMV + than CMV – 
subjects, indicating potential immunological functions against CMV.In future 
work, CD56+ T cell clones could be derived and stimulated with CMV antigens to 
more definitively show their range of gene expression. Expression of a wider 
range of immune-related genes could also be studied at the protein level. 
To conclude, the findings of this comprehensive study on CD56+ T-cells in 
relation to CMV infection increase the overall knowledge about these cells, and 
add significant information on their possible role in response to CMV. They 
suggest that CD56+ T-cells participate at some level in the immune response 
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toward kidney grafts especially during CMV syndrome as there is the potential for 
increased levels of non-MHC restricted cytotoxic function.  
Future work on these cells might involve study of their prevalence and functions 
against other pathogens in kidney or other organ transplant patients. Their 
involvement in graft rejection might also be investigated. This could most readily 
be done by obtaining pre-transplant blood samples and sequential samples post-
transplantation and assessing CD56+ T cell numbers and activation status in 
relation to episodes of CMV viraemia or graft rejection. Moreover, following up 
to the functional studies of these genes there is a possibility of knocking out these 
genes in mice and looking at responses in an animal model or by knocking down 
genes in cultured cells to see if removing them changes the infectivity of CMV or 
changes the response of CD56+ T cells to CMV lysate.  
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Appendix  
Table of genes information collected from genes bank mainly 
www.genecards.org, otherwise the source is mentioned.    
Gene Symbol Function 
APOL6 Helps lipids cytoplasm 
BST2 
IFN-induced gene, Acts as a direct physical tether to block the release of 
enveloped viruses 
C1orf173 Chromosome 1 Open Reading Frame 173 
CACNA1A 
Voltage-gated calcium channels which mediate calcium influx in response to 
depolarisation. 
CD38 
Multifunctional ectoenzyme and functions in cell adhesion, signal 
transduction and calcium signalling. 
CIB2 calcium homeostasis and participate in calcium regulation 
CMPK2 participate in dUTP and dCTP synthesis in mitochondria 
CNP RNA metabolism in the myelinating cell 
CPSF7 Cleavage Factor 
CREM cAMP-mediated signal transduction 
CYP2J2 encodes a member of the cytochrome P450 superfamily of enzymes 
DDX58 
Involved in viral double-stranded (ds) RNA recognition and the regulation of 
immune response, which encode innate immune receptor that detect and 
sense viral nucleic acids 
DDX60 
Positively regulates DDX58/RIG-1 and  IFIH1/MDA5- Type 1 inducible 
gene in response to viral infection. 
DDX60L DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 60-Like, 
DHX58 
Encode DHX58 which regulate of DDX58/RIG-I and IFIH1/MDA5 mediated 
antiviral signalling 
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ECE1 
The protein encoded by this gene is involved in proteolytic processing of 
endothelin precursors to biologically active peptides. 
EIF2AK2 
The protein encoded by this gene is an  IFN-induced dsRNA-dependent 
serine/threonine-protein kinase which plays a key role in the innate immune 
response to viral infection and is also involved in the regulation of signal 
transduction, apoptosis, cell proliferation and differentiation 
EPSTI1 Epithelial Stromal Interaction 1 
ETV7 Transcriptional regulators 
FRMD3 FERM Domain Containing 3, a tumour suppressor gene 
FTSJD2 Interferon-Stimulated Gene 
GALM Encodes an enzyme that catalyzes the epimerization of hexose sugars 
GBP1P1 Interferon-Inducible Pseudogene 
GBP3 
encoded protein interacts with a member of the germinal center kinase family 
and exhibits antiviral activity against influenza virus 
GBP4 Interferon-induced Gene and hydrolyze GTP to both GDP and GMP 
GCH1 Encodes a member of the GTP cyclohydrolase family 
GMPR 
Encodes an enzyme that catalyzes the irreversible and NADPH-dependent 
reductive deamination of GMP to IMP 
HERC5 
Member of the HERC family of ubiquitin ligases and encodes a protein with 
a HECT domain and five  RCC1 repeats. Pro-inflammatory cytokines 
upregulate expression of this gene in endothelial cells. The protein localizes 
to the cytoplasm and perinuclear region and functions as an interferon-
induced E3 protein ligase that mediates ISGylation of protein targets 
HERC6 
Member of the HERC family of ubiquitin ligases, E3 ubiquitin-protein ligase 
which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form 
of a thioester and then directly transfers the ubiquitin to targeted substrates 
HES4 Encode a protein that function as transcriptional repressor 
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HRASLS2 
Encode a protein that catalyzing the calcium-independent hydrolysis of acyl 
groups in various phosphatidylcholines (Upragarin et al.) and 
phosphatidylethanolamine (PE) 
IFI35, IFI44L, IFI44 Interferon-induced 
IFI6 interferon Alpha-Inducible and encode a protein involved in apoptosis 
IFIH1 
interferon Beta-Inducible and part of innate immune response, cell growth 
and division 
IFIT1 
Also called ISG56, and it’s encoded protein involved in vrial replication 
inhibition 
IFIT2 
interferon Alpha-beta Inducible, also called ISG54, and it encodes protein 
involved in inhibition of viral mRNA 
IFIT3 
Interferon inducible also called ISG60 and encodes protein inhibits viral 
processes 
IFIT5 
Also called ISG58 and encodes protein involved in recognition of viral 
ssRNA 
IFITM1 
A protein encoding genes of interferon induced transmembrane protein 1 and 
prevents virus migration into the cells 
IFITM2 
A protein encoding genes of interferon induced transmembrane protein 2 and 
prevents virus migration into the cells 
IFITM4P interferon induced transmembrane protein 4 pseudogene 
IFNG Encodes IFN-γ protein 
IGFBP7 Encodes insulin-like growth factor binding protein 
IL15RA Encodes IL-15 cytokine receptor 
IL2RA Encodes IL-2 cytokine receptor 
IRG1 
Encodes and protein involved in negative regulation of TLR mediated 
inflammatory immune response 
ISG15 Encodes ubiquitin-like protein due to activation by IFN-α and β 
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ISG20 
Encodes ubiquitin-like protein that involved in antiviral  function of 
interferon against RNA viruses 
KLHDC7B Portion coding gene 
LAG3 Lymphocytes activation gene -3 
LAP3 
Leucine aminopeptidase and encodes protein involved in intracellular protein 
processing 
LOC79015 Uncharacterised 
MOV10 Encodes protein included in RNA-mediated gene slicing 
MT1B Metallothionein 1B 
MT1L Metallothionein 1L 
MX1 
Myxovirus (Influenza Virus) Resistance 1, Interferon-Inducible Protein 
encodes protein involved in antiviral response 
MX2 
Myxovirus (Influenza Virus) Resistance 2, Interferon-Inducible Protein 
encodes protein involved in antiviral response 
NEXN 
Encodes a filamentous actin-binding protein that may function in cell 
adhesion and migration 
NT5C3 encodes a member of the 5'-nucleotidase family of enzymes 
OAS1 
2'-5'-Oligoadenylate Synthetase 1 and it is interferon induced  encodes 
protein essential in anti-viral innate immune response 
OAS2 
2'-5'-Oligoadenylate Synthetase 2 and it is interferon induced  encodes 
protein essential in anti-viral innate immune response 
OAS3 
2'-5'-Oligoadenylate Synthetase 3 and it is interferon induced  encodes 
protein essential in anti-viral innate immune response 
OASL 
2'-5'-Oligoadenylate Synthetase-like and it is interferon induced  encodes 
protein essential in anti-viral adaptive immune response 
PARP10 
Poly (ADP-Ribose) Polymerase Family, Member 10, and works as a 
transcriptional factor 
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PARP12 
Poly (ADP-Ribose) Polymerase Family, Member 12 and catalyses the post-
translational modification of proteins 
PARP9 
Poly (ADP-Ribose) Polymerase Family, Member 9 and catalyses the post-
translational modification of proteins 
PGAP1 Post-GPI Attachment To Proteins 1 
PI4K2B Phosphatidylinositol 4-Kinase Type 2 Beta 
PLSCR1 Enhance interferon antiviral response 
PML 
Promyelocytic Leukemia, and function as  transcription factor and tumour 
suppressor 
PNPT1 
Polyribonucleotide Nucleotidyltransferase 1, and involved in RNA 
processing and degradation 
PRIC285 transcriptional coactivator  (phosphosite.org) 
RGS16 Regulator Of G-Protein Signalling 16, and inhibits signal transduction 
RNF43 
Ring Finger Protein 43, E3 ubiquitin-protein ligase, is a HAP95 (AKAP8L; 
MIM 609475) binding ubiquitin ligase that promotes cell growth 
RRAGC Ras-Related GTP Binding C 
RTP4 Receptor (Chemosensory) Transporter Protein, interferon responsive 4 
SAMD9L Sterile Alpha Motif Domain Containing 9-Like 
SLC27A2 Solute Carrier Family 27 (Fatty Acid Transporter), Member 2 
SLC38A5 Solute Carrier Family 38, Member 5 
SOCS1 Suppressor Of Cytokine Signaling 1 
SP140 SP140 Nuclear Body Protein 
STAG3 Stromal Antigen 3 
TMEM140 Transmembrane Protein 140 
TNFSF10 
Tumor Necrosis Factor (Ligand) Superfamily, Member 10, encodes cytokine 
of  TNF ligand family which induce apoptosis in stressed cells 
TRIM5 Tripartite Motif Containing 5,  function as a E3 ubiquitin-ligase and 
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ubiqutinates itself to regulate its subcellular localization 
USP18 
Ubiquitin Specific Peptidase 18, belongs to the ubiquitin-specific proteases 
(UBP) family of enzymes that cleave ubiquitin from ubiquitinated protein 
substrates 
USP41 
Ubiquitin Specific Peptidase 41, encodes a protein that recognize and 
hydrolyze the peptide bond at the C-terminal Gly of ubiquitin 
XLOC_000755 
Alternative name  lnc-IFI6-1,  (LNCipedia.org) 
XLOC_001609 Alternative name  lnc-mrps9-3,  (LNCipedia.org) 
XLOC_001966 Alternative name   lnc-CMPK2-1, (LNCipedia.org) 
ZC3HAV1 
Zinc Finger CCCH-Type, Antiviral 1, encodes a CCCH-type zinc finger 
protein that is thought to prevent infection by retroviruses 
ZNFX1 Inc Finger, NFX1-Type Containing 1 
BAIAP2 
BAI1-Associated Protein 2, encodes a brain-specific angiogenesis inhibitor 
protein 
C15orf52 Chromosome 15 Open Reading Frame 52 
EGR3 
Early Growth Response 3, transcription factor involved in muscle spindle 
development and lymphocytes development 
FLJ40288 Uncharacterized FLJ40288 
FRY Furry Homolog (Drosophila) 
GAS7 
Growth arrest-specific 7, encodes a protein play a role in promoting 
maturation and morphological differentiation of cerebellar neurons 
HSD17B1 Hydroxysteroid (17-Beta) Dehydrogenase 1 
LOC100505746 Uncharacterised 
LOC388242 Coiled-Coil Domain Containing 101 Pseudogene 
MUC5B 
Mucin 5B, encodes a member of the mucin family of proteins, which are 
highly glycosylated macromolecular components of mucus secretions 
MYLK4 Myosin Light Chain Kinase Family, Member 4 
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NAV2 
Encodes a member of the neuron navigator gene family, which may play a 
role in cellular growth and migration 
NRARP NOTCH-Regulated Ankyrin Repeat Protein 
PLIN5 
Members of the perilipin family, such as PLIN5, coat intracellular lipid 
storage droplets and protect them from lipolytic degradation 
PTGFRN Prostaglandin F2 Receptor Inhibitor, 
SIGLECP3 Sialic acid binding Ig-like lectin 17, pseudogene 
UBXN11 UBX Domain Protein 11 
VCAN 
Versican, the protein encoded  is involved in cell 
adhesion, proliferation, proliferation, migration and angiogenesis and plays a 
central role in tissue morphogenesis and maintenance 
XLOC_001338 Inc RNA4563-3 (LNCipedia.org) 
XLOC_011215 Inc-C15orf54-2  (LNCipedia.org) 
XLOC_011218 Inc-EIF2AK4-1 (LNCipedia.org) 
XLOC_012522 Inc-MBTD1-1 ,(LNCipedia.org) 
XLOC_l2_012135 Uncharacterised , (LNCipedia.org) 
XLOC_l2_015033 Uncharacterised, (LNCipedia.org) 
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An example of percentage different cells expression before and after PBMCs 
stimulation overall no signifancnt difference was there: 
 NK cells CD56+ T-cells CD56-T-cells 
Unst Stim Unst Stim Unst Stim 
Seronegative 6 6.7 2.6 4.3 66 75 
 13.3 14 1.8 15 38.5 49.1 
5.3 3.1 1.2 1.3 75 76.2 
7.6 7.4 2.3 3.1 34 32 
 10.7 11 2.3 2.5 59 54 
Seropositive 9.5 9.5 7.4 8 65 65.5 
16.1 15.2 8.5 9.9 57.2 57.8 
39.5 39 3.3 4 47 50.2 
20 18 7.5 7.8 66.1 57.8 
33 32 13.1 14.5 44.5 52.1 
 
